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ABSTRACT
Activated blood coagulation factor XIII (FXIIIa) is a transglutaminase that stabilises fibrin clots 
and associates with platelets. In the present study, the role of factor XIII (FXIII) in modulating 
physiological platelet functional responses including adhesion, signal transduction and 
spreading were examined. Under static conditions, platelets adhered to surface-immobilised 
plasma-purified and recombinant human FXIII leading to the formation of filopodia and 
lamellipodia. Adhesion to FXIIIa was mediated through integrin-dependent mechanisms, 
since it was abolished by treatment with RGDS. Moreover, platelet adhesion to FXIIIa was 
reduced partially, but significantly by either the specific integrin dnbPs antagonist tirofiban or 
the selective avp3-blocking antibody LM609, and abolished when used in combination. 
However, spreading was exclusively mediated by OubPs since it was ablated by tirofiban, but 
unaffected by LM609. Importantly, FXIIIa-mediated platelet accrual was preserved under 
venous and arterial flow conditions where both integrins played essential roles. Under these 
conditions, platelet adhesion to immobilised activated FXIII (FXIIIa) was apparent at a shear 
rate of 300s"1, significantly reduced at 800s"1, but absent above 1000s"1 . These platelet-FXIII 
interactions occurred independently of FXIII transglutaminase and protein disulfide 
isomerase activities. However, platelet adhesion and spreading were abolished by the Src 
family inhibitor PP1 indicating a tyrosine kinase-dependent mechanism. Consistent with this, 
FXIIIa stimulated tyrosine-phosphorylation of several proteins including Syk, SLP-76 and 
PLCv2 but not LAT, in adherent platelets. FXIIIa immobilised rapidly on collagen, and 
enhanced collagen-induced thrombus formation at a shear rate of 800s"1 . When co- 
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immobilised with fibrinogen and vWF, the coagulation factor also accentuated platelet 
accrual by these key platelet adhesive proteins also at arterial shear. These data provide 
evidence that FXIIIa supports platelet adhesion under flow and potentiates the thrombogenic 
effects of established platelet ligands, suggesting a novel role for FXIIIa in enhancing platelet- 
dependent haemostasis.
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Chapter 1
CHAPTER 1 - GENERAL INTRODUCTION
1.1 Introduction
Haemostasis is initiated following blood vessel injury to preclude loss of blood. It involves 
concerted actions of blood platelets and soluble coagulation factors in forming blood clots at 
sites of vascular injury. Platelets are recruited from flowing blood and become activated to 
fulfil their haemostatic roles (Marcus, 1969, Ruggeri and Mendolicchio, 2007). Coagulation 
factors are also spatially activated at these sites where they initiate, promote or reinforce 
platelet activity (Heemskerk et al., 2002). Interactions between these two elements of the 
haemostatic machinery enhance clot formation and stabilisation. Although platelets provide 
an essential defence against life-threatening haemorrhage, their superfluous or unregulated 
activation can also lead to pathological outcomes (Ruggeri, 2002). For instance, chronic 
vascular damage sustained in atherosclerosis results in platelet-mediated vascular occlusion 
(Ross, 1986). The consequent restriction of blood supply to organs and tissues results in 
ischemia, which leads to myocardial infarction (Ml) and stroke when the heart and brain are 
affected respectively. This chapter will review literature forming the basis of current 
understanding of platelet biology, coagulation factor XIII (FXIII) function and known 
interactions between the two.
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1.2 Platelets
Platelets are the smallest blood cells and they are crucial for maintaining vascular integrity. 
Their continuous synthesis and replenishment ensures constant availability in blood, while 
their structure is well-adapted for haemostatic roles.
1.2.1 Platelet synthesis
Pluripotent stem cells in the bone marrow, liver and kidney differentiate into 
megakaryocytes which release platelets through mechanisms critically dependent on 
thrombopoeitin (Kelemen et al., 1958, Lok et al., 1994, de Sauvage et al., 1994). Mature 
megakaryocytes extend their peripheral membranes into long projections with terminal ends 
swollen into structures called proplatelets (Italiano et al., 1999). Proplatelets endowed with 
organelles from parent megakaryocyte cytoplasm eventually bud off to enter the circulation 
as platelets (Becker and De Bruyn, 1976). A single megakaryocyte gives rise to 1000 to 3000 
platelets and approximately Ixl0n new platelets are produced each day; maintaining normal 
human blood platelet concentration at ISOxlO9 - 400*109 platelets/L (Kaushansky, 2005). 
Platelet lifespan is around 10 days and senescent platelets are depleted from blood by the 
reticuloendothelial system in the spleen (Cohen and Leeksma, 1956, Aas and Gardner, 1958, 
Aster, 1966). About a third of the body's platelet pool is normally sequestered in the spleen 
and platelets are released from this storage site to meet situations of increased demand 
(Aster, 1966).
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1.2.2 Platelet uitrastructure
Platelet uitrastructure has become well-defined from observations made under electron 
microscopy (White, 1979). Human platelets are 2-5|jm in diameter and are approximately 
0.5u,m thick with a mean cell volume of 6 to 10 femtolitres. Under resting conditions, 
platelets are biconvex discs. However, their shapes can change dramatically following 
activation (Figure 1.1).
1.2.2.1 Platelet membranes and cytoskeleton
Platelets are surrounded by a plasma membrane which has numerous infolding crevices that 
give it an appearance resembling sulci and gyri on the brain surface (White et al., 1995). 
Similar to other cells, the platelet plasma membrane is a phospholipid bilayer comprising the 
phospholipids: phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine 
(Marcus, 1978). An important feature is the presence of multiple invaginations which form a 
convoluted network of channels through the cytoplasm called the open canalicular system 
(OCS) (White and Clawson, 1980). This increases the platelet surface available for interaction 
with plasma and enhances absorption and release of substances. Moreover, the OCS 
provides extra membrane required for platelet spreading (White and Clawson, 1980, White, 
2005). In addition to the OCS, platelets also possess a separate channel network called the 
dense tubular system (DTS); a remnant of megakaryocyte smooth endoplasmic reticulum 
which serves as a calcium storage site (White, 2002).
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Figure 1.1: Platelet ultrastructure. (A) Discoid platelet photographed in the low-voltage, 
high-resolution scanning electron microscope (LVHR-SEM). The outside of the cell has a 
wrinkled appearance resembling gyri and sulci on the surface of the brain. Magnification 
x30,000. (B) Platelet in early activation viewed by LVHR-SEM. Fine processes (filopodia) 
extend in all directions. Magnification xi3,000. (C) Early spread platelet with observable 
lamellipodia. The central body of the cell remains convoluted, but is gradually disappearing 
as the cytoplasm spreads and fills the spaces between filopodia. Magnification xll,000. (D) 
Spread platelet viewed by conventional SEM. Magnification x9,000. Figure and legend are 
compiled from figures in reference (White, 2002).
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Release of calcium from this store into the cytoplasm drives a number of platelet activation 
responses. The DTS is also the site of platelet cyclo-oxygenase 1 (COX-1) which plays a critical 
role in the generation of thromboxane A2 (TXA2 ); a major contributor to platelet recruitment 
at sites of thrombus formation (Gerrard et al., 1978, Carey et al., 1982).
Immediately beneath the platelet membrane is a framework of proteins that form the 
platelet cytoskeleton. The organisation of the cytoskeleton controls resting platelet structure 
and also drives morphological changes that accompany platelet activation (Escolar et al., 
1986). The cytoskeleton comprises of microtubules, actin filaments, spectrin strands and 
other associated proteins. Some platelet surface receptors such as integrins and GPlb are 
attached to it at their cytoplasmic tails; thus mediating firm linkage between the 
cytoskeleton and externally bound ligands (Hartwig and DeSisto, 1991, Shattil and Newman, 
2004). The discoid platelet appearance is maintained by a single microtubule which coils 
around itself about 9 times along the wider edge of a platelet (White, 2002). Following 
platelet stimulation, globular actin polymerises into filaments in an energy-dependent 
manner that utilises cytoplasmic ATP (Jennings et al., 1981). Actin filaments facilitate platelet 
shape changes by pressing outwards against the inner face of the membrane. Through 
interactions with myosin, actin also takes part in several contractile responses involved in 
stabilising platelet thrombi (Shepro et al., 1970, Pollard, 1980)
1.2.2.2 Platelet receptors
The external platelet membrane surface is covered a myriad of glycoprotein (GP) receptors 
which form a prominent coat called the glycocalyx (Kieffer and Phillips, 1990). The receptors
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present on the platelet surface perform diverse functions including adhesion to exogenous 
ligands leading to signal transduction which either activates or inhibits platelet haemostatic 
function. Platelet surface receptors can be divided into several receptor families including; 
integrins, G-protein-coupled receptors (GPCR), tyrosine kinase receptors, tetraspanins, 
receptors belonging to the immunoglobulin superfamily, the C-type lectin family and leucin 
rich-repeat family (Kieffer and Phillips, 1990, Rivera et al., 2009). Noteworthy among platelet 
receptors are various GPCRs including those for TXA2 and adenosine 5'-diphosphate (ADP), 
collagen receptors GPIV and GPIalla (integrin a23l), the von Willebrand factor (vWF) receptor 
complex GPlb-IX-V, and the fibrinogen-binding receptor GPIIbllla (integrin ctnbPs) which are 
critical for platelet thrombus formation. There are approximately 80,000 copies of ctnbPs on 
the platelet surface, making it the most highly expressed surface receptor (Wagner et al., 
1996).
1.2.2.3 Platelet organelles and granules
Similar to other cells, platelet cytoplasm contains different organelles, some of which play 
important roles during thrombus formation. Like erythrocytes, platelets distinctly lack a 
nucleus, which limits their proteome to proteins synthesised by their parent megakaryocytes. 
However, platelets retain residual mRNA from megakaryocytes which may enable them to 
synthesise new proteins when activated such as the proinflammatory cytokine interleukin 13 
(Lindemann et al., 2001a, Lindemann et al., 2001b).
Platelet cytoplasm has a diverse granular content including alpha (a) granules, dense (6) 
granules and lysosomes. a-granules are the most abundant and number 40-80 per platelet
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(White, 2002). They are 0.2-0.4u.m in diameter and are identifiable under electron
microscopy by densely staining cores (White, 2002). They contain various pro-thrombotic 
mediators which are secreted into the OCS following platelet activation. These include vWF, 
fibrinogen, thrombospondin, vitronectin, platelet derived growth factor (PDGF), platelet 
factor 4 (PF4), 3-thromboglobulin, factor V and FXIII (Marx et al., 1993, White, 2002). P- 
selectin and ctubPs integrins are present on the membranes of alpha granules and become 
exposed on the platelet surface following fusion of a-granule membranes with the external 
platelet membrane. By comparison, 6-granules are smaller than a-granules, appear more 
densely stained under electron microscopy and are less abundant. They are about 0.15urn in 
diameter and typically 3-8 6-granules are found per platelet (McNicol and Israels, 1999, 
White, 2002). 6-granules also secrete their contents during platelet activation. These include 
ADP, adenosine 5'-triphosphate (ATP), calcium ions (Ca2+), pyrophosphates and serotonin (5- 
HT). Platelet lysosomes maintain an internal acidic pH and contain hydrolytic enzymes. A few 
glycogen granules are also present within platelets which provide an energy store since 
glycogen can be metabolised into glucose. Platelets are able to carry out both anaerobic and 
aerobic respiration, with the latter being facilitated by mitochondria which are also present 
in the platelet cytoplasm (Kitchens and Newcomb, 1968).
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1.2.3 The roles of platelets in haemostasis
Platelets have been described as "sentinels of vascular integrity, [that] adhere where 
alterations are detected, and signal the abnormality to other platelets and blood cells" 
(Ruggeri, 2008). This essentially summarises their haemostatic roles since they permeate the 
vasculature in quiescent states with their spatial activation being restricted to sites of 
vascular injury. A continuous layer of endothelium lines the lumens of blood vessels and 
provides an inert surface that is normally refractory to platelet adhesion. Due to collisions 
with larger red blood cells (RBC) in flowing blood, platelets are forced away from the centre 
of vascular lumens towards the endothelium through a process termed margination (Aarts et 
al., 1988, Hathcock, 2006). This well positions them to detect changes in the structure and 
continuity of the endothelium. When such changes are detected, platelets are activated in 
stages which have been conceptually divided into initiation, extension and perpetuation 
phases (Figure 1.2) (Brass, 2003).
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Figure 1.2: Stages of platelet plug formation. (A) Prior to vascular injury, platelets are 
restrained from activation by inhibitory factors that include prostacyclin (PGI 2 ) and nitric 
oxide (NO) released from endothelial cells, the presence of the ectonucleotidase CD39 on the 
surface of endothelial cells, and the inability of normal plasma von Willebrand factor (VWF) 
to bind spontaneously to the platelet surface. (B) The development of the platelet plug can 
be initiated by the exposure of collagen and VWF in the vessel wall. Rolling platelets adhere 
and spread on the collagen matrix, forming a monolayer of activated platelets. (C) The local 
generation of thrombin occurs rapidly on the surface of activated platelets and together with 
secreted adenosine diphosphate (ADP), and Thromboxane A2 (TxA2 ) facilitates the 
recruitment of flowing platelets. (D) During the perpetuation stage, close contacts between 
platelets promote the growth and stabilization of the haemostatic plug, in part through 
contact-dependent signalling mechanisms. Figure and legend are reproduced in modified 
form from reference (Brass, 2003).
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1.2.3.1 Initiation phase
The initiation phase is triggered by discontinuation in the endothelium caused by vascular 
injury which exposes platelets to various adhesive subendothelial ligands (Figure 1.2B). These 
include collagen, fibronectin, thrombospondin and vWF (Ruggeri and Mendolicchio, 2007). 
Collagen in particular is the major subendothelial platelet adhesive protein which recruits 
flowing platelets to injury sites where they adhere and form a primary monolayer 
(Baumgartner, 1977, Nieswandt and Watson, 2003). However, under high shear (above a 
threshold of 800s-1 ) typically found in the arterial circulation, platelets require vWF to enable 
their interactions with collagen (Weiss et al., 1978a). vWF is a multimeric protein produced 
by endothelial cells with a presence in the subendothelium, platelet a-granules and plasma. 
Plasma vWF can localise on exposed collagen fibres where its conformation is changed to one 
that allows rapid interactions with platelet GPlb/IX/V receptor complexes (Ruggeri and 
Ware, 1993). Although transient, platelet-vWF interactions retard platelet flow velocity, 
enabling the occurrence of less rapid receptor-ligand interactions such as those with collagen 
(Ruggeri and Mendolicchio, 2007).
The platelet receptors facilitating adhesion to collagen are ct23i integrins and GPVI (Farndale 
et al., 2004). When bound to GPVI, collagen stimulates biochemical signalling events that 
lead to platelet activation. Collagen cross-links GPVI resulting in tyrosine phosphorylation of 
Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) on Fc receptor y-chains (FcRy) 
which are co-expressed and physically associated with GPVI on the platelet surface (Gibbins 
et al., 1997, Poole et al., 1997, Tsuji et al., 1997). These phosphorylation events are mediated
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by Src-family kinases, namely Lyn and Fyn and lead to the recruitment of the tyrosine-kinase 
Syk to phosphorylated FcRy ITAMs where it becomes activated by autophosphorylation 
(Ezumi et al., 1998, Suzuki-lnoue et al., 2002, Watson et al., 2005). Activated Syk 
phosphorylates multiple targets including the adaptor proteins; linker for activation of T-cells 
(LAT) and SH2 domain containing leukocyte protein of 76 kilodaltons (SLP-76) (Watson et al., 
2001). This leads to the assembly of a signalosome that results in the phosphorylation and 
activation of the gamma2 isoform of phospholipase C (PLCv2) (Daniel et al., 1994, Asselin et 
al., 1997) and phosphatidylinositol 3-kinase (PI 3-K) (Pasquet et al., 1999). PLCy2 hydrolyses 
membrane phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) into diacylglycerol (DAG) and 
inositol-l,4,5-triphosphate (IP3). DAG activates the serine-threonine kinase protein kinase C 
(PKC) while IPs binds to its receptors on the DTS leading to calcium release into the 
cytoplasm. While PKC activation and intracellular calcium mobilisation can each initiate 
platelet shape change, spreading, secretion and aggregation, full platelet activation occurs 
through synergism between the two mediators (Kaibuchi et al., 1983). PI 3-K phosphorylates 
phosphoinositides in the membrane on the third position hydroxyl group of 
phosphatidylinositol (PI) thus transforming PI(4,5)P2 and PI(4)P to PI(3,4,5)P3 and PI(3,4)P2 
respectively. This facilitates pleckstrin homology (PH)-domain mediated membrane 
recruitment of PLCy2 and Bruton's tyrosine kinase; a Tec kinase implicated in PLCy2 
activation (Kaibuchi et al., 1983).
Primary adherent platelets undergo activatory morphological changes following stimulation 
(Alien et al., 1979). An early change is the disintegration of the microtubule coil which
transforms discoid platelets into spheres. Actin filaments are then cleaved by gelsolin which
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is activated by elevated intracellular calcium (Lind et al., 1982). New actin polymerisation 
beneath the membrane then causes extension of finger-like projections called filopodia. 
Membrane segments between filopodia gradually coalesce, forming planar regions called 
lamellipodia and eventually platelets attain a fully spread morphology (Figure 1.1). Platelet 
spreading increases the surface area covered by each platelet and facilitates stable adhesion 
that resists shear forces imposed by flowing blood.
1.2.3.2 Extension phase
Once a primary adherent monolayer of platelets has been deposited, the extension phase 
follows (Figure 1.2C). This involves capture of free-flowing platelets from the blood by 
adherent platelets to form thrombi, a process termed platelet aggregation (Born, 1962, 
Jackson, 2007).
Activated adherent platelets release ADP and TXA2, secondary agonists which act locally to 
activate proximal platelets. ADP is released by degranulation of platelet 6-granules which 
associate with the plasma membrane to empty their contents. Platelets have two purinergic 
receptors for ADP on their surfaces; P2Yi and P2Y12 . P2Yi is coupled to GOq which activates 
the beta isoform of phospholipase C (PLC0). Similarly to the mechanism described for PLCy2 
(section 1.2.3.1), PLC3 triggers calcium mobilisation and PKC activation. P2Yi also signals 
through Gdi2/i3 (Jin et al., 1998). P2Yi2, is coupled to Gctj which inhibits adenylate cyclase 
thereby decreasing platelet intracellular cyclic adenosine 5'-monophosphate (cAMP) levels 
(Jin and Kunapuli, 1998). Since cAMP triggers a platelet inhibitory cascade, ADP signalling 
through P2Yi2 potentiates platelet activation by several agonists (Herbert and Savi, 2003).
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Intracellular calcium mobilisation activates cytoplasmic phospholipase A (PLA) which cleaves 
phosphatidylcholine in the platelet membrane, liberating arachidonic acid. Following 
metabolic changes involving COX-1 and thromboxane synthase, arachidonic acid is converted 
to TXA2 . TXA2 then diffuses out of the platelet where it binds TPa and TPP receptors which 
are both linked to Gaq and Gcti2/i3 (Shen and Tai, 1998, Klages et al., 1999).
While ADP and TXA2 are able to initiate platelet aggregation, the most potent physiological 
agonist for this process and hence the extension phase is thrombin (Davey and Luscher, 
1967). Following activation by collagen, platelets in the monolayer express negatively 
charged phosphatidylserine on their external surfaces by membrane ruffling which provides 
an ideal surface for the capture of soluble coagulation factors and initiation of the 
coagulation cascade that leads to thrombin generation (Lindhout et al., 1982, Severs et al., 
1985, Solum, 1999). Thrombin is a serine protease that cleaves terminal ends of its platelet 
G-protein coupled receptors which then rejoin as tethered ligands (Vu et al., 1991). 
Thrombin-mediated platelet activation occurs through protease activated receptors 1 and 4 
(PAR1 and PARA) which are linked to the Goq G-protein subtype and activate PLC3 (Vu et al., 
1991, Xu et al., 1998, Kahn et al., 1999). PAR1 and PAR4 are also linked to the Ga12/i3 G- 
protein subtype that triggers platelet shape changes by facilitating myosin interactions with 
actin in a Rho-A kinase dependent manner (Offermanns et al., 1994, Klages et al., 1999).
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As described for ADP, TXA2 and thrombin, the major platelet agonists mediating the 
extension phase bind to GPCR's (Figure 1.3). Other mediators signalling through GPCR's 
include 5-HT and epinephrine. However, their contributions to the extension phase are 
comparatively modest. Through ensuing signalling events, these agonists transform platelet 
surface integrins, particularly an b 33, from low affinity conformations in resting platelets to 
the high affinity conformations found in activated platelets. The intracellular biochemical 
protein interactions stimulated by receptor ligation which lead to otnb33 activation are 
collectively termed "inside-out signalling" (Ginsberg et al., 1992). Platelets with activated 
aMb 33 integrins aggregate by binding divalent plasma fibrinogen and multivalent vWF which 
bridge associations between platelets in thrombi.
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Figure 1.3: Signalling mechanisms linking platelet receptors to integrin activation. GPVI 
ligation activates the ITAM-signalling pathway, whereas stimulation of G protein-coupled 
receptors triggers pathways involving Gctq, Gctj/2 , and 612/13 and adenylate cyclase. DAG 
indicates diacylglycerol; IP3/ inositol-l,4,5-trisphosphate; PI-3-K3/V, phosphoinositide-3- 
kinase P/y; PIP2, phosphatidylinositol-4,5-bisphosphate; PIP3/ phosphatidylinositol-3,4,5- 
trisphos-phate; PKC, protein kinase C; PLC32/3, phospholipase C-32/3; RhoGEF, Rho-specific 
guanine nucleotide exchange factor. Figure and legend are reproduced in modified form 
from reference (Varga-Szabo et al., 2008).
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1.2.3.3 Perpetuation phase
Once platelets have been recruited into thrombi, the perpetuation phase ensures long-term 
stability of adhesive contacts (Figure 1.2D). The most well understood mechanism operating 
to that effect is triggered by fibrinogen binding to aM b33 which stimulates "outside in" signal 
transduction (Phillips et al., 2001). This perpetuates intracellular calcium mobilisation, PKC 
and PI 3-K activation thus maintaining high integrin ligand-affinity (Shattil et al., 1998). It also 
causes clot retraction which in addition to strengthening thrombi, reduces thrombus volume, 
thus limiting obstruction to vascular blood flow (Cohen et al., 1982, Shattil et al., 1998). 
Recent advances have revealed other mediators involved in thrombus stability including 
ephrins and platelet surface ephrin kinase receptors (Prevost et al., 2002), growth arrest 
specific gene 6 (Gas-6) (Angelillo-Scherrer et al., 2005), CD40 (Andre et al., 2002) and 
semaphorin 4D (Zhu et al., 2007). Clot stability ensures successful haemostasis, prevents 
embolism which may cause fatal vascular occlusion and localises platelets at sites where their 
secretion of various growth factors facilitates wound healing.
1.2.4 Platelet integrin receptors
Integrins are type I membrane receptors with an intracellular C-terminal, a single 
transmembrane domain and an extracellular N-terminal that facilitate cell-cell and cell-ligand 
contacts. They are heterodimeric glycoproteins consisting of a and 3 chains. To date, 18ot and 
83 chains have been identified on various cell types and these complex in different 
combinations giving 24 known integrins (Shattil et al., 2010). Platelets express 6 integrins 
including anb33 which binds fibrinogen, av3s (vitronectin), a2 3i (collagen), ct5 3i (fibronectin),
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(laminin) and aLp2 which has poorly defined ligand specificity. Through attempts to 
identify ligands selectively bound by each integrin, it emerged that many integrins are 
promiscuous and bind multiple ligands (Ruoslahti and Pierschbacher, 1987). For example, 
although ctnbps is commonly referred to as the "platelet fibrinogen receptor" it also binds 
vWF, vitronectin and fibronectin (Phillips et al., 1988). Broad integrin ligand-specificity is 
caused by the binding of specific amino acid sequences found on several different proteins. 
Platelet avPs, ctsPx and OePi integrins bind their ligands through an arginine-glycine-serine 
(RGD) sequence while a2pi binds collagen at glycine-phenylalanine-hydroxyproline-glycine- 
glytamic acid-arginine (GFOGER) sequences (Humphries et al., 2006). Although a^Ps binds 
vWF, thrombospondin, vitronectin and fibronectin through RGD, it has been demonstrated 
that physiological fibrinogen binding by the integrin is critically dependent on a lysine- 
glutamine-alanine-glycine-aspartic acid-valine (KQAGDV) sequence present on fibrinogen y- 
chains (Kloczewiak et al., 1982, Kloczewiak et al., 1983). This occurs despite the presence of 
two RGD sequences on fibrinogen Act-chains which play less important roles in platelet 
haemostasis (Zaidi et al., 1996).
1.2.4.1 Integrin structure
The crystal structures of the two platelet P3 integrins (ctnbPs and ctvp3 ) have been solved 
(Xiong et al., 2001, Xiong et al., 2002, Xiao et al., 2004). From their membrane insertions to 
N-terminals, the extracellular regions of a,i b and av are divided into calf domains, thigh 
domains and p-propellers consisting of repeated amino acid sequences arranged into 7 
blades. The P3 chain consists of a P tail domain, cysteine-rich EGF repeats with 3 disulphide 
bonds, a hybrid domain, a p-A domain and a Plexin-Semaphorin-lntegrin (PSI) domain that
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forms an inverted N-terminus (Figure 1.4). All three chains have "genu" which are kinks along 
their lengths that give ctnbPs and avp3 bent conformations associated with low-affinity resting 
states. Ligand binding is mediated by (3-propellers in the a-chains and the 3-A domain of the 
3s chain which together appear like a "head" supported by two "stalks" under electron 
microscopy. Several divalent cation sites are present on a and 3 chains that are important for 
tertiary structure and for ligand binding. The 3s chain in particular has 3 metal ion binding 
sites that are involved in ligand binding: a metal ion dependent adhesion site (MIDAS) that 
prefers Mg2+/Mn2+ which bind aspartic acid in RGD sequences, an adjacent to MIDAS 
sequence (ADMIDAS) whose cation regulates the interaction and a ligand induced metal 
binding site (LIMBS) whose cation stabilises ligand binding (Xiong et al., 2003).
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Figure 1.4: Integrin structure. Integrins are heterodimeric adhesive receptors consisting of 
an a- and a p-subunit. In mammals, there are 24 canonical integrins formed from 
combinations of 18 a-subunits and 8 3-subunits. The 'bent conformation' seen in crystal 
structures (see the figure; left) can be unfolded to facilitate visualization of the domains (see 
the figure; right). In most integrins the amino-terminal domain in the a- and P-integrin 
subunits (the 3-propeller and the PA domain, respectively), assemble by non-covalent 
interactions to form a 'head 1 and provide a ligand binding site. In 8 ct-integrin subunits (al, 
a2, alO, all, al_, aM, aX and aD), the oA domain, which is homologous to the PA domain of 
the P-integrin subunit, is inserted into the P-propeller domain and is the main ligand-binding 
site in these integrins. In integrins that lack an A domain, such as ctnbPs integrin, which is 
depicted here, the PA domain forms the main ligand-binding site. Note that the plexin, 
semaphorin and integrin (PSI) domain is at the N terminus of the P-integrin subunit, but is 
joined by disulphide bonds to more carboxy-terminal residues. The remaining C-terminal 
extracellular domains of each subunit comprise two long 'legs'. The low affinity state of the 
integrin for its ligands is maintained by non-covalent interactions between the a- and P- 
integrin transmembrane and cytoplasmic domains. Figure and legend are reproduced from 
reference (Shattil et al., 2010).
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1.2.4.2 Integrin signalling in platelet function
The cytoplasmic tails of integrin a and 3 chains bind various proteins that are involved in both 
"inside-out" and "outside-in" signalling. As described in section 1.2.3.2, "inside-out" 
signalling consists of the biochemical events that culminate in integrin activation. Although 
the mechanisms are still incompletely defined, recent advances have revealed that talin is a 
major mediator of integrin activation (Tadokoro et al., 2003). Talin comprises a C-terminal 
rod domain concealing an N-terminal head domain with high affinity for integrin 3-chain 
cytoplasmic tails (Calderwood et al., 1999). Activated PLCP and PLCy2 raise platelet calcium 
and DAG levels (section 1.2.3.1). Subsequently, elevated intracellular calcium levels activate 
calpain, a protease which cleaves talin and liberates its head from the rod (Van et al., 2001). 
Simultaneously, calcium and DAG activate a guanine nucleotide exchange factor (CalDAG- 
GEFI) that activates a Ras-family GTPase called Raplb which also requires PI 3-K (Dupuy et al., 
2001).
Raplb then binds to an effector adaptor protein called Rapl-GTP-interacting adaptor 
molecule (RIAM) causing its migration to the membrane where it binds through PH-domains. 
RIAM also binds talin, recruiting it to the membrane, proximal to integrin cytoplasmic tails 
(Lafuente et al., 2004, Man et al., 2006). It is believed that integrins are constrained in 
inactive low-affinity conformations through salt-bridges holding a and 3-chain cytoplasmic 
regions together (Hughes et al., 1996). Talin-binding disturbs these bonds, separates the 
chains and causes integrins to assume high affinity, active conformations. These events have 
been demonstrated for 3i, 3z and 3s integrins (Shattil et al., 2010). Other proteins have also
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been shown to activate integrins through cytoplasmic tail binding including kindlins and 3s- 
endonexin (Shattil et al., 1995, Shattil et al., 2010). The principles of integrin "inside-out" 
signalling are outlined in Figure 1.5.
Extracellular ligand binding can itself activate integrins to cause "outside-in" signalling. This 
depends on integrin oligomerisation, also known as clustering which brings together various 
signalling proteins bound to cytoplasmic tails. Integrin clustering also increases the number 
and strength of interaction sites between platelets and ligands a process called avidity 
modulation (Shattil et al., 1998). Following a- and 3-chain separation by "inside-out" 
signalling, ligand-binding causes ct-chains to cluster with other a-chains and 3-chains with 
other 3-chains (homotypic oligomerisation). This has been demonstrated in vitro with 
Chinese Hamster Ovary (CHO) cells transfected with ct^ and 3s and shown to stimulate 
phosphorylation of the tyrosine kinase Src which is constitutively bound to 3s (Obergfell et 
al., 2002, Buensuceso et al., 2003).
In resting integrins, associated Src is maintained in an inactive conformation by 
phosphorylation on an inhibitory site (Tyrosine529 ) by c-Src kinase (Csk) which is also 
constitutively bound to 3s (Obergfell et al., 2002). Ligand binding causes Src Tyrosine529 
dephosphorylation by protein tyrosine phosphatase-lB (PTP-1B), Csk dissociation, Src 
autophosphorylation on an activatory site (Tyrosine418 ) leading to its activation (Obergfell et 
al., 2002). Src then phosphorylates Tyrosine747 and Tyrosine759 residues on 3s which serve as 
docking sites for the recruitment of Syk.
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Figure 1.5: Integrin "inside-out signalling". The schematic represents the minimal elements 
of one pathway of ctubPa integrin activation by thrombin receptors, which were identified 
through the synthetic reconstruction of pathway components in Chinese hamster ovary cells 
and studies of gene-targeted platelets. Thrombin cleavage or ligand occupancy of the 
thrombin receptor proteinase-activated receptor 1 (PAR1; also known as F2R) in human 
platelets, or PAR4 receptors in mouse platelets, stimulates phospholipid hydrolysis, which 
results in the generation of inositol trisphosphate (IP3 ) and diacylglycerol (DAG). IP 3 
stimulates an increase in cytosolic free Ca 2+, activating Ca 2+- and DAG-regulated (CALDAG- 
GEFI; also known as RASGRP1), which in turn converts its encoded protein, RAP1, from a 
GDP-bound to an active GTP-bound form. Ca 2+ and DAG also activate certain protein kinase C 
(PKC) isoforms, including PKCa, which among other actions may facilitate the activation of 
CALDAG-GEFI. Activation of RAP1 leads to recruitment of its effector, RAPl-GTP-interacting 
adaptor molecule (RIAM; also known as APBB1IP), and its binding partner, talin 1, to the 
plasma membrane. This enables talin binding to the 33 integrin tail and talin-induced 
activation of dnbPs integrin. Kindlin 3 plays a crucial role in this process, but because its 
mechanistic role is uncertain, it is not depicted here. Figure and legend are reproduced from 
reference (Shattil et al., 2010).
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Syk becomes activated by autophosphorylation and phosphorylates various proteins 
including the adaptor proteins SLP-76 and NcK, and the guanine exchange factor Vavl (Figure 
1.6) (Watson et al., 2005). SLP-76 is required for PLCy2 activation which raises cellular 
calcium and activates PKC. Vavl activates the Ras-family GTPases Rac and cdc42 which are 
involved in actin polymerisation, while Nek recruits Pakl, the effector protein for Rac. PI 3-K 
is also activated downstream of OnbPs ligation and together with Src, activates focal adhesion 
kinases FAK which also mediates reorganisation of the actin cytoskeleton (Shattil and 
Newman, 2004).
1.2.5 Regulation of platelet activity
The luminal endothelial lining of blood vessels plays a major role in negatively regulating 
platelet activation which restricts the initiation of thrombus formation to vascular injury 
sites. Endothelial cells release nitric oxide (NO), in response to shear forces imposed by 
flowing blood (Furchgott and Zawadzki, 1980, Palmer et al., 1988). NO is a potent vasodilator 
that relaxes vascular smooth muscle and diffuses across platelet membranes to activate 
intracellular soluble guanylate cyclase (sGC) to produce cyclic guanosine monophosphate 
(cGMP). cGMP activates a dependent serine/threonine kinase; protein kinase G (PKG) which 
in turn mediates various inhibitory phosphorylation events (Radomski et al., 1987a, Radomski 
etal., 1987b, Feiletal., 2003).
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Figure 1.6: Integrin "outside-in signalling". Outside-in signalling through ligand engagement 
or clustering of integrin a.\\$3 generates intracellular signalling cascades. Src-dependent 
activation of Syk leads to activation of PLCy2 through a pathway that is likely to be 
dependent on SLP-76 and Vav. Figure and legend are reproduced in modified form from 
reference (Watson et al., 2005).
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Notable among these are inhibition of Raplb (Reep and Lapetina, 1996), TXA2 receptors
(Wang et al., 1998) and IP3 receptors on the DTS (Schlossmann et al., 2000). Moreover, PKG 
activates sarcoendoplasmic reticulum calcium ATPase (SERCA) which pumps cytoplasmic 
calcium back into the DTS, returning its concentration to basal levels (Trepakova et al., 1999). 
Endothelial cells also release prostacyclin (PGI2 ) which binds Gcts-linked IP receptors on 
platelets. Gcts activates adenylate cyclase, which converts ATP to cAMP (Moncada et al., 
1976, Gryglewski et al., 1976, Tateson et al., 1977, Dutta-Roy and Sinha, 1987). cAMP 
activates protein kinase A (PKA), a serine/threonine kinase that inhibits platelet TXA2 
synthesis and like PKG, also inhibits IP3 receptors and Rapl while activating SERCA (Schwarz 
et al., 2001).
CD39 and CD73 are ecto-5'-nucleotideases present on the endothelium which break down 
ADP to AMP and AMP to adenosine respectively, thus reducing platelet recruitment by 
diminishing ambient ADP levels (Marcus et al., 1997, Kawashima et al., 2000, Koszalka et al., 
2004). Endothelial thrombomodulin binds plasma thrombin and alters its ligand specificity, 
diminishing its ability to activate platelets (Esmon et al., 1983). Furthermore, several 
phosphatases present within platelets reverse activatory phosphorylation events such as 
those occurring downstream of tyrosine kinases linked'to GPVI and integrins (Cicmil et al., 
2002, Newman and Newman, 2003).
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1.2.6 Platelets in atherosclerosis
Atherosclerosis is a condition of chronic vascular inflammation implicated in many 
cardiovascular diseases which together are the greatest cause of mortality in the developed 
world (Ross, 1999). Fatty streaks gradually deposit on vascular lumens with age in a manner 
influenced by blood lipid levels. Despite its continuity, the endothelium is dynamic with small 
crevices continuously opening and closing between adjacent endothelial cells, through which 
cholesterol-rich low density lipoproteins (LDL) can enter the subendothelium (Gimbrone, 
1999). Oxidative stress causes LDL oxidation by reactive oxygen species (ROS) such as 
hydroxyl ions (OH ) and superoxide (O2 ) to generate oxidised LDL (oxyLDL) which stimulates 
immunogenic responses by vascular dendritic and endothelial cells (Ross, 1999, Young and 
McEneny, 2001). This triggers monocyte recruitment to these regions where they 
differentiate into macrophages. Macrophages phagocytose oxyLDL, but due to their limited 
ability to process it, they transform into "foam cells". Various inflammatory mediators are 
released and concentrate at atherosclerotic sites, stimulating further monocyte recruitment.
In addition to their classical role in thrombosis, it has been suggested that platelets may also 
play a role in atherogenesis (Gawaz et al., 2005). OxyLDi and other inflammatory mediators 
cause endothelial dysfunction which is thought to result in a phenotype where the 
endothelium produces less PGI 2 and NO, releases vWF from Weibel-Palade bodies and 
expresses various cell adhesion molecules. This leads to platelet accrual on its surface, where 
they further aggravate endothelial dysfunction (Ware and Heistad, 1993, Andre et al., 2000).
Platelets release proinflammatory mediators including CD40 ligand, PDGF, interleulkin-13,
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PF4 and transforming growth factor 3 (TGF-3) which enhance monocyte recruitment (Figure 
1.7) (Henn et al., 1998, Gawaz et al., 2005). Platelets also bind monocytes directly through 
GPlb/IX/V-mediated interactions with monocyte P-selectin glycoprotein ligand-1 (PSGL-1) 
and integrin ctM 32 (Mac-1) (Simon et al., 2000). Inflammatory mediators also stimulate 
vascular smooth muscle to proliferate, produce collagen and encapsulate subendothelial lipid 
material forming atherosclerotic plaques (Ross, 1999). These plaques are subsequently 
broken down and weakened by matrix metalloproteinases released by platelets and 
macrophages (Fernandez-Patron et al., 1999). Shear forces imposed by blood or other 
physical pressure may eventually rupture the plaques and expose platelets to prothrombotic 
collagen fibres leading to vascular occlusion (Gawaz et al., 2005). Atherosclerosis is 
implicated in various morbidities including peripheral vascular disease (PVD), Ml and strokes. 
Targeting platelet function has proven an effective clinical strategy in controlling mortality 
due to these pathologies as evidenced by successful interventions with anti-platelet drugs 
such as aspirin, clopidogrel and anb33 receptor antagonists (Lincoff et al., 2000, Bhatt et al., 
2006).
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Figure 1.7: Hypothetical model of atheroeenesis triggered by platelets. Activated platelets 
roll along the endothelial monolayer via GPIbct/P-selectin or PSGL-1/P-selectin. Thereafter, 
platelets firmly adhere to vascular endothelium via p3 integrins, release pro-inflammatory 
compounds (IL-lp, CD40L), and induce a proatherogenic phenotype of endothelial cells 
(chemotaxis, MCP-1; adhesion, ICAM-1). Subsequently, adherent platelets recruit circulating 
leukocytes, bind them, and inflame them by receptor interactions and paracrine pathways, 
thereby initiating leukocyte transmigration and foam cell formation. Thus, platelets provide 
the inflammatory basis for plaque formation before physically occluding the vessel by 
thrombosis upon plaque rupture. Figure and legend are reproduced in modified form from 
reference (Gawaz et al., 2005).
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1.3 The coagulation cascade
The haemostatic system is a physiological response to injury that is initiated to limit blood 
loss and preserve bodily homeostasis. The rapid activation of platelets and their roles at sites 
of vascular injury constitutes primary haemostasis. However, the initial haemostatic plug is 
fragile, easily dislodged by flowing blood and requires stabilisation. Hence, a parallel system 
is simultaneously initiated to reinforce and stabilise the developing platelet plug. This 
secondary haemostasis involves a series of complex proteolytic reactions that culminate in 
the formation of a stable fibrin clot. The majority of enzymes involved are vitamin K- 
dependent serine proteases and their glycoprotein cofactors synthesised in the liver.
The sequential nature of protein activation during secondary haemostasis has led to the term 
coagulation cascade. This has become well established since its inception in 1964 (Davie and 
Ratnoff, 1964, Macfarlane, 1964). Thrombin is the main effector protein of the cascade and 
two pathways lead to its generation. The first is the intrinsic (contact activation) pathway, so 
named as all the mechanisms required to activate it are endogenously present in the blood 
and it can be initiated in vitro following blood contact with negatively charged surfaces. The 
second is the extrinsic (tissue factor) pathway which is triggered by blood exposure to 
subendothelial tissue factor (TF). However, a constitutive presence of potentially 
thrombogenic plasma TF under normal conditions has been reported (Giesen et al., 1999). 
Moreover, secretion of TF by monocytes and platelets has also been described (Osterud, 
1998, Rauch et al., 2000, Siddiqui et al., 2002). Both pathways converge at a final common
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pathway through which thrombin is activated from its zymogen precursor, prothrombin
(Figure 1.8). Critical to the progression of the coagulation cascade is the spatial localisation of 
mediators involved in some of the key reactions. This occurs at the surface of activated 
platelets and is facilitated by their exposure of negatively charged phosphatidylserine which 
provides the essential reactive surface (Heemskerk et al., 2002). The major components of 
the coagulation cascade are called coagulation factors and they are named by their 
designated roman numerals prefixed with the letter "F" for "factor". Their activated forms 
are suffixed by the letter "a".
In the intrinsic pathway, high molecular weight kininogen (HMWK) and prekallikrein serve as 
cofactors for the activation of FXII to generate FXIIa which then activates FXI. FXIa in turn 
activates FIX. In the presence of calcium and its cofactor FVIIIa, FIXa transforms FX to FXa at 
the platelet surface in what is called the tenase complex. The route to the tenase complex 
via the extrinsic pathway is triggered by TF binding to FVIIa. The TF-FVIIa complex then 
directly causes FX activation at the platelet surface. In a calcium dependent reaction, FXa 
associates with its cofactor FVa in cleaving prothrombin (Fll) to form thrombin (FXIIa). This is 
referred to as the prothrombinase complex which executes the common pathway of 
thrombin activation. Thrombin cleaves fibrinopeptides A and B from Act and B3 fibrinogen 
chains respectively causing them to assemble in an insoluble fibrin polymer that reinforces 
platelet thrombi. Thrombin also activates FXIII which stabilises fibrin through covalent 
transglutaminase cross-linking reactions.
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The description above is a simplified outline of the inherent events. Considerable crosstalk
occurs between the pathways since FVIIa can activate FIX and thrombin can activate FXI, FV, 
FVIII and platelets (Pieters et al., 1989, Gailani and Broze, 1991). The cascade is also tightly 
controlled with the principal regulator being antithrombin III, a plasma protein which inhibits 
the serine proteases of the cascade (Olson et al., 1993). Its affinity is raised by endothelial 
surface heparin sulphates and therapeutically by heparin. Thrombomodulin on the 
endothelium also alters thrombin substrate specificity resulting in its activation of protein C 
which inhibits FVa and FVIIIa (Esmon et al., 1982, Esmon et al., 1993).
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Figure 1.8: The blood coagulation cascade. Haemostasis is the body's physiological response 
to vascular injury and involves formation of a primary occlusive platelet plug (primary 
haemostasis) which is stabilised by a fibrin gel formed through a series of events mediated by 
serine proteases (secondary haemostasis) which constitute the coagulation cascade. 
Thrombin is the main effector enzyme of the cascade as it cleaves fibrinogen to form fibrin, 
activates the transglutaminase FXIII to cross-link and stabilise fibrin and is also the major 
agonist stimulating platelet aggregation. Thrombin (Flla) is activated from its precursor 
zymogen (prothrombin, Fll) in the common pathway of the coagulation cascade which 
requires phosphatidylserine exposure by activated platelets. As shown in the figure, two 
pathways converge on the common pathway. These are the intrinsic (contact activation) 
pathway and extrinsic (tissue factor) pathway. The intrinsic pathway is stimulated by contact 
of high molecular weight kininogen (HMWK) with negatively charged surfaces such as 
negative species in the ECM while the intrinsic pathway is initiated by tissue factor (TF) 
associating with FVIIa. Further descriptive details are provided in the text.
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1.4 Factor XIII
FXIII belongs to the transglutaminase family of enzymes which join peptide chains through 
e(y-glutamyl)lysine cross-links (Folk, 1983). FXIII-deficiency was first identified as a cause of 
clinical bleeding in a young boy in 1960 (Duckert et al., 1960), and in 1963, FXIII received 
formal recognition as a blood coagulation factor.
1.4.1 FXIII structure
FXIII circulates in plasma comprised of two globular, catalytic A-subunits (FXIII-A) 
encapsulated by two strand-like, carrier B-subunits (FXIII-B) giving it a tetrameric structure 
(A2B2 ). FXIII-A is a 731 amino acid protein of 83kDa encoded by a gene on chromosome 6 
(Board et al., 1988). It is divided into 5 well-characterised domains: an N-terminal activation 
peptide, beta sandwich, catalytic core, barrel 1 and barrel 2 at the C-terminus (Yee et al., 
1994). FXIII-A is expressed by haematopoietic cells and has been found in megakaryocytes, 
platelets, monocytes, macrophages, and their precursor stem cells (Muszbek et al., 1996, 
Adany and Bardos, 2003). Intracellular FXIII-A is found in the cytoplasm in dimeric form (A2 ) 
and is thought to be released into plasma following cell destruction. FXIII-A has 9 cysteine 
residues, with at least one disulphide bond (Takahashi et al., 1986). Its free thiols may 
mediate a recently described protein disulphide isomerase (PDI) activity (Lahav et al., 2009).
FXIII-B is a glycoprotein produced by hepatic cells (Muszbek et al., 1996). It is 641 amino acids 
long, 80kDa and its gene lies on chromosome 1 (Webb et al., 1989). Unlike FXIII-A, FXIII-B has
a signal sequence and is secreted into blood where it complexes with FXIII-A. In plasma, the
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presence of FXIII-B in 50% excess over FXIII-A ensures that all FXIII-A is in complex form with 
FXIII-B, protecting it from premature activation (Yorifuji et al., 1988). FXIII-B consists of ten 60 
amino acid sequence repeats called "sushi domains" (Ichinose et al., 1986). These are known 
to facilitate protein-protein contacts and may mediate FXIII-B dependent FXIII-binding to C- 
terminal ends of fibrinogen y'-chains in plasma (Siebenlist et al., 1996). The variant y'-chains 
have a 20 amino acid C-terminal extension and are found in 15% of plasma fibrinogen 
(Wolfenstein-Todel and Mosesson, 1980). FXIII-B is also believed to stabilise FXIII-A in plasma 
maintaining its half-life at about 10 days. In the absence of FXIII-B, FXIII-A is rapidly depleted 
from plasma with its half-life reduced to around 3 days (Saito et al., 1990).
1.4.2 Activation of FXill
Similar to other coagulation factors, FXIII circulates in plasma as an inactive zymogen; only 
becoming activated at sites of vascular injury. Activation of FXIII is triggered by thrombin- 
mediated cleavage of a 4kDa N-terminal activation peptide from FXIII-A at arginine37- 
glycine38 . B-subunits then dissociate in a calcium-dependent manner, exposing a free thiol at 
cysteine314 in A-subunit catalytic sites, allowing them to engage substrate molecules (Lorand, 
1986) (Figure 1.9). Fibrinogen greatly enhances B-subunit dissociation, thus facilitating FXIII 
activation (Naski et al., 1991).
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Figure 1.9: Structure and activation of coagulation factor XIII. Factor XIII (FXIII) circulates in 
plasma as a tetramer comprising of 2 A-subunits and 2 B-subunits. The carrier B-subunits 
bound to the catalytic A-subunits prevent premature enzyme activation maintaining the half- 
life of FXIII at about 10 days. Activation of FXIII follows thrombin-mediated cleavage of 
activation peptides from A-subunits. B-subunits then dissociate from the complex in a 
calcium-dependent step which is greatly enhanced by fibrinogen. Activated FXIII (FXIIIa) then 
engages its substrates to catalyse e(y-glutamyl)lysine cross-links.
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The exposed cysteine314 on activated FXIII (FXIIIa) associates with a substrate y-glutamine
through an intermediate thioester bond. This rate-limiting step releases ammonia which is 
reduced in the plasma under physiological conditions. Although there is substantial 
heterogeneity in protein sequences surrounding substrate y-glutamines selected by 
transglutaminases (Griffin et al., 2002), it is surmised that the charge and structure around 
them as determined by primary structure may be involved (Muszbek et al., 1996). y- 
glutamines are transferred to e-lysine residues linking the two in isopeptide bonds. This 
covalently joins two peptide chains while leaving FXIIIa free to engage more substrate 
molecules (Figure 1.10).
Cellular FXIII-A is thought to become activated independently of proteolytic cleavage 
following intracellular calcium elevation that accompanies cell activation (Polgar et al., 1990). 
Since FXIII-B is not expressed by haematopoietic cells and is therefore absent, calcium is not 
required for B-subunit dissociation in this case. Rather, it is hypothesised that intracellular 
calcium mediates a slow progressive conformational change in FXIII-A through which it 
exposes its reactive cysteine.
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Figure 1.10: Transelutaminase reaction of FXIIIa. (1) Activated factor XIII (FXIIIa) exposing its 
catalytic thiol at cysteine314 initially forms a thioester bond with a protein-bound glutamine 
residue such as that on protein 1 in the figure. This rate-limiting reaction releases ammonia. 
(2) Through the thioester intermediate, FXIIIa transfers the glutamine residue to a primary 
amine from a protein-bound lysine residue, resulting in an isopeptide bond, FXIIIa then 
emerges free to engage more substrates.
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1.4.3 Functions of FXHI
FXIIIa plays a critical role in haemostasis through stabilising fibrin clots formed by the 
coagulation cascade, where its activation constitutes the final step (Figure 1.8). FXIIIa cross­ 
links both fibrin and fibrinogen, however, the reaction with fibrinogen is slower (Kanaide and 
Shainoff, 1975). Fibrin(ogen) a and y-chains are joined through the transglutaminase reaction 
illustrated in Figure 1.10 (Mosesson, 1997). The y-chains are rapidly cross-linked into dimers 
whereas a-chains are more slowly assembled into multimers. In addition, FXIIIa also 
incorporates other proteins into fibrin(ogen) clots. Importantly, ct2-antiplasmin, a major 
antagonist to the fibrinolytic enzyme plasmin, is cross-linked to fibrin(ogen) a-chains thus 
protecting clots from premature degradation (Sakata and Aoki, 1982). This latter activity of 
FXIIIa has been described as its most important haemostatic role (Muszbek et al., 1999). It is 
believed that FXIIIa imparts early clot stability through y-chain cross-linking while long-term 
resistance to shear forces of flowing blood and fibrinolytic degradation are attained through 
a-chain cross-linking and ot2-antiplasmin incorporation (Muszbek et al., 1999). Other anti- 
fibrinolytic agents that are incorporated into clots by FXIIIa include thrombin activatable 
fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor type 2 (PAI-2) (Muszbek et al., 
2008).
FXIIIa is also involved in wound healing and about 15% of FXIII-deficient patients are limited 
in this respect (Lorand et al., 1980). FXIII-A deficient mice displayed markedly limited wound- 
healing which was alleviated by FXIII supplementation (Inbal et al., 2005). Moreover, human
supplementation with FXIII concentrates hastened the healing of wounds in patients who
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had undergone surgery for removal of head and neck tumours (Brockmeier et al., 1998). 
Mediation of wound-healing is believed to occur through both direct cell binding and 
reorganisation of the ECM. Fibroblasts critically facilitate wound healing by producing ECM 
proteins that form a scaffold for reparative scars. Surface-bound FXIII increases fibroblast 
proliferation (Bruhn and Pohl, 1981). In addition, fibroblasts adhere to immobilised FXIIIa in 
an integrin-dependent manner that stimulates activatory signal transduction and shape 
changes in these cells (Ueki et al., 1996). Through cross-linking ECM proteins such as 
collagen, fibronectin, vWF and thrombospondin as well as incorporating plasma proteins 
such as fibrinogen into the ECM, FXIIIa alters its structure, thereby providing a more 
favourable surface for fibroblast migration (Corbett et al., 1997, Grinnell et al., 1980, 
Muszbek et al., 1996).
FXIIIa was also shown to bind endothelial cells through avB3, stimulating their proliferation 
and migration in a manner dependent on its transglutaminase activity (Dardik et al., 2003). 
Proliferation and migration of endothelial cells are instrumental in angiogenesis which also 
aids wound healing. However, other investigators reported that FXIIIa-endothelial 
interactions inhibit angiogenesis independently of transglutaminase activity (Dallabrida et al., 
2000). These contradictory findings reveal the complexity of FXIII-cellular interactions, but 
may be due to differences in experimental methods between studies.
FXIII-deficient women cannot carry a pregnancy to term (Ichinose et al., 2005), since FXIII is 
required for the formation of the Nitabuch's layer and the cytotrophoblastic shell which
enable placental attachment to the uterus (Asahina et al., 2000). Uterine macrophages are
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believed to be the source of FXIII in this organ, yet plasma supplementation with FXIII
concentrate alleviates spontaneous abortions by FXIII-deficient women. Thus, the 
mechanisms of FXIII delivery to the uterus are still poorly understood.
1.4.4 Regulation of FXIlia activity
Endogenous mechanisms that lead to the demise of FXIlia activity are poorly defined. In 
rabbits, FXIIIa-mediated fibrinogen a-chain cross-linking was shown to continue for over 6 
hours (Finlayson and Aronson, 1974), and a2-antiplasmin cross-linking to clots had a half-life 
of 20min (Robinson et al., 2000). Since thrombin substrate-specificity is altered by 
thrombomodulin on the endothelial surface, it has been suggested that this may reduce 
thrombin-mediated FXIlia cleavage (Muszbek et al., 1999, Philippou et al., 2003).
Catani et al., (1998) demonstrated in vitro inhibition of FXIlia by NO. They suggested that NO 
reacts with the reactive cysteine of FXIlia through a nitrosylation reaction which inhibits its 
interaction with substrates (Catani et al., 1998). Although NO is a physiological antagonist 
that is constantly secreted into blood, FXIlia inhibitory effects were only observed at 
supraphysiological levels of NO in that study. Inhibitory FXIII-A cleavage by proteases 
released by neutrophils including elastase and cathepsin-G have also been described as 
possible regulatory mechanisms (Bagoly et al., 2007). Since association with FXIII-B constrains 
FXIII-A activity, FXIII-B may potentially inhibit plasma FXIlia. However it is yet to be tested 
whether FXIII-B can reassemble with FXIlia in vivo. Thus, although a number of potential 
biochemical mechanisms capable of regulating the activity of FXIlia have emerged, evidence
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of whether they are able to operate in the complex and dynamic in vivo environment is still 
insufficient.
A common Valine34Leucine polymorphism in the FXIII-A gene present in 25% of Caucasians is 
activated faster by thrombin cleavage (Muszbek, 2000). Leucine34 was shown to interact 
more avidly with hydrophobic sequences in the thrombin substrate-binding site than Valine34 
thus facilitating its cleavage at Arginine37-Glycine38 (Trumbo and Maurer, 2000, Trumbo and 
Maurer, 2003). While Leucine34 has a faster rate of activation, at full activation, both enzyme 
forms have equal specific transglutaminase activity. Paradoxically, the variant Leucine34 has 
been shown to be protective against Ml (Suzuki et al., 1996, Kohler et al., 1998), with this 
being dependent on fibrinogen concentration (Muszbek et al., 2008). There is no protective 
effect at low fibrinogen concentration, however, at high concentration, Leucine34 cross-links 
fibrin into a loose and open mesh that is more prone to fibrinolysis (Lim et al., 2003).
1.4.5 FXIII deficiency
The average human plasma FXIII (A2B2 ) concentration is 21.6u.g/mL (0.07u,M) (Yorifuji et al., 
1988). However, normal plasma enzyme concentration ranges widely from 66% to 134% 
(Katona et al., 2000), while enzyme activity ranges from 53% to 221% (Anwar et al., 1999). 
Surprisingly, less than 5% of the average plasma enzyme concentration level is sufficient to 
allay bleeding (Walls and Losowsky, 1968). Congenital FXIII deficiency is a heritable disorder 
which follows autosomal recessive genetics (Anwar and Miloszewski, 1999). It is a rare 
condition with a morbidity of 1 in 3-5 million and is caused by severe reduction or absence of
the functional enzyme in platelets and plasma of affected individuals (Board et al., 1993).
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Patients with mutations in genes encoding FXIII-A (chromosome 6p24-25) and FXIII-B 
(chromosome Iq31-32.1) resulting in failure to express either protein have been described, 
however, the majority of cases involve abnormalities in FXIII-A (Anwar and Miloszewski, 
1999). Since FXIII is activated in the terminal stage of the coagulation cascade, after 
formation of the fibrin clot, its deficiency is not detectable using standard tests of 
haemostatic function. Thus, prothrombin time (PT), activated partial thromboplastin time 
(APTT) and thrombin time are normal in FXIII deficient patients. The disease is instead 
detected by testing for rapid clot solubility in 5M urea or 1% monochloroacetic acid which is 
indicative of FXIII deficiency. This can then be followed by more sophisticated quantitative 
analyses.
The first clinical case of FXIII deficiency was documented by Duckert et al, (1960) and over 
the years, the symptoms of the disease have become well characterised. The most distinctive 
symptom (appearing in 80% of cases) is umbilical bleeding occurring a few days after birth 
(Anwar and Miloszewski, 1999). Although FXIII levels are typically lower in neonates than in 
adults, under normal conditions they are sufficient to prevent bleeding. Other symptoms 
include post-operative bleeding, intramuscular and joint haemorrhage and superficial 
bruising. Poor wound healing has been described, but is not a universal symptom, reported in 
only 14% of patients (Anwar and Miloszewski, 1999). Intracranial haemorrhage is a more 
widespread symptom (30% of patients) and the major cause of mortality in affected patients 
(Anwar et al., 2002). All symptoms are managed by supplementation with FXIII concentrate 
(Anwar and Miloszewski, 1999, Hsieh and Nugent, 2008). Currently, plasma-derived FXIII
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concentrate is indicated for this purpose, but recombinant FXIII concentrate has been 
developed and is undergoing clinical trials (Lovejoy et al., 2006, Hsieh and Nugent, 2008).
FXIII deficiency can also be an acquired trait, whereby individuals born with a capacity to 
produce normal amounts of FXIII experience a pathological decline in their plasma levels. 
This may be caused by depletion of FXIII and other coagulation factors through disseminated 
intravascular coagulation (DIG). Alternatively, abnormal synthesis of "inhibitor" auto- 
antibodies which attack the host's own FXIII-A has been described (Board et al., 1993). 
Production of inhibitor antibodies may be spontaneous, drug-induced or be caused by 
autoimmune disease. Additionally, liver disease may result in less production of carrier FXIII- 
B (Muszbek et al., 1996), causing a reduction in the plasma half-life of FXIII-A (Saito et al., 
1990).
1.4.6 The roles of platelet intracellular FXIII
Approximately half of the FXIII-A found in the body resides as dimers (A2) within the platelet 
cytoplasm, where it is present at a concentration between 100-150 times greater than in 
plasma (Buluk, 1955, Muszbek et al., 1996). A small amount of tetrameric FXIII (A2B2 ) is found 
in platelet a granules (Marx et al., 1993), which is thought to be passively absorbed from 
plasma as platelets permeate the vasculature. Granular FXIII (A2B2) may be released during 
platelet activation and thus increase local FXIIIa concentrations at sites of thrombosis.
The mechanisms involved in the release of platelet cytoplasmic FXIII (cFXIII) to plasma are not
well understood, although it is assumed that this occurs following platelet destruction
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(Lopaciuk et al., 1976). There is widespread consensus that platelets are the major sources of 
plasma FXIII-A (Muszbek et al., 1999). However, a radical view that monocytes, not platelets 
perform this role has recently been proposed (Cordell et al., 2010). The investigators of that 
study reported normal plasma FXIII-A levels in thrombocytopenic mice. However, the mice 
used in the study possessed residual blood platelets which given their high cytoplasmic FXIII- 
A content, may still have been able to replenish plasma levels of the enzyme. Moreover, the 
direct secretion of FXIII-A by monocytes/macrophages was not demonstrated.
Despite its intracellular abundance, the roles of platelet cFXIII are poorly established. Several 
studies have reported that activated platelet cytoplasmic FXIII (cFXIIIa) can cross-link various 
intracellular substrates (Cohen et al., 1981, Serrano and Devine, 2002, Adany and Bardos, 
2003). Following platelet activation, elevated cellular calcium is thought to elicit cFXIII 
activation through slow, progressive conformational change (Polgar et al., 1990, Muszbek et 
al., 1993). Elements of the cytoskeleton including actin, myosin and vinculin were 
demonstrated to be cFXIIIa substrates, fuelling speculation of its involvement in cytoskeleton 
stability and clot retraction (Cohen et al., 1981). Zhu et al., (1994) surmised that the small 
heat-shock protein HSP27 associates with cFXIIIa and transports it to the cytoskeleton where 
it performs cross-linking reactions.
Surprisingly, Kulkarni and Jackson (2004) showed that cFXIIIa negatively regulated aMb33 and 
mediated the development of a procoagulant platelet phenotype under conditions of 
prolonged elevated intracellular calcium levels. These results were contradicted by a more
recent study where FXIII-A deficient platelets showed reduced anbPs-mediated fibrinogen
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binding (Jayo et al., 2009). Furthermore, spreading responses were also diminished, 
supporting hypothetical involvement of cFXIIIa in cytoskeletal organisation (Jayo et al., 2009). 
Notwithstanding these findings, there is still limited evidence supporting contributions of 
cFXIIIa to in vivo platelet function.
1.4.7 Platelet interactions with plasma FXIII
In elegant studies involving swapping normal and FXIII-A deficient platelets with FXIII-A 
deficient and normal plasma respectively, platelets were revealed to greatly influence FXIII 
activity (Francis and Marder, 1987, Reed et al., 1992). While the presence of normal platelets 
in FXIII-A deficient plasma resulted in fibrin cross-linking, it was much less than that induced 
by platelet-depleted normal plasma. This suggested that although platelet FXIII-A may be 
released, it plays a modest role in cross-linking fibrin. However, the mere presence of 
platelets in normal plasma, whether FXIII-A deficient or not, greatly accelerated FXIIIa- 
mediated fibrin cross-linking compared to platelet-depleted plasma (Hevessy et al., 1996). 
This can be explained by the fact that platelets provide a reactive surface which facilitates 
thrombin generation. Thrombin then mediates FXIII activation by proteolytic cleavage.
Adhesive interactions between platelets and exogenous FXIII were first described in 1984 by 
Greenberg and Shuman who reported that platelets activated uniquely by thrombin attained 
a FXIII-binding site on their surfaces (Greenberg and Shuman, 1984). They further suggested 
that the interactions were mediated by FXIII-A not FXIII-B, required FXIII activation, but not 
its activity and occurred independently of aMbp3- The latter was deduced from normal FXIII- 
binding by platelets from people with Glanzmann's thrombasthenia (GT) which lack
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functional aMbP3 on their surfaces. This observation was however contradicted ten years later 
by a study demonstrating major dependency of FXIII-platelet adhesive interactions on anbpS 
integrins using multiple approaches including the use of platelets from people with GT (Cox 
and Devine, 1994). In the same study, the investigators also showed that platelets could be 
stimulated to bind FXIIIa by a broader range of agonists and not just thrombin alone (Cox and 
Devine, 1994). Nevertheless, the physiological roles of platelet FXIII-binding remained poorly 
defined.
Recently, platelet-dependent clot retraction was found to be severely compromised in FXIII-A 
deficient mice (Kasahara et al., 2010). This is consistent with an earlier study using human 
platelets where clot retraction was found to be critically dependent on platelet a^Ps, 
fibrin(ogen) and FXIIIa transglutaminase activity (Cohen et al., 1982). However, it is unclear 
whether platelet-FXIII interactions are directly involved or rather that FXIIIa stabilises already 
retracted clots by cross-linking fibrin. In any case, FXIII-A deficient mice were shown to suffer 
extended bleeding times due to unstable thrombi (Lauer et al., 2002).
Although FXIII binds platelet aubPs, its involvement in platelet aggregation is unclear. While 
an early study described normal in vitro aggregation to ADP, ristocetin and collagen (Ozsoylu 
and Hicsonmez, 1976), a more recent investigation using platelets from 3 FXIII-A deficient 
patients showed abnormal responses to collagen, ADP and epinephrine (Anwar et al., 2002). 
In addition, by incorporating fibronectin into fibrin at developing thrombi, FXIIIa enhanced 
human platelet aggregation under flow (Cho and Mosher, 2006). FXIIIa was also revealed to
be involved in the formation of highly thrombogenic "COAT" platelets which bear released a-
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granule proteins cross-linked to serotonin on their membrane surfaces (Dale et al., 2002). 
However, later work using murine platelets could not establish a role for FXIIIa in this process 
(Jobe et al., 2005), possibly due to another transglutaminase fulfilling this role in mice. Thus, 
despite wide recognition of platelet-FXIII interactions and their potential implications to 
platelet function, understanding of their physiological roles remains limited.
1.4.8 Platelet-FXIII interactions in cardiovascular disease
Through its transglutaminase-mediated clot stabilisation, FXIII imparts fibrinolytic resistance 
to preformed clots. This has rejuvenated interest in the study of its involvement in the 
pathogenesis of cardiovascular disease since it may affect patient responses to fibrinolytic 
therapy (Muszbek et al., 1999). However, little is known about potential pathological 
consequences of platelet-FXIII associations.
Platelets from patients with PVD were observed to circulate with higher levels of bound FXIII 
than matched healthy controls (Devine et al., 1993). This observation was important for two 
reasons. Firstly, it demonstrated that platelet-FXIII interactions occur in vivo. Secondly, it 
suggested that these interactions may have pathological implications. Indeed, plasma FXIII 
was found to mediate abnormal adhesion of stimulated platelets to dysfunctional 
endothelium by binding to a,ib33 and avp3 respectively (Dardik et al., 2002a). This suggests 
potential roles for FXIII in accentuating pathological platelet-endothelial interactions that 
hallmark atherosclerotic progression. Certainly, when considered in unison with the 
involvement of platelets in the progression of atherosclerosis (section 1.2.6), the fact that
women with elevated plasma FXIII antigen and activity levels are predisposed to PVD
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(Shemirani et al., 2008) and Ml (Bereczky et al., 2007) demands further investigation of 
platelet-FXIII interactions to clarify their roles in cardiovascular pathologies.
1.5 Aims of the study
It is established that blood platelets play a key role in the formation of haemostatic plugs at 
sites of vascular injury. This occurs through their interaction with a number of adhesive 
ligands generally in the form of proteins found in the extracellular matrix. More recently, it 
has been demonstrated that proteins involved in the coagulation cascade such as FXI and 
protein C may also contribute to platelet entrapment upon vascular injury (White et al., 
2008, White-Adams et al., 2009). These findings suggest a potentially new level of interaction 
between primary and secondary haemostatic systems.
FXIII plays a key role in the haemostatic process through the cross-linking of fibrin 
monomers. Moreover, it is also known to adhere to platelet surfaces, although the 
importance of this to platelet function has remained elusive. The present project tested the 
hypothesis that immobilised FXIII stimulates functional responses in adherent platelets which 
influence their roles in haemostasis. In order to achieve this greater understanding of 
platelet-FXIII interactions, the experiments performed were designed to fulfil a number of 
aims:
• To determine the ability of immobilised FXIII to support platelet adhesion and 
spreading
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To examine the ability of FXIII to support adhesion and thrombus formation under 
conditions of flow
• To clarify the roles of FXIII enzymatic activity in this process
• To identify which receptor(s) are responsible for the interactions between FXIII and 
platelets.
• To dissect the signal transduction pathways activated by FXIII in platelets
• To determine if FXIII can potentiate the thrombogenic potential of established 
platelet-adhesive ligands
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CHAPTER 2 - MATERIALS AND METHODS
2.1 Antibodies
Normal mouse IgG, anti-phosphotyrosine, anti-LAT, anti-SLP76, anti-avp3 (LM609) and anti-B- 
tubulin monoclonal antibodies were purchased from Millipore (Watford, UK). Rabbit 
monoclonal anti-PLCy2 antibody and mouse monoclonal anti-Syk were purchased from Santa 
Cruz (Heidelberg, Germany). Fluorescein Isothiocyanate (FITC)-conjugated mouse 
monoclonal anti-fibrinogen and anti-P-selectin antibodies were from BD Biosciences (Oxford, 
UK). Mouse monoclonal and polyclonal anti-FXIII-A, FITC-conjugated goat anti-mouse 
antibody, and rabbit polyclonal anti-fibrinogen antibody were from Abeam Pic (Cambridge, 
UK).
2.2 Chemicals and reagents
Phe-Pro-Arg-Chloromethylketone (PPACK) was purchased from Cambridge Bioscience Ltd 
(Cambridge, UK). H-Arg-Gly-Asp-Ser-OH (RGDS), l,2-bis-(o-aminophenoxy)ethane-tetra-acetic 
acid tetra-(acetoxymethyl)ester (BAPTA-AM), phorbol 12-myristate 13-acetate (PMA), (Ro- 
31-8200, bisindoylmaleimide I (BIM I) and bisindoylmaleimide V (BIM V) were all purchased 
from Calbiochem, UK. 4-Amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-c/]-pyrimidine 
(PP1) was purchased from BIOMOL International (Exeter, UK). U73122 was purchased from 
Tocris Bioscience (Bristol, UK). Prestained molecular weight protein ladder was from New
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England Biolabs (Ipswich, UK). Collagen horm reagent was purchased from Nycomed (Zurich, 
Switzerland). Purified vWF (LFB; Lyon, France) and purified, human plasma-derived FXIII 
(Fibrogammin P; CIS Behring, UK) were generously donated by the Haematology Unit at 
Bradford Royal Infirmary (Bradford, UK). Tirofiban (Aggrastat; Iroko Pharmaceuticals, USA) 
was a kind gift from the Haematology Unit at Castle Hill Hospital (Hull, UK). Recombinant 
fibrinogen purified from culture media of Chinese Hamster Ovary cells stably transfected 
with the three chains of fibrinogen as previously described (Ajjan et al., 2008), was provided 
by Dr. Ramzi Ajjan (University of Leeds, UK). Dr. Ajjan also provided human recombinant 
FXIII-A (rFXIII-A) expressed in BL21-Gold DE3 E. coli (Stratagene, UK). Pooled, heat- 
inactivated human serum (HS) was from Sheffield University Hospital, (Sheffield, UK). Human 
a-thrombin, ethyleneglycoltetraacetic acid (EGTA), bovine serum albumin (BSA), bacitracin 
and all other reagents were purchased from Sigma (Poole, UK).
2.3 Methodology used in the activation of FXIII 
2.3.1 In vitro activation of FXIII
Plasma-purified FXIII in Fibrogammin P concentrate was reconstituted to a final 
concentration of 500U/mL (l.lmg/mL), while rFXIII-A was provided at a stock concentration 
of 300u.g/mL Both FXIII preparations were activated by incubation with human a-thrombin 
(lOU/mL) in the presence of CaCI 2 (lOmM) for Ih at 37°C. The reaction was terminated by a 
10 minute incubation with PPACK (20u,M) at 37°C to inactivate thrombin (Dardik et at., 
2002b). Complete inhibition of thrombin under these conditions was confirmed by assessing 
its diminished ability to stimulate platelet shape change and aggregation.
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2.3.2 Measurement of FXIII transglutaminase activity
FXIII activity was monitored by measuring the cross-linking of biotinylated amines to 
fibrinogen through adapting a previously described method (Song et al., 1994). Wells of a 
96-well microplate were coated with fibrinogen (40u,g/mL) in Tris-buffered saline (IBS; 
40mM Tris, 140mM NaCI, pH 8.3) for 45min at room temperature on an orbital shaker. The 
wells were then emptied and uncoated surfaces blocked with BSA/TBS (1%) for Ih at room 
temperature. After blocking, wells were washed three times with IBS. The following were 
then added at the indicated final reactive concentrations: FXIII or rFXIII-A (both 22u.g/mL), 5- 
(biotinamido)pentylamine (ImM), dithiothreitol (O.SmM), CaCb (lOOmM) and thrombin 
(lOU/mL). Thrombin cleaved FXIII/rFXIII-A which became activated in the presence of calcium 
ions. Dithiothreitol maintained exposure of catalytic thiols in the activated enzymes, allowing 
them to cross-link 5-(biotinamido)pentylamine to fibrinogen immobilised on the wells which 
was allowed to proceed at room temperature. The reaction was stopped after lOmin by 
addition of Ethylenediaminetetraacetic acid (EDTA, ImM) to chelate calcium ions. Wells were 
then washed 3 times with TBS-Tween (0.01%). Streptavidine-alkaline phosphatase (lu.g/mL in 
0.1% BSA/TBS) was subsequently added to conjugate specifically with fibrinogen-bound 5- 
(biotinamido)pentylamine. This reaction was allowed to proceed for Ih at room temperature 
on a shaker. The wells were subsequently washed 3 times with TBS-Tween (0.01%) and 
incubated with p-nitrophenylphosphate (Img/mL in 1M diethanolamine, pH 9.8, containing 
O.SmM MgCI 2 ) for 30min at 37°C. The latter was converted to yellow p-nitrophenol following 
hydrolysis of a phosphate group by alkaline phosphatase. Colour development was stopped 
by addition of NaOH (4M) and optical density measured at 405nm using a microplate reader.
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In some instances, FXIIIa and rFXIIIa activated as described in section 2.3.1, were inhibited by 
incubation with the alkylating agent iodoacetamide (3mM) for 30 minutes at 22°C (Dardik et 
al., 2003). Alternatively, both proteins were heat-denatured by incubation in a water-bath at 
60°C for 1 hour. Inhibition of transglutaminase activity under each of these conditions was 
assessed by carrying out the activity assay described above.
2.4 Methodology used for the preparation of platelets
Platelets were prepared from whole blood obtained from healthy, adult volunteers. Exclusion 
criteria were smoking, chronic illness, and taking medication within 14 days prior to bleeding. 
In all cases, informed consent was obtained in accordance with the Declaration of Helsinki. 
Ethical permission for the use of human blood in this project was granted by the ethics 
committe at the Postgraduate Medical institute (Hull York Medical School, Hull, UK). Blood 
was acquired by ante-cubital venepuncture using a 21-gauge butterfly needle. The first 3mL 
were discarded to exclude activated platelets. Subsequently, blood was collected into 20mL 
syringes and mixed with acid citrate dextrose (ACD; 29.9mM sodium citrate, 113.8mM 
glucose, 72.6mM NaCI and 2.9mM citric acid, pH 6.5) 5:1 (v/v) as anticoagulant (Riba et al., 
2008).
2.4.1 Isolation of platelets from whole biood
Blood was centrifuged at 200g at 20°C for 20 min. This caused its separation into 3 layers; an 
upper layer of platelet-rich plasma (PRP) suspended over a narrow band of leukocytes (buffy
coat) which overlaid a layer of red blood cells packed at the bottom of the centrifugation
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tube. Washed platelets were prepared using the prostaglandin EI (PGEi) method adapted 
from Vargas et al., (1982). This method relies on transient platelet inhibitory effects 
mediated by PKA which is activated following PGErinduced cAMP elevation. Avoiding the 
buffy coat, PRP was carefully isolated with a Pasteur pipette then centrifuged at 800g at 20°C 
for 12 min in the presence of PGEi (50ng/mL), to pellet suspended platelets. Depending on 
pellet size, platelets were resuspended in l-2mL of modified Tyrode's buffer (150mM NaCI, 
5mM HEPES, 0.55mM NaH 2PO4, 7mM NaHCO3, 2.7mM KCI, O.SmM MgCI 2 and 5.6mM 
glucose, pH 7.4) and left to recover from PGEi treatment for 1 hour prior to use.
2.4.2 Isolation of red blood cells from blood
Red blood cells (RBC) were pelleted from whole blood during the isolation of PRP described 
above (section 2.4.1). After removing PRP supernatant, the leukocyte-rich buffy coat was also 
carefully removed and discarded. RBCs were resuspended in 30mL of wash buffer (lOmM 
EDTA, 50mM glucose, 90mM NaCI, 36mM citric acid, 50mM KCL, pH 6.5) and washed twice 
by sequential buffer replacement and centrifugation at 800g. A final wash was carried out 
with 30mL of modified Tyrode's buffer. When required, RBCs were reconstituted with 
autologous washed platelets in modified Tyrode's buffer to final concentrations of 50% (v/v) 
and 2xl08 platelets/ml_ respectively.
Page | 55
__ Chapter 2
2.4.3 Quantification of platelet numbers
Platelet quantification was performed manually using a haemocytometer. This device is a 
specialised microscope slide on which perpendicular lines have been engraved to form two 
grids in a central chamber burrowed O.lmm beneath the surface of one side (Figure 2.1). 
When a cover-slip is placed over the chamber, the resulting confined space holds a defined 
volume of cell suspension O.lmm above the grids. Cells are allowed time to settle and then 
counted under a phase contrast microscope.
A sample of washed platelet suspension was diluted 1:100 in ammonium oxalate solution 
(1%, w/v). This concentration of ammonium oxalate lyses any red blood cells present while 
platelets remain intact (Brecher and Cronkite, 1950). After thorough mixing followed by 
incubation for 10 minutes, the diluted platelet suspension was loaded onto the 
haemocytometer to cover each grid and left for a further 10 minutes to allow platelets to 
settle over the grids prior to counting.
Each of the two grids engraved on a haemocytometer is divided into 9 large squares 
measuring 1mm x Imm (1 mm2). The central 1mm2 square is further divided into 25 smaller 
squares, each with an area of 0.04mm2. After loading the haemocytometer with diluted 
platelet suspension, 10 of the 0.04mm2 squares were chosen for platelet counting from each 
grid as shown by an "X" in Figure 2.1. Platelet numbers obtained from both grids were 
averaged to give the mean number of platelets in ten 0.04mm2 squares (mean number of
platelets/0.4mm2).
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Since the height of the platelet suspension above the grids was O.lmm and volume = area x 
height, it follows that this number of platelets was suspended in; 0.4mm2 x O.lmm = 
0.04mm3 .
Considering that 1mm3 = 10"3 ml and by letting the mean number of counted platelets be x; 
There were x platelets/0.04mm3 = (x/0.04) platelets/mm3 = (x/0.04) platelets/10"3 mL 
= [(x/0.04) x 103] platelets/mL = 25000x platelets/mL in the diluted sample.
Thus, the concentration of platelets in the original suspension prior to a 1:100 dilution in 
ammonium oxalate
= (25000 x 100 x x) platelets/mL 
= 25x x 105 platelets/mL
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Figure 2.1: A haemocytometer. Platelets were counted from the squares marked with an "X" 
on each of the two grids
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2.5 Methodology for the examination of platelet adhesion under 
static conditions
During the project, platelet adhesion was studied under various conditions. Initial 
experiments sought to establish and characterise the nature of platelet adhesion to FXIII 
under static conditions with a view to progress into more physiological, flow-based models. 
Adhesion experiments involved quantitative analysis of platelets bound to surface- 
immobilised adhesive proteins using either a microplate reader or fluorescence microscopy.
2.5.1 Micropiate-based platelet adhesion assay
An adhesion assay adapted from Bellavite et al., (1994) was used to examine adhesive 
interactions between platelets and exogenous FXIII. In this assay, wells of a microplate are 
coated with platelet adhesive proteins and uncoated regions blocked with serum albumin. 
Platelets are allowed to adhere to the coated wells and non-adherent platelets are washed 
out. A buffered solution containing detergent for membrane lysis and p- 
nitrophenylphosphate is then added to the wells. Platelets contain the enzyme acid- 
phosphatase in their lysosomes which catalyses the hydrolysis of a phosphate group from p- 
nitrophenylphosphate. The reaction produces yellow p-nitrophenol which is optically dense 
and maximally absorbs light with a wavelength of 405nm. Colour development is stopped by 
adding alkali solution and optical density is then measured with a plate reader. The intensity 
of the colour obtained is proportional to the amount of enzyme and consequently, the total 
number of platelets present (Bellavite et al., 1994).
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FXIII or FXIMa (both 200ug/mL) or human serum (HS, 5%) were used to coat 96-well 
microplates overnight at 4°C. Residual coating protein was removed by two washes with 
phosphate buffered saline (PBS) and the wells subsequently blocked for SOmin at room 
temperature with HS (5%). In some experiments, platelets were preincubated with the 
required inhibitors for 20min at 37 °C. Washed platelets (IxlO8 platelets/mL) were added to 
each well and left to adhere at 37 "C for 1 hour. Non-adherent platelets were emptied and 
the wells washed twice with PBS. Adherent platelets were incubated with reaction buffer 
(31mM citric acid, 5mM sodium citrate dehydrate, 5mM p-nitrophenylphosphate, 0.1% (v/v) 
Triton X-100, pH 5.4) for 1 hour at room temperature. The reaction was stopped by addition 
of NaOH (2M) to each well and optical density measured at 405nm.
2.5.2 Fluorescence microscopy
A fluorescence microscope takes advantage of the ability of some materials to discharge light 
to facilitate their experimental observation and analysis. Although some substances such as 
chlorophyll, crystals and vitamins can autofluoresce, most require staining with special 
fluorescent dyes called fluorochromes to enable visualisation. Fluorochromes are particularly 
useful when they selectively stain structures within a biological specimen, allowing specific 
analysis. For example, 3,3'-Dihexyloxacarbocyanine iodide (DiOCs) and mepacrine stain 
platelet endoplasmic reticulum (Terasaki, 1989) and dense granules (Skaer et al., 1981) 
respectively. Where a specific fluorochrome for a given biological structure is unavailable, a 
generic one can be conjugated to an antibody generated against that structure, thereby 
producing a specific fluorescent stain.
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Fluorochromes maximally absorb light of specific wavelength, resulting in their electrons 
gaining energy to migrate from ground energy states to excited states. However, they rapidly 
lose this energy by giving it off as light of longer wavelength, thereby returning to their 
ground energy states. This principle was fist postulated by Sir George Stokes in 1852 and has 
become known as "Stokes shift". A fluorescence microscope detects low energy light emitted 
by fluorochromes after separating it from the high energy light irradiated for their excitation 
by guiding it through wavelength-selective filters. Emitted light is guided towards the 
microscope eye-piece or a specialised digital camera, allowing visual observation and capture 
of images for further analysis (Figure 2.2A).
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Figure 2.2: Equipment used to visualise fluorescentlv-stained platelets adherent on a 
protein-coated surface. (A) An illustration showing a fluorescence microscope, highlighting 
the separation of sample excitation and emission light through a system of wavelength- 
specific filters. Image from reference (Spring and Davidson, 2010). (B) Wells measuring 0.5cm 
x 1cm (0.5cm2) were cut into electric tape adhered to glass microscope slides. The wells were 
coated with required proteins to study adhesion of fluorescently-labelled platelets using a 
fluorescence microscope.
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2.5.2.1 Platelet adhesion to immobilised proteins under static conditions
Platelet adhesion under static conditions was also assessed using fluorescence microscopy. 
For this method, platelets were adhered to proteins coated on microscope slides. Adherent 
platelets were then stained with a fluorochrome and visualised under a microscope.
Specific areas of microscope slides (O.Scmxicm) were coated overnight with HS (5%), 
plasma-purified FXIII (200u,g/mL), FXIIIa (200u.g/mL), recombinant FXIII (rFXIII, 200u.g/mL), 
activated recombinant FXIII (rFXIIIa, 200u.g/mL), or fibrinogen (200u,g/mL). Residual protein 
was removed by washing slides in phosphate buffered saline (PBS). Uncoated glass surfaces 
were blocked by HS (5%) for 30min at room temperature. Washed platelets (5xl07 
platelets/mL) were then adhered for 1 hour at 37°C. Slides were processed as previously 
described (Roberts et al., 2008). Briefly, non-adherent platelets were removed by washing 
with PBS then stably adherent platelets were fixed with 4% paraformaldehyde in PBS for 
SOmin. Adherent platelets were then permeabilised with 0.3% Triton X-100 for 7min and F- 
actin was stained with Tetramethyl Rhodamine Iso-Thiocyanate (TRITC)-conjugated 
phalloidin (10u,g/mL) for 1 hour to enable visualisation under fluorescence. The platelets 
were subsequently overlaid with histomount under a cover-slip. Slides were observed with 
an Olympus 1X71 fluorescence microscope equipped with an XM10 CCD camera (Olympus, 
Japan). Images were captured under a *60 oil immersion objective lens and analysed using 
ImageJ software from the National Institutes of Health (NIH, USA). For each experiment, 
platelet numbers from random visual fields with a total area of O.lmm2 were added and
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results calculated as mean number of adherent platelets ± standard deviation (SD) per
O.lmm2.
In some experiments, platelets were preincubated with U73122 (5|iM) to inhibit 
phospholipase C, BAPTA-AM (20u.M) to chelate intracellular Ca2+, apyrase (lU/mL) to 
scavenge ADP, indomethacin (10u.M) to block thromboxane A2 (TXA2) synthesis, PPI (20u.M) 
to inhibit Src-family kinases, GSNO (10u.M) to inhibit platelet activation, RGDS (SOOuJvl) or 
EGTA (ImM) to broadly inhibit platelet integrins, anti-avB3 (LM609, 20ug/mL) to block avB3, 
tirofiban (2uJvl) to specifically inhibit OnbPa function or modified Tyrode's buffer as a control. 
Incubations were for 20 minutes at 37°C.
2.5.2.2 Analysis of granular secretion by adherent platelets
Platelet adhesion to various proteins is often followed by activatory responses such as shape 
change, spreading and granular secretion. Platelet a-granules contain proteins including P- 
selectin and fibrinogen which become more abundant on the platelet surface following 
activation-dependent degranulation. These proteins can be detected by probing adherent 
platelets with specific fluorochrome-conjugated antibodies which enable visualisation under 
a fluorescence microscope.
To investigate whether secretion occurred in FXIIIa-adherent platelets, platelets were 
adhered to FXIIIa-coated slides as described in section 2.5.2.1. However, lysis of platelet 
membranes with 0.3% Triton X-100 was omitted and adherent platelets were covered with 
1% BSA/PBS for 30 minutes to block non-specific antibody binding. The presence of secreted
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P-selectin and fibrinogen on adherent platelet surfaces was examined by probing for each
protein using the respective specific FITC-conjugated antibodies (1:100 in 1% BSA/PBS) for Ih 
at room temperature. Unbound antibodies were washed off with PBS and the slides covered 
with histomount under a cover-slip. Images were then captured using a x60 objective of a 
fluorescence microscope under oil immersion.
2.5.2.3 Adhesion of FXIII to collagen
Interactions between FXIII(a) and immobilised collagen were analysed using methodology 
adapted from a study investigating FXII binding to collagen (van der Meijden et al., 2009). 
Wells on glass slides were coated with collagen (100ug/mL) overnight at 4°C. After removal 
of unbound collagen with PBS, BSA (lOmg/mL) was used to block uncoated surfaces for 
30min at 22°C. The wells were then overlaid with FXIII (200ug/mL) or FXIIIa (200u.g/mL) for 
15 minutes at 37°C. After rinsing with PBS, collagen-bound FXIII or FXIIIa were probed with a 
primary mouse monoclonal antibody (1:100 in PBS containing 1% BSA) specific for FXIII-A for 
Ihour at 22°C. Unbound antibody was washed off with PBS. The wells were subsequently 
covered with secondary FITC-conjugated anti-mouse antibody (1:2000 in PBS containing 1% 
BSA). After thorough washes to remove excess antibody, cover-slips were placed over the 
slides and fluorescent images were captured under oil immersion using a xlOO objective lens.
2.6 Analysis of platelet adhesion under flow
While useful as first-line methodology to establish possible platelet interactions with various
exogenous components, platelet adhesion assayed under static conditions is limited in its
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simulation of physiological events. Platelets circulate in flowing blood. Therefore,
interactions between platelet receptors and their ligands occur within a haemodynamic 
environment. The velocity of blood moving in a vessel is not uniform. It is lowest nearest to 
the vessel wall, due to frictional forces opposing the direction of flow and highest at the 
centre of the vessel lumen (Kroll et al., 1996). This gradation in speed of flow between 
alternate fluid layers creates a shearing effect. Considering that this shearing effect is dually 
dependent on blood velocity and distance from the wall, its quantification (the shear rate) is 
measured in centimetres moved per second per centimetre from the wall, which simplifies to 
inverse seconds (s"1 ).
In the normal circulation, blood is under high pressure from the heart in the arterial 
circulation where it travels at its highest velocity with estimated shear rates ranging from 500 
to 5,000s"1 (Tangelder et al., 1988). Even higher shear rates of up to 20,000s 1 have been 
reported in stenotic vessels (Siegel et al., 1994). In contrast, blood is under lower pressure in 
the venous system where it relies on skeletal muscle contraction and a system of valves to 
return it to the heart. Shear rates in this circulation range from 20 to 200s"1 (Kroll et al., 
1996).
2.6.1 Platelet adhesion to FXIil under flow
The method of Cooke et al., (1993), modified as previously published from the laboratory 
(Roberts et al., 2009), was used to study platelet adhesion under flow. This involved real-time 
imaging of thrombus formation by fluorochrome-stained platelets using fluorescence 
microscopy (Figure 2.3).
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Figure 2.3: Set-up of equipment used to study platelet adhesion and thrombus formation 
under flow. Fluorescently-stained platelets in whole blood or reconstituted with autologous red 
blood cells were perfused through protein-coated microslide capillary tubes connected to a 
syringe pump by a series of plastic tubes. Images and videos of thrombus formation were 
captured using a fluorescence microscope fitted with a digital camera connected to a 
workstation computer. Microscope image from reference (Olympus, 2010).
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In brief, washed platelets (4xl08 platelets/mL) were incubated with DIOC6 (luJvl) at 37°C for
lOmin before reconstitution with autologous washed RBC to final concentrations of 2xl08 
platelets/mL and 50% (v/v) RBC. Cells were washed to exclude confounding effects of plasma 
proteins. Flow studies were performed using glass microslide capillary tubes coated with FXIII 
(200u.g/mL) or FXIIIa (200u.g/mL) for 12 hours and blocked with BSA/PBS (lOmg/mL) for Ih at 
room temperature. Using a syringe pump, platelet/RBC suspension was drawn from a 
reservoir through coated tubes at desired shear rates for 4min, followed by washing with 
modified Tyrode's buffer for a further 4min at equivalent shear to remove unstably bound 
platelets (McCarty et al., 2005). The ability of platelets in whole blood treated with PPACK 
(40u,M) to interact with immobilised FXIII was similarly assessed.
In order to quantify platelet arrest, real-time videos and images of stably adherent 
platelets/thrombi were recorded under the fluorescence microscope (x60 objective). ImageJ 
software was then used to analyse and process captured images. For each experimental 
condition, images of random view fields covering a total area of O.lmm2 were used to 
calculate platelet surface area coverage (%), since the software could not fully discriminate 
between single platelets and platelet aggregates. To measure surface coverage, images were 
saved in 8-bit grayscale format. Adherent platelets appeared white against a black 
background. ImageJ software was used to calculate the specific areas covered by the white 
regions relative to the entire image, expressing the result as percentage area coverage. 
Measurement of thrombus volume was performed as previously described (Ross et al., 
1995). Briefly, images were captured and stored in 8-bit grayscale format. Thrombus area
values were then multiplied by their corresponding mean gray values which coincided with
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fluorescence intensity. The product was regarded as thrombus volume and measured in
arbitrary units (Ross et al., 1995, Savage et al., 1998, Matsui et al., 2002).
For some flow experiments, increasing FXIIIa concentrations (20-200u,g/mL) were co- 
immobilised with vWF (20u.g/mL) on the capillary tubes. To investigate how FXIIIa bound to 
collagen and influenced its ability to support platelet arrest, collagen (100u,g/mL) was initially 
incubated with FXIIIa (200u,g/mL) for 15min at 37°C. The mixture was then used to coat 
capillary tubes. Platelet adhesion under flow, video or image capture and analysis were 
subsequently carried out as described above. In other experiments, platelets were 
pretreated with RGDS (500u.M) to broadly inhibit platelet integrins, anti-avp3 (LM609, 
20ug/mL) to block av33, tirofiban (2uJv1) to specifically inhibit a^Ps function or modified 
Tyrode's buffer as a control. Incubations were for 20 minutes at 37°C.
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2.7 Measurement of aggregation and secretion in suspended 
platelets
Light-transmission aggregometry was developed by Born in 1962 and revolutionised the 
investigation of processes which initiate and influence platelet aggregation. The technique is 
based on changes in light scattering through a platelet suspension which is detected by a 
photocell. It is assumed that when using small volumes of platelet suspension with stirring, 
resting platelets are uniformly distributed. This forms an optically dense medium which is 
refractory to the passage of light. However, following their activation, platelets aggregate 
into clumps generating transparent gaps that allow light to pass through (Figure 2.4A). The 
amount of light transmission is proportional to the extent of platelet aggregation which is in 
turn dependent on the level of platelet activation (Figure 2.4B).
2.7.1 Light-transmission aeeregometrv
Aggregation was monitored using a Chrono-log dual-channel light aggregometer. Washed 
platelets (3*108 platelets/mL) were incubated at 37°C with stirring (lOOOrpm) for Imin to 
allow temperature equilibration and then stimulated with the required agonists for 3 
minutes at 37°C. Percentage aggregation was recorded after 3 minutes from the aggregation 
traces produced by Aggro/Link computer software from Chrono-log.
2.7.2 Lumi-aggregometrv
ATP is an essential cofactor in the oxidation of luciferin to oxyluciferin catalysed by firefly 
luciferase. In the reaction, yellow light and AMP are given off as by-products. Hence, ATP
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released from dense granules of activated platelets in the presence of Chronolume reagent
(firefly luciferin/luciferase) leads to fluorescent-light generation which is detected by a 
luminescence (lumi)-aggregometer.
Platelet dense granule secretion was measured using a Chrono-log lumi-aggregometer. 
Chrono-lume reagent (2nM) was added to washed platelets (3xl08 platelets/mL) followed by 
stirring (lOOOrpm) for Imin to allow temperature equilibration. Platelets were then 
stimulated with the desired agonist for 4min at 37°C under stirring conditions (lOOOrpm). 
Using ATP (InM) as standard (100%) to calibrate the machine, the percentage platelet ATP 
secretion after 4 minutes was recorded from traces produced by Aggro/Link computer 
software from Chrono-log.
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Figure 2.4: Measurement of platelet aggregation using a light-transmission aggregometer.
(A) Upon agonist stimulation, platelets aggregate, allowing increased transmission of incident 
light. This change is detected by a photocell in the aggregometer and quantified using 
specialist computer software. (B) A typical aggregation trace generated from measurements 
by the aggregometer software showing changes in optical density (platelet aggregation) 
relative to time.
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2.8 Methods for the assessment of platelet signalling events
Platelet adhesion to certain exogenous proteins such as collagen and fibrinogen is known to 
trigger biochemical signal transduction resulting in activatory responses. Such signalling often 
involves sequential phosphorylation of intracellular proteins which may alter their functional 
states. To enable examination of individual cellular proteins, adherent platelet lysates can be 
separated using gel electrophoresis. The proteins can then be identified and further analysed 
through western blotting.
2.8.1 Gel electrophoresis
Electrophoresis is the movement of charged molecules such as proteins in an electric field. 
When an electric field is applied across a porous matrix such as a gel, it can be used to 
separate proteins which migrate through the gel to different extents depending on their 
molecular weight and charge. In polyacrylamide gel electrophoresis (PAGE), gels consisting of 
polymerised acrylamide are used to separate proteins by distinctive electrophoretic 
migration. Acrylamide molecules polymerise into long linear chains which are cross-linked by 
bis-acrylamide. This polymerisation is accelerated by the presence of free radicals which are 
generated by the addition of ammonium persulphate (APS). Tetramethylethylenediamine 
(TEMED) is also added to catalyse the generation of free radicals from APS (Shi and 
Jackowski, 1998). The percentage of the acrylamide used determines gel pore size and 
therefore the relative separation of proteins within a mixture.
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Electrophoretic mobility is influenced by protein shape, charge-density and molecular 
weight. In order to separate proteins solely by molecular weight, sodium dodecyl sulphate 
(SDS) is added to the protein mixture (Shapiro et al., 1967). SDS is an anionic detergent that 
binds and denatures proteins leaving them with similar, rod-shaped tertiary structure. 
Furthermore, it confers equal negative charge per unit protein mass (1.4g SDS per Ig 
protein). In the presence of a reducing agent such as 2-mercaptoethanol, disulphide bonds 
are broken and proteins become fully denatured. Proteins treated this way are then 
separated by their differential migration through a polyacrylamide gel under an electric field 
(SDS-PAGE).
2.8.1.1 Sample preparation for SDS-PAGE
To investigate signalling events occurring in FXIII-adherent platelets; 6-well culture plates 
were coated with either HS (5%), FXIIIa (200ug/mL) or fibrinogen (200ng/mL) overnight at 
4°C. Uncoated surfaces were blocked for 30min with HS (5%). Washed platelets (5xl08 
platelets/mL) were added to the wells in the presence of apyrase (lU/mL) and indomethacin 
(10nM) to preclude signalling events downstream of secreted ADP and TXA2 respectively. 
Platelets were allowed to adhere for 45min at 37°C. For each investigated parameter, 
duplicate wells were prepared in order to increase the yield of adherent platelets. Non- 
adherent platelets were removed by 2 washes with PBS and adherent platelets lysed with 
ice-cold Laemmli buffer (4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 50mM trizma base, 
bromophenol blue (trace), pH 6.8). Lysates were scraped from the wells using a rubber 
policeman, transferred to eppendorfs and left on ice for 30min. They were then centrifuged 
at 85000 for 5min to pellet insoluble debris. The supernatant was separated and retained in
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fresh eppendorfs. Aliquots were withdrawn to measure protein concentration (section
2.8.1.2).
2.8.1.2 Protein Assay
To facilitate equal protein loading of samples during electrophoresis, their protein 
concentrations were quantified using a Bio-Rad detergent compatible (DC) protein assay kit 
(Bio-Rad, UK). The principle of the assay stems from reactions occurring between proteins in 
alkaline copper tartrate solution and Folin reagent. Firstly, the proteins reduce copper in an 
alkaline medium which then reduces Folin reagent turning it from yellow to blue in colour 
with maximal light absorption at 750nm (Lowry et al., 1951). The change in light absorption 
can then be detected using a plate reader or a spectrophotometer.
BSA was used as protein standard and 5 dilutions (0.3, 0.6, 0.9, 1.2 and 1.5mg/mL) were 
prepared in modified Laemmli buffer to measure protein concentrations of whole-cell lysates 
or immunoprecipitation lysis buffer to measure that of immunoprecipitates. Samples and 
protein standards were added to the wells of a microplate in triplicate. This was followed by 
addition of copper tartate solution and Folin reagent. The microplate was then placed on a 
shaker for 15 minutes. Light absorption at 750nm was determined using a plate reader. 
Absorption values from the protein standards were used to plot a standard curve from which 
protein concentrations of the samples were derived by interpolation.
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2.8.1.3 Methodology used for SDS-PAGE
All samples were run under discontinuous SDS-PAGE under reducing conditions according to 
the method of Laemmli (1970) (Figure 2.5; points 1 and 2). 1.5mm thick polyacrylamide gels 
comprising 4% acrylamide stacking gels (pH 6.8) overlying 10-18% gradient acrylamide 
resolving gels (pH 8.8) were prepared to separate proteins (Table 1). The stacking gel 
contained wells for protein loading and 30u,g of sample protein were loaded in each well. 
Biotinylated and prestained protein molecular weight markers were also added alongside the 
samples. After running buffer (25mM trizma base, 192mM glycine, 0.1% w/v SDS, pH 8.3) had 
been added to a gel tank, gels were left to run at a constant voltage (120V) for 2.5 hours. 
Under these conditions, proteins had net negative charges and migrated downwards toward 
the anode.
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1. Proteins are loaded into the stacking 
gel and electric current applied for SDS- 
PAGE. Due to the alkaline running 
buffer, they migrate to the anode.
Gel in running 
buffer
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2. In the resolving gel, small 
proteins travel the furthest 
and large proteins the least, 
thus separating the mixture.
Power supply
Sponge Gel with
separated
proteins
PVDF membrane
Blotting sheets
3. Proteins are transferred from the gel 
to a PVDF membrane in alkaline buffer 
under an electric field; again moving 
towards the anode.
Photographic film
4. The PVDF membrane is probed with 
protein-specific primary antibodies. 
Subsequent incubation with HRP-linked 
secondary antibodies allows exposure of 
photographic films by ECL.
Figure 2.5: Outline of the procedures involved in separating proteins by SDS-PAGE and 
Western blotting. SDS-PAGE, sodium dodecyl sulphate polyacrylamide gel electrophoresis; 
PVDF, polyvinylidene fluoride; ECL, enhanced chemiluminescence; HRP, horse-radish 
peroxidise.
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Table 1: Composition of polyacrylamide gels used for electrophoretic protein separation
4% stacking gel 10% resolving gel 18% resolving gel
Deionised water
Acrylamide (30%) 
Buffer I * 
Buffer II ** 
Ammonium 
persulphate (10%) 
Tetramethylethyl- 
enediamine
* Buffer I: 1.5M trizma base, 0.4% w/v sodium dodecyl sulphate, pH 8.8
** Buffer II: 0.5M trizma base, 0.4% w/v sodium dodecyl sulphate, pH 6.8
4.87mL
0.75mL
-
1.87mL
75uL
1.418mL
1.182mL
0.886mL
-
18ul
0,708mL
1.961mL
0.886mL
-
18ul
lOul 2uJ 2ul
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2.8.2 Immunoprecipitation
Immunoprecipitation is a method used to isolate proteins from a mixture such as a cell 
extract (Figure 2.6). An antibody selective for a target protein is added to the mixture to form 
antibody-antigen complexes. The complexes are then precipitated by adsorbing the 
antibodies to an insoluble matrix such as agarose or sepharose beads conjugated to protein A 
or G. The latter two proteins derive from bacterial walls and are stably bound by antibody Fc 
regions. Using centrifugation, the beads are pelleted and the supernatant with unwanted 
proteins is aspirated and discarded. After several washes, the antibody-antigen complex is 
liberated from the beads by boiling in Laemmli buffer (Rosenberg, 2005). The isolated protein 
may be further studied through electrophoresis and western blotting (sections 2.8.1 and
2.8.3 respectively). In addition to concentrating proteins that would otherwise be too scant 
to detect by ordinary western blotting, immunoprecipitation enables biochemical analysis of 
single, purified proteins.
2.8.2.1 Methodology used in immunoprecipitation
Platelets were adhered to protein-coated 6-well plates as outlined in section 2.8.1.1. 
Adherent platelets were lysed with immunoprecipitation lysis buffer (150mM NaCI, lOmM 
Tris, ImM EDTA, ImM EGTA, 1% Igepal, ImM PMSF, 5u,g/mL leupeptin, 5u,g/mL aprotinin, 
0.5u,g/mL pepstatin, 2.5mM Na3V04, pH 7.4). Syk, LAT, PLCv2 and SLP-76 were subsequently 
immunoprecipitated as previously described (Riba et al., 2005). Briefly, a suspension of either 
protein A or G sepharose beads (50%, w/v) in TBS-T was prepared (slurry). Equal aliquots of 
slurry were distributed in the required number of eppendorfs. For each target protein, a
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1. Antibodies are incubated 
with protein A/G sepharose 
beads
Antibody
Protein A/G
sepharose
bead
2. Antibody-bead conjugates 
are then added to a protein 
mixture
3. The antibodies are 
allowed to bind their antigen 
(protein targeted for 
isolation)
Target protein
Unwanted protein
Laemmli buffer
4. The mixture is centrifuged to 
deposit the beads in a pellet, 
and the supernatant is removed 
and discarded.
5. After several washes and 
repeating step 4, Laemmli buffer 
is added and the mixture boiled 
to liberate the antibodies and 
proteins from the beads. Further 
separation and analysis by SDS- 
PAGE can then follow.
Figure 2.6: Summary of principles involved in isolating a protein from a mixture bv 
immunoprecipitation.
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predetermined optimal amount of selective antibody was then added to the slurry. An 
isotype-matched control IgG antibody was used to control against non-specific antibody- 
protein interactions. The mixture was incubated with constant agitation for Ihr at 4°C to 
allow antibodies to bind to the beads.
In parallel, lysates were precleared by incubation with aliquots of slurry for Ihr at 4°C with 
agitation. Precleared lysates were centrifuged at 8500g for Imin to pellet the beads and any 
insoluble cell debris. The supernatant was subsequently separated and equally dispensed 
into the eppendorfs containing antibody-bound beads.
The mixture was agitated overnight at 4°C to allow antibodies to bind their target proteins. It 
was then centrifuged at 8500g for Imin to isolate the beads. The supernatant was removed 
and beads washed sequentially, once with lysis buffer and twice with TBS. After these washes 
to remove any proteins remaining from the supernatant, the beads were boiled in Laemmli 
buffer to liberate the antibodies and target proteins. Finally, the isolated proteins were 
separated by SDS-PAGE (section 2.8.1.3) and further analysed by western blotting (section 
2.8.3.1).
2.8.3 Western blotting
To identify specific proteins separated by SDS-PAGE, western blotting is routinely used. This 
involves transferring proteins from a gel to an adhesive matrix such as nitrocellulose or 
polyvinylidene fluoride (PVDF) membranes under an electric field. Once transferred, the
membranes are probed with specific primary antibodies against the targeted proteins. A
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secondary antibody raised against the primary antibody species is then added. Secondary 
antibodies are commonly conjugated to horseradish peroxidise (HRP) which allows the 
detection of their position on the membrane through exposure of photographic film by 
enhanced chemiluminescence (ECL). ECL is the emission of light caused by oxidation of 
luminol by hydrogen peroxide, catalysed by HRP and perpetuated by an "enhancer" such as 
p-coumaric acid (Thorpe et al., 1985, Haan and Behrmann, 2007). The principal methodology 
involved in SDS-PAGE and western blotting is summarised in Figure 2.5.
2.8.3.1 Methodology used in western blotting
Proteins separated by SDS-PAGE (section 2.8.1.3) were transferred to PVDF membranes at 
constant voltage (100V) for 2.5hrs. This involved arranging the gel and membrane in a 
transfer cassette immersed in alkaline transfer buffer (25mM trizma base, 192mM glycine, 
20% v/v methanol, pH 8.3) as shown schematically in Figure 2.5 (point 3). Under these 
conditions, proteins migrating towards the anode were captured by the PVDF membrane. 
The membranes were blocked with BSA/TBS-T (10%, w/v) for Ihr to prevent non-specific 
antibody binding and subsequently probed with an anti-phosphotyrosine monoclonal 
antibody (1:1000 in 2% BSA/TBS-T) overnight at 4°C. The membranes were rinsed with TBS-T 
for 10 minutes, probed with HRP-conjugated secondary antibodies; anti-rabbit or anti-mouse 
(both 1:10000) and anti-biotin (1:2000) for 1 hr, washed with TBS-T (4 washes, 15 minutes 
each). Membranes were incubated with enhanced chemiluminescence (ECL) solutions for 90s 
and used to expose photographic film for times ranging from 5s to lOmin.
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In some cases, membranes were subsequently stripped by agitated incubation with Restore™ 
western blot stripping buffer (Thermo Scientific, UK) for 20min at room temperature 
followed by two lOmin washes with TBS-T as per manufacturer's instructions. After blocking 
with BSA/TBS-T (10%, w/v) for 30min, the membranes were reprobed overnight with anti-3- 
tubulin (1:1000) to assess equal loading of proteins in each lane. For immunoprecipitation 
experiments (2.8.2.1), equal protein loading was assessed using the same antibodies that had 
been used to immunoprecipitate each protein. Namely, these were: anti-Syk (1:1000), anti- 
LAT (1:1000), anti-PLCy2 (1:1000), anti-SLP-76 (1:1000) or anti-FXIII-A (1:1000).
2.9 Statistical analysis
Results are expressed as means ± standard deviation (SD) and were analysed using the 
Student's t-test or analysis of variance (ANOVA) as described in the relevant sections. 
Statistical significance was taken at levels P<0.05 and P<0.01. Statistical tests were applied 
using Microsoft Office Excel (2007) and the Statistical Package for Social Sciences (SPSS, 
version 15).
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CHAPTER 3 - IMMOBILISED FXIII SUPPORTS PLATELET ADHESION 
AND SPREADING
3.1 Introduction
Physiologically, platelets adhere to suspended proteins such as fibrinogen as well as 
immobilised proteins like collagen (Ruggeri and Mendolicchio, 2007, Rivera et al., 2009). 
Although numerous studies have investigated platelet binding to FXIII in suspension 
(Greenberg and Shuman, 1984, Kreager et al., 1988, Cox and Devine, 1994, Nagy et al., 2009), 
to date only a single unconfirmed study has explored these interactions with the immobilised 
enzyme (Dardik et al., 2002b). Findings from this study suggested that both surface- 
immobilised FXIII and FXIIIa support platelet adhesion. However, the independence of the 
adhesive interaction from the enzymatic activity of FXIIIa was not definitively shown nor was 
contamination of the plasma FXIII preparation used with other platelet adhesive proteins 
strictly attested. Moreover, the study did not examine whether physiological platelet 
responses followed adhesion to FXIII, in particular, whether adherent platelets became 
activated and spread.
Characterisation of platelet interactions with immobilised FXIII is of interest because the 
enzyme may localise on the ECM (Blanchy et al., 1986, Kikuchi et al., 1986, Gautheron et al., 
1988), where it cross-links a number of matrix proteins (Mosher, 1984, Bockenstedt et al.,
1986). This reorganisation of the ECM facilitates cell attachment and migration, thereby
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explaining the significant involvement of FXIII in wound healing (Biel et al., 1971, Cario et al., 
1999, Inbal et al., 2005).
Aims:
The experiments described in this chapter were designed to characterise the nature of
platelet adhesion to immobilised FXIII. More specifically, the objectives were to:
• Establish whether platelets can adhere to immobilised FXIII independently of other 
proteins.
• Investigate the importance of FXIII enzymatic activity in supporting platelet adhesion.
• Determine whether FXIII can stimulate platelet spreading.
3.2 Absence of contaminating fibrinogen from Fibrogammin P
Human FXIII used throughout the study was derived from Fibrogammin P; a commercial 
purified and concentrated plasma FXIII preparation. Since plasma FXIII circulates bound to 
fibrinogen (Greenberg and Shuman, 1982, Siebenlist et al., 1996), which is an established 
platelet ligand, it was necessary to test the purity of Fibrogammin P before performing 
platelet adhesion experiments. This was achieved by applying two different methods.
Proteins present in Fibrogammin P were separated by SDS-PAGE and stained with Coomassie 
brilliant blue to reveal their positions within the gel. Fibrogammin P separated into 3 distinct
bands under SDS-PAGE (Figure 3.1A, lane 2). The uppermost band had a molecular weight
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corresponding to FXIII-A2 and FXIII-B2 dimers (approximately 160kDa). The band beneath it 
appeared at the characteristic molecular weight of monomeric FXIII-A and FXIII-B under 
denaturing SDS-PAGE (approximately SOkDa) (Schwartz et al., 1971). According to the 
manufacturer, albumin is the only other protein present in Fibrogammin P apart from FXIII 
(Electronic Medicines Compendium, 2010). Consistent with this, the third observable band 
appeared at the molecular weight of albumin (67kDa; Figure 3.1A, lane 2). To aid with 
identification of proteins, rFXIII-A, fibrinogen and BSA were also loaded into separate wells 
on the same gel. Fibrinogen separated into its three constituent chains (Act, B|3 and y) under 
SDS-PAGE (Figure 3.1A; lane 1). BSA was also used as a negative control for fibrinogen and 
only one protein band (67kDa) was recognisable (Figure 3.1A, lane 4). Importantly, all three 
fibrinogen chains were visibly absent from rFXIII-A (Figure 3.1A, lane 3). Although albumin 
masked the position of fibrinogen Act chains which have a comparable molecular weight 
(64kDa), BP and y chains could not be seen, strongly suggesting the absence of fibrinogen 
from Fibrogammin P (Figure 3.1A, lane 2).
Western blotting was used as secondary methodology to confirm the absence of fibrinogen 
from Fibrogammin P. After separation of fibrinogen, Fibrogammin P, rFXIII-A and BSA by SDS- 
PAGE, they were transferred to PVDF membranes which were probed with a polyclonal anti- 
fibrinogen antibody (Figure 3.IB). The antibody detected all three fibrinogen chains in the 
positive control (Figure 3.1B, lane 1). However, none could be detected in the BSA negative 
control (Figure 3.1B, lane 4), Fibrogammin P (Figure 3.IB, lane 2) or rFXIII-A (Figure 3.IB, lane 
3).
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Figure 3.1: The purity of Fibroeammin P and recombinant FXIII-A as assessed bv SDS-PAGE 
and immunoblotting. The purities of Fibrogammin P and recombinant FXIII-A (rFXIII-A) were 
assessed by gel electrophoresis and immunoblotting. Fibrinogen, Fibrogammin P, rFXIII-A and 
bovine serum albumin (BSA) were loaded onto a 10-18% gradient polyacrylamide gel (20u.g 
of protein/well except for rFXIII-A: 4u,g/well). Electrophoresis was then carried out for 2.5h at 
120V under reducing conditions. (A) Proteins in the gel were stained with Coomassie blue 
staining solution before being photographed. (B) Proteins were transferred to polyvinylidene 
fluoride (PVDF) membranes for 2.5h at 100V, and immunoblotted with a polyclonal anti- 
fibrinogen antibody overnight at 4°C. Membranes were then incubated with a HRP- 
conjugated secondary antibody for Ih at room temperature and used to expose 
photographic film by enhanced chemiluminescence (ECL). Blots are representative of 4 
independent experiments with the individual batches of Fibrogammin P used in this study. 
Labelled in lane 1 are the 3 constituent chains of fibrinogen. MW: molecular weight. IB: 
Immunoblot.
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3.3 FXIII-A is present in Fibrogammin P and & rFXIII-A
Having ensured the absence of contaminating fibrinogen, the presence of FXIII-A in 
Fibrogammin P was tested by immunoblotting using a FXIII-A specific monoclonal antibody. 
The antibody detected a distinct band in Fibrogammin P at the expected molecular weight of 
FXIII-A (83kDa) (Figure 3.2A, lane 1). The antibody also detected a band of identical molecular 
weight in a lane loaded with rFXIII-A (Figure 3.2A, lane 2), but failed to bind in a BSA negative 
control (Figure 3.2A, lane 3). Thus, FXIII-A was present in both Fibrogammin P and the 
recombinant FXIII-A preparation. Moreover, human and recombinant FXIII-A were 
indistinguishable in terms of molecular weight.
Since human serum was to be used as a blocking agent, it was also analysed for FXIII-A 
content by western blotting using a monoclonal antibody specific for FXIII-A subunits. In 
contrast to Fibrogammin P which displayed a distinct band representing FXIII-A (Figure 3.2B, 
lane 1), none was detected in the human serum preparation (Figure 3.2B, lane 2). The human 
serum was therefore considered free from FXIII-A, and was not expected to influence 
analyses of FXIII-mediated platelet adhesion.
3.4 Enzymatic activation of FXIII by thrombin in vitro
Fibrogammin P (FXIII) and rFXIII were incubated with thrombin (lOU/ml) in the presence of 
calcium (lOmM) and transglutaminase activity was monitored by measuring cross-linking of
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biotinylated pentylamine to immobilised fibrinogen using the method of Song (1994) (section 
2.3.2) without further addition of thrombin and calcium. Under this method, FXIIIa and 
rFXIIIa both induced significantly increased absorption values of 1.331 (P<0.01 vs FXIII) and 
1.318 (P<0.01 vs rFXIII) compared to their respective controls. Importantly, both appeared to 
have similar specific activity as there was negligible difference in their absorption values 
(P>0.05). In contrast FXIII and rFXIII induced no cross-linking as evidenced by minimal light 
absorption values of 0.105 and 0.101 respectively (P>0.05) (Figure 3.3). Similarly, catalase, 
which was used as a negative control for transglutaminase activity, also gave a low 
absorption value of 0.100 (P>0.05 vs FXIII and rFXIII). These data, show that FXIIIa and rFXIIIa 
acquired transglutaminase activity under the conditions used to activate them.
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Figure 3.2: FXHI-A subunits are present in Fibrogammin P and recombinant FXtll-A. but not 
human serum. (A) Fibrogammin P, recombinant FXIII-A (rFXIII-A) and bovine serum albumin 
(BSA) were loaded onto a 10-18% gradient polyacrylamide gel (20u.g of protein/well except 
for rFXIII-A: 4u,g/well). Electrophoresis was then carried out for 2.5h at 120V under reducing 
conditions. Proteins were then transferred to polyvinylidene fluoride (PVDF) membranes for 
2.5h at 100V, and probed with a monoclonal anti-FXIII-A antibody overnight at 4°C. 
Membranes were then incubated with a HRP-conjugated secondary antibody for Ih at room 
temperature and used to expose photographic film by enhanced chemiluminescence (ECL). 
The blot is representative of those from 4 independent experiments with the individual 
batches of Fibrogammin P used in this study. (B) As in (A) except human serum (20u,g of 
protein/well) was also loaded in the gel. MW: molecular weight. IB: Immunoblot.
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Figure 3.3: Factor XIII acquires transglutaminase activity following activation in vitro.
Plasma factor XIII (FXIM, 200u.g/mL) and recombinant human factor XIII-A (rFXIII, 200u.g/mL) 
were incubated with thrombin (lOU/mL) in the presence of calcium (lOmM) for Ih at 37°C. 
Thrombin was then inactivated by addition of Phe-Pro-Arg-Chloromethylketone (PPACK, 
20u.M) for lOmin at 37°C. Transglutaminase activity was measured by amine incorporation 
into fibrinogen as described by Song et al., (1994). Briefly, wells of a 96-well microplate were 
coated with fibrinogen (40u.g/mL) for 45min and uncoated surfaces blocked with BSA/TBS 
(1%) for Ih at room temperature. The following were then added at the indicated final 
reactive concentrations: FXIM, FXIIIa, rFXIII, rFXIIIa and catalase (all 22u.g/mL), 5- 
(biotinamido)pentylamine (ImM) and dithiothreitol (O.SmM) and left for lOmin. 
Streptavidine-alkaline phosphatase (lug/mL in 0.1% BSA/TBS) was added for Ih to conjugate 
specifically with fibrinogen-bound 5-(biotinamido)pentylamine then the wells were 
incubated with p-nitrophenylphosphate for 30min at 37°C. NaOH (4M) was subsequently 
added to stop colour development and optical density measured at 405nm using a 
microplate reader. Data shown are mean ± SD of 3 independent experiments. **: P<0.01.
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3.5 PPACK eliminates thrombin reactivity with platelets
Since FXIII was activated by thrombin, a potent platelet agonist (Crawley et al., 2007), it was 
important to establish that any residual platelet activating potential of thrombin was 
completely eliminated by PPACK as previously described (Dardik et al., 2002b). PPACK 
(20(iM) eliminated thrombin-stimulated platelet aggregation when applied to thrombin 
(lOU/mL) separately or within FXIIIa (200ng/mL) (Figure 3.4A). Moreover, when PPACK- 
treated thrombin was immobilised on glass slides it failed to support any platelet adhesion 
beyond that of human serum used to block platelet adhesion to uncoated glass (P>0.05) 
(Figure 3.4B). This was consistent with a previous report where PPACK inhibited thrombin 
activity and its ability to support platelet adhesion (Weeterings et al., 2006).
3.6 Platelets adhere to FXIII and FXIIIa under static conditions 
3.6.1 FXIII and FXIIIa support similar levels of platelet adhesion
The ability of immobilised native and activated FXIII to support platelet adhesion was 
examined by a colorimetric assay (Bellavite et al., 1994) Washed platelets (Ixio8 
platelets/mL) were adhered to either FXIII or FXIIIa (both 200u,g/mL) immobilised on the 
wells of a microplate. Using this methodology, platelets were found to bind to both forms of 
enzyme to a similar extent, with absorption values of 0.92±0.10 for FXIII compared to 
0.91±0.13 for FXIIIa (P>0.05) (Figure 3.5). In comparison, fibrinogen (200ng/mL) supported a 
significantly greater level of platelet adhesion as evidenced by an absorption value of
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1.621±0.154 (P<0.05 vs FXIII and FXIIIa). As previously described, human serum supported 
negligible platelet adhesion (Maxwell et al., 2007), giving an absorption value of 0.208±0.012 
(P<0.01 vs FXIII and FXIIIa, ANOVA).
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Figure 3.4: PPACK-treated thrombin neither stimulates platelets nor supports their 
adhesion. (A) Thrombin (lOU/mL) was used to stimulate aggregation of washed platelets 
(3xi08 platelets/mL) for 3min at 37°C under constant stirring (lOOOrpm). Platelet aggregation 
was measured using a Chrono-log dual channel light-transmission aggregometer and 
aggregation traces were generated by Aggro/Link computer software (Chrono-log, USA). In 
some cases thrombin was pretreated with Phe-Pro-Arg-Chloromethylketone (PPACK, 20u.M) 
for lOmin at 37°C. FXIIIa containing thrombin (lOU/mL) which had been similarly inhibited by 
PPACK was also assessed for its ability to stimulate platelet aggregation. Shown are 
representative traces of 3 independent experiments with separate blood donors. (B) Glass 
slides were coated overnight with human serum or thrombin (lOU/mL) which had been 
incubated with PPACK (20u.M) for lOmin at 37°C. Uncoated surfaces were blocked by overlay 
with human serum (5%) for 30min at room temperature. Washed platelets (5xl07 
platelets/mL) were then allowed to adhere to each surface for 1 hour at 37°C. Adherent 
platelets were stained with TRITC-phalloidin and viewed under the x60 objective of an 1X71 
fluorescent microscope (Olympus, Japan). Platelets from random visual fields with a total 
area of O.lmm2 were counted. Data shown are means ± SD and are from 3 independent 
experiments with separate blood donors. NS: not significant.
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Figure 3.5: Platelets adhere equally to immobilised FXIII and FXIIIa as measured by the 
microplate method of Bellavite et al.. (1994). Wells of a 96-well microplate were coated 
overnight with inactive or activated factor XIII (FXIII and FXIIIa respectively, 200u.g/mL), 
human serum (5%) or fibrinogen (200|ig/mL). Uncoated surfaces were blocked by overlay 
with human serum (5%) for 30min at room temperature. Washed platelets (Ixio8 
platelets/mL) were then allowed to adhere to each surface for 1 hour at 37°C. Adherent 
platelets were incubated with reaction buffer (31mM citric acid, 5mM sodium citrate 
dehydrate, 5mM p-nitrophenylphosphate, 0.1% (v/v) Triton X-100, pH 5.4) for 1 hour at room 
temperature. The reaction was stopped by addition of NaOH (2M) to each well and optical 
density measured at 405nm. Data shown are means ± SD from 4 independent experiments 
with separate blood donors. **: P<0.01, *: P<0.05, NS: not significant.
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The colorimetric assay suggested that FXIII and FXIIIa supported platelet adhesion equally, 
but it was important to confirm these findings by an independent method and perform a 
visual analysis to ensure that the increased absorption was due to adhesion and not 
aggregation or agglutination. Platelets were therefore adhered to wells on glass microscope 
slides coated with FXIII and FXIIIa (both adjusted to 200u.g/mL) (section 2.5.2.1). FXIII(a) at a 
concentration of 200u.g/mL (lOU/mL) has previously been shown to support quantifiable 
platelet adhesion under static conditions (Dardik et al., 2002b). In addition, washed platelets 
were used at a concentration of 5xi07 platelets/mL which allowed them to adhere as a 
monolayer of single cells that could be counted separately under this methodology 
(Hagmann, 1993). Both FXIII and FXIIIa supported platelet adhesion when they were 
immobilised on the slides. Similar numbers of adherent platelets were observed on each 
surface with 783±108 platelets/0.1mm2 for FXIII compared to 713182 platelets/O.lmm2 for 
FXIIIa (P>0.05), suggesting equal platelet binding capacities (Figure 3.6). This was 
reproducible with native and activated forms of the recombinant enzyme with 548±92 
platelets/O.lmm2 adhering on rFXIII compared to 608±155 platelets/O.lmm2 for rFXIIIa 
(PXJ.05). Platelets also adhered readily to slides coated with fibrinogen (200|ig/mL) which 
was used as a positive control. In fact, fibrinogen supported 1711±233 platelets/O.lmm2, 
significantly more than FXIII and FXIIIa (P<0.05, ANOVA). Importantly, negligible platelet- 
binding (33112 platelets/O.lmm2 ) occurred on slides coated with human serum as a negative 
control.
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Figure 3.6: Platelets adhere similarly to FXIII and FXIIIa immobilised on glass slides as 
measured bv fluorescence microscopy. Glass slides were coated overnight with inactive or 
activated factor XIII (FXIII and FXIIIa respectively, 200u.g/mL), inactive or activated 
recombinant factor XIII-A (rFXIII and rFXIIIa respectively, 200u.g/mL) or fibrinogen 
(200u.g/mL). Uncoated surfaces were blocked by overlay with human serum (HS, 5%) for 
SOmin at room temperature. Washed platelets (5xl07 platelets/mL) were then allowed to 
adhere to each surface for Ih at 37°C. Adherent platelets were stained with TRITC-phalloidin 
and viewed under the x60 objective of an 1X71 fluorescent microscope (Olympus, Japan). 
Platelets from random visual fields with a total area of O.lmm2 were counted. Data shown 
are means ± standard deviation and are from 4 independent experiments with separate 
blood donors.
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3.6.2 Adherent platelets spread on immobilised FXIII and FXIIIa
Platelet adhesion to immobilised reactive proteins stimulates spreading responses (Behnke 
and Bray, 1988). To examine if this occurred with FXIII, washed platelets adherent on slides 
coated with either FXIII or FXIIIa (both 200u.g/ml_) were stained for filamentous actin (F-actin) 
using TRITC-phalloidin (section 2.5.2.1). This allowed observation of their actin-based 
cytoskeleton using fluorescence microscopy. Platelets adherent on both surfaces showed 
activatory morphological changes including filopodia extension and lamellipodia formation 
(Figure 3.7A). After 1 hour, most platelets were fully spread, displaying actin stress fibres. 
FXIII and FXIIIa stimulated platelet spreading to similar extents giving platelet surface areas of 
24±5 and 28±3um2 (P>0.05) respectively. Moreover, this was comparable to spreading 
occurring on rFXIII, rFXIIIa and fibrinogen (all 200u.g/mL) where platelet surface areas were 
25±5, 26±3 and 24±lu,m2 respectively (P>0.05, ANOVA) (Figure 3.7B). Thus, in addition to 
supporting comparable levels of platelet adhesion, both FXIII and FXIIIa activated adherent 
platelets to induce spreading.
3.6.3 The influence of FXIII and FXIIIa concentration on platelet adhesion
Microscope slides were coated with a range of FXIII and FXIIIa concentrations (0-400u,g/mL) 
and platelets adhered for 1 hour. Increasing the concentration of FXIII or FXIIIa resulted in 
proportional increases of adherent platelet numbers (Figure 3.8). Measuring the Pearson 
product moment correlation coefficient (r) for the number of adherent platelets against 
protein concentration gave r values of 0.96 (P<0.01) and 0.98 (P<0.01) for FXIII and FXIIIa 
respectively. This indicated closely linear relationships between adherent platelet numbers
and FXIII or FXIIIa concentration up to the highest concentration studied. Moreover,
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differences in adherent platelet numbers between FXIII and FXIIIa at each concentration 
were statistically insignificant, suggesting that both enzyme forms had an equal tendency to 
support more adherent platelets with an increase in their concentration (Figure 3.8).
3.6.4 The influence of time on FXIII/FXIIla-mediated platelet adhesion
To study the effect of time on platelet adhesion, slides were coated with FXIII and FXIIIa 
(both 200u,g/mL) and platelets adhered for up to 90min. Increasing the incubation time led to 
a proportional increase in platelet adhesion to both forms of the enzyme (Figure 3.9). The 
association between time and adherent platelet numbers was again investigated using the 
Pearson product moment correlation coefficient. Here, r values of 0.98 (P<0.01) and 0.99 
(P<0.01) were obtained for FXIII and FXIIIa respectively, indicating strong linear correlation 
between adherent platelet numbers and time during the 90 minutes studied. No statistically 
significant differences between platelet numbers on FXIII and FXIIIa were observed at each 
time point (P>0.05), suggesting that platelet adhesion on both surfaces was similarly 
dependent on time. In comparison, human serum did not support significant platelet 
adhesion even after 90min.
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Figure 3.7: Platelets adherent on factor XIII become stimulated and spread. Wells on glass 
slides were coated overnight with inactive or activated factor XIII (FXIII and FXIIIa 
respectively, 200u.g/mL), inactive or activated recombinant factor XIII (rFXIII and rFXIIIa 
respectively, 200u,g/mL) or fibrinogen (200u.g/mL). Uncoated surfaces were blocked by 
overlay with human serum (5%) for 30min at room temperature. Washed platelets (5xl07 
platelets/mL) were then allowed to adhere to each surface for Ihr at 37°C. Adherent 
platelets were stained for filamentous actin (F-actin) with TRITC-phalloidin and viewed under 
the x60 oil immersion objective of an 1X71 fluorescent microscope (Olympus, Japan). (A) 
Shown are representative images from 4 independent experiments with separate blood 
donors. (B) The images were used to evaluate platelet spreading using ImageJ software (NIH, 
USA) with data here presented as the mean platelet surface area ± SD. NS: not significant.
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Figure 3.8: Numbers of platelets adherent to FXMI and FXIUa increase with enzyme 
concentration. Glass slides were coated overnight with inactive or activated factor XIII (FXIII 
and FXIIIa respectively, 20-400u,g/mL) and uncoated surfaces blocked by overlay with human 
serum (HS, 5%) for 30min at room temperature. Washed platelets (5xl07 platelets/mL) were 
then adhered to either FXIII (circles) or FXIIIa (squares) for Ih at 37°C. Adherent platelets 
were stained with TRITC-phalloidin (10u,g/mL) for Ih at room temperature then observed 
under the x60 objective of an 1X71 fluorescence microscope (Olympus, Japan). Platelets from 
random visual fields with a total area of O.lmm2 were counted. Data are from 3 independent 
experiments with separate blood donors and are presented as mean ± SD. NS: not significant 
(for FXIII vs FXIIIa).
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3.7 The role of enzymatic activity in platelet adhesion to FXIII 
3.7.1 The influence of transelutaminase activity on platelet adhesion
The similar levels of platelet adhesion observed on FXIII and FXIIIa-coated surfaces (Figures 
3.5 and 3.6) suggested that FXIII transglutaminase activity was not involved in these events. 
In order to confirm this, rFXIIIa was treated with iodoacetamide, an alkylating agent which 
irreversibly blocks its catalytic site (Curtis et al., 1974, Prasa and Sturzebecher, 2002). 
Consistent with a previous report (Dardik et al., 2003), incubation of rFXIIIa (200u.g/mL) with 
iodoacetamide (3mM) inhibited transglutaminase activity of FXIII, as evidenced by a 
reduction in absorption values with the transglutaminase activity assay (section 2.3.2) from 
1.265 to 0.110 with iodoacetamide (P<0.05) (Figure 3.10). In fact, absorption values were 
similar to those of rFXIII and catalase (0.103 and 0.101 P>0.05, ANOVA), indicating that 
iodoacetamide completely blocked FXIIIa transglutaminase activity under these conditions 
(Figure 3.10). lodoacetamide-treated rFXIIIa (200u.g/mL) was then immobilised on glass slides 
and its ability to support platelet adhesion assessed. In the control, rFXIIIa supported the 
adhesion of 713±82 platelets/O.lmm2 which was maintained at 5891103 platelets/O.lmm2 
when it had been treated with iodoacetamide (P>0.05 vs rFXIIIa control) (Figure 3.11).
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Figure 3.9: Numbers of platelets adherent to FXIII and FXIIIa increase with time. Glass slides 
were coated overnight with inactive or activated factor XIII (FXIII and FXIIIa respectively, 
200ug/mL) and uncoated surfaces were blocked by overlay with human serum (HS, 5%) for 
30min at room temperature. Washed platelets (5 x io7 platelets/mL) were then adhered to 
FXIII (circles), FXIIIa (squares) or HS (triangles) for different times (15-90 minutes) at 37°C. 
Adherent platelets were stained with TRITC-phalloidin (10u.g/mL) for Ih at room temperature 
then observed under the x60 objective of an 1X71 fluorescence microscope (Olympus, Japan). 
Platelets from random visual fields were counted. Data are from 3 independent experiments 
with separate blood donors and are presented as mean ± SD. NS: not significant (for FXIII vs 
FXIIIa).
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Figure 3.10: Iodoacetamide ablates factor XIII transglutaminase activity. Activated 
recombinant factor XIII-A (rFXIIIa, 200u.g/mL) was treated with iodoacetamide (lo, 3mM) for 
30min at 20°C to inhibit transglutaminase activity (Dardik et al., 2003). Transglutaminase 
activity was then measured by amine incorporation into fibrinogen as described by Song et 
al., (1994). For comparison, the transglutaminase activities of inactive recombinant factor 
XIII-A (rFXIII, 200u.g/mL) and catalase (200u,g/mL) were also measured. Data shown are mean 
± SD of 3 independent experiments. *: P<0.05, NS: not significant.
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Figure 3.11: FXIIIa-mediated platelet adhesion does not depend on its transglutaminase 
activity. Wells on glass slides were coated overnight with activated recombinant factor XIII 
(rFXIIIa, 200u,g/mL) and uncoated surfaces were blocked by overlay with human serum (HS, 
5%) for SOmin at room temperature. In some cases, rFXIIIa was incubated with 
iodoacetamide (3mM) at 20°C for 30min to inhibit transglutaminase activity (Dardik et al., 
2003) prior to immobilisation on the slides. Washed platelets (5xi07 platelets/mL) were then 
allowed to adhere on coated slides for Ih at 37°C. Adherent platelets were stained with 
TRITC-phalloidin (10u.g/mL) for Ih at room temperature then observed under the x60 
objective of an 1X71 fluorescence microscope (Olympus, Japan). Adherent platelets from 
random visual fields were counted. Data are from 3 independent experiments with separate 
blood donors and are presented as mean ± SD. NS: not significant.
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3.7.2 The influence of protein disulphide isomerase activity on platelet 
adhesion
It had recently been reported that FXIII possesses protein disulfide-isomerase (PDI) activity 
which is independent of its function as a transglutaminase (Lahav et al., 2009). Thus, the 
potential involvement of PDI activity in platelet binding to FXIII was investigated. rFXIIIa was 
incubated with bacitracin (ImM), an established inhibitor of PDI activity (Mandel et al., 
1993), for 1 hour at 37°C (Lahav et al., 2009), prior to measuring platelet adhesion. 
Incubation of FXIIIa with bacitracin did not affect platelet binding to rFXIIIa (713±82 vs 
755±115 platelets/O.lmm2 for the absence and presence of bacitracin respectively) (Figure 
3.12). Together with data obtained with transglutaminase inhibitors, these results suggest 
that platelet binding to FXIII occurs independently of any recognised inherent enzymatic 
activity.
3.8 Dependence of platelet adhesion on the structure of FXIII-A
Data obtained with iodoacetamide and bacitracin suggested that platelets may bind to FXIII-A 
on a region(s) distinct from a catalytic site. To further investigate the availability of its binding 
site(s) to platelets, rFXIII and rFXIIIa were heat-denatured to distort their protein 
conformations. Heat-treatment prior to immobilisation ablated their ability to support 
platelet adhesion, diminishing it from 713±82 and 648±92 platelets/O.lmm2 to 58±15 and 
64±13 platelets/O.lmm2 respectively (P<0.01) (Figure 3.13). This suggested a dependence of 
adhesion events on specific higher level FXIII protein structure.
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Figure 3.12: FXIII-mediated platelet adhesion does not depend on its Protein Disulphide 
Isomerase (PDI) activity. Wells on glass slides were coated overnight with activated 
recombinant factor XIII (rFXIIIa, 200u.g/mL) and uncoated surfaces were blocked by overlay 
with human serum (HS, 5%) for SOmin at room temperature. In some cases, rFXIIIa was 
incubated with bacitracin (ImM) at 37°C for Ih to inhibit PDI activity (Lahav et al., 2009) prior 
to immobilisation on the slides. Washed platelets (5xl07 platelets/mL) were then allowed to 
adhere on coated slides for Ih at 37°C. Adherent platelets were stained with TRITC-phalloidin 
(10u.g/mL) for Ih at room temperature then observed under the x60 objective of an 1X71 
fluorescence microscope (Olympus, Japan). Adherent platelets from random visual fields with 
a total area of O.lmm2 were counted. Data are from 3 independent experiments with 
separate blood donors and are presented as mean ± SD. NS: not significant.
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Figure 3.13: Correct factor XIII protein conformation is required for platelet adhesion. Wells 
on glass slides were coated overnight with inactive and activated recombinant factor XIII 
(rFXIII and rFXIIIa respectively, both 200u.g/mL) and uncoated surfaces were blocked by 
overlay with human serum (HS, 5%) for 30min at room temperature. In some cases, rFXIII and 
rFXIIIa were denatured by incubation at 60°C for Ih prior to immobilisation on the slides. 
Washed platelets (5xl07 platelets/mL) were then allowed to adhere on coated slides for Ih 
at 37°C. Adherent platelets were stained with TRITC-phalloidin (10u.g/mL) for Ih at room 
temperature then observed under the x60 objective of an 1X71 fluorescence microscope 
(Olympus, Japan). Adherent platelets from random visual fields were counted. Data are from 
3 independent experiments with separate blood donors and are presented as mean ± SD. *: 
P<0.05, **: P<0.01.
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3.9 Platelet adhesion to FXIII occurs independently of proteins 
secreted from a-granules
Platelet a-granules contain vWF, fibrinogen, thrombospondin and fibronectin which are 
ligands for platelet adhesion as well as FXIII substrates (Muszbek et al., 1999). While the 
absence of contaminating proteins from Fibrogammin P and rFXIII-A had been established 
(section 3.2), it remained feasible for platelet binding to be indirectly mediated by secreted 
a-granule proteins which interacted with the immobilised FXIIIa surface.
To determine whether FXIIIa-adherent platelets indeed secreted their a-granule contents, 
adherent platelets were probed with FITC-conjugated antibodies against surface P-selectin 
and fibrinogen, two markers for a-granule secretion (Holmsen and Weiss, 1979, Rendu and 
Brohard-Bohn, 2001). Adherent platelets secreted their a-granule contents as indicated by 
increased expression of both P-selectin and fibrinogen on their surfaces (Figure 3.14A). To 
assess whether secreted a-granule proteins contributed to platelet adhesion, platelets were 
treated with PKC antagonists that inhibit granular secretion (Konopatskaya et al., 2009, 
Harper and Poole, 2010) prior to adhesion. The PKC antagonists Ro-31-8220 and BIM I (both 
10u,M) prevented secretion as evidenced by a lack of surface-expressed fibrinogen and P- 
selectin. However, BIM V (10u.M), an inactive analogue was without effect (Figure 3.14A). 
Importantly, the extent of platelet adhesion was unaffected by inhibiting secretion since 
adherent platelet numbers in the control (850±246 platelets/O.lmm2 ) were maintained 
under treatment with Ro-31-8220, BIM I and BIM V (705±93, 781157 and 695±57
platelets/O.lmm2 respectively; P>0.05, ANOVA) (Figure 3.14B).
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Inhibition of granular secretion by Ro-31-8220 and BIM I was confirmed by lumi- 
aggregometry (section 2.7.2). Here, platelet dense granule secretion induced by PMA 
(lOOnM), a specific PKC agonist, was abolished by BIM I and Ro-31-8220, but unaffected by 
BIM V (Figure 3.15). These data together with those showing platelet adhesion to plasma 
protein-free recombinant FXIII-A (Figure 3.6), strongly suggest that FXIII-A supports platelet 
adhesion independently of other proteins.
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Figure 3.14: Platelet adhesion to FXIil is independent of secreted granular proteins. Wells 
on glass slides were coated overnight with FXIIIa (200u.g/mL) and uncoated surfaces were 
blocked by overlay with human serum (HS, 5%) for SOmin at room temperature. Washed 
platelets (5xl07 platelets/mL) were incubated with the protein kinase C antagonists Ro-31- 
8220 and BIM I (both lO\iM), their inactive analogue BIM V (10u.M) or 0.01% DMSO (control) 
for 20min at 37°C. Treated platelets were allowed to adhere to the coated slides for Ihr at 
37°C. In some cases, adherent platelets were lysed to permeabilise them, followed by 
overlay with TRITC-conjugated phalloidin (10u.g/mL) for Ihr at room temperature. In all other 
instances, lysis was omitted and surface expressed fibrinogen and P-selectin were probed 
using specific FITC-conjugated antibodies for Ihr at room temperature. Platelets were then 
viewed under a fluorescence microscope. (A) Shown are representative images from 3 
independent experiments. (B) Platelets adherent to FXIIIa following each treatment were 
counted and are presented as mean ± SD. Data are from 3 independent experiments with 
separate blood donors. NS: not significant.
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Figure 3.15: Protein kinase C (PKC) inhibitors block platelet granular secretion. Washed 
platelets (3xl08 platelets/mL) were incubated with the PKC antagonists Ro-31-8220 and BIM 
I (both 10u.M) or their inactive analogue BIM V (10u.M) for 20min at 37°C. Secretion of 
adenosine triphosphate (ATP) from platelet dense granules was stimulated with phorbol 
myristate acetate (PMA, lOOnM) under constant stirring conditions (lOOOrpm) and was 
measured over 4min using a Chrono-log dual light-transmission and luminescence 
aggregometer. Luciferin/luciferase (2nM) and ATP (InM) were used as standards for machine 
calibration. Curves were recorded by Aggro/Link software from Chrono-log.
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3.10 Discussion
Interactions between platelets and FXIII were first studied about 25 years ago (Greenberg 
and Shuman, 1984). Since then, subsequent studies have focused almost exclusively on 
characterising platelet-FXIII interactions in suspension, yielding conflicting results. While 
some investigators argued that the ability to bind platelets is restricted to FXIIIa (Greenberg 
and Shuman, 1984, Cox and Devine, 1994), an unconfirmed report suggested that suspended 
FXIII may also bind platelets (Dardik et al., 2002b). In the same study, immobilised FXIII and 
FXIIIa were also shown to support platelet adhesion. However, possible background 
activation of FXIII caused by experimental procedures was not excluded. For instance, it is 
known that FXIII can become activated by conformational change even in the absence of 
thrombin cleavage (Polgar et al., 1990, Muszbek et al., 1993). Since proteins are likely to have 
altered conformations when immobilised on electrostatic surfaces such as glass and plastic 
(Baugh and Vogel, 2004), FXIII could have become activated upon immobilisation resulting in 
only circumstantial evidence for the redundancy of transglutaminase activity in platelet 
binding.
In the present project, particular focus was made on studying platelet associations with 
immobilised FXIII due to its ability to localise at sites of vascular injury either by interacting 
with the ECM (Mosher, 1984, Kikuchi et al., 1986, Sane et al., 1988) or through its 
associations with fibrinogen chains entangled within blood clots (Greenberg and Shuman, 
1982, Siebenlist et al., 1996). Using established methodology to investigate platelet adhesion
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and spreading on protein coated surfaces, the adhesive capacities of FXIII and FXIIIa were
explored.
Since Fibrogammin P contained FXIII sourced from plasma and FXIII circulates bound to 
fibrinogen (Siebenlist et al., 1996), a major platelet ligand, care was taken to ensure that 
potential platelet-adhesive contaminants were absent from Fibrogammin P prior to 
investigating its ability to support platelet adhesion. Using gel electrophoresis and western 
blotting, FXIII and albumin were the only two proteins detectable in Fibrogammin P (Figures 
3.1A and 3.2). Given that platelets do not adhere to the latter, it was not expected to affect 
the results of adhesion experiments. In fact, albumin is the major protein component of 
human serum which was used as a blocking agent to prevent platelet adhesion to glass 
(section 2.5.2.1). Crucially, fibrinogen was undetectable from Fibrogammin P using both gel- 
staining and immunoblotting techniques (Figure 3.1). After this rigorous testing, observations 
of platelet adhesion on immobilised Fibrogammin P were more confidently believed to be 
mediated by FXIII. This was confirmed by reproducible platelet adhesion on immobilised 
recombinant FXIII-A which was not exposed to plasma proteins throughout its synthesis 
(Figure 3.6). A remaining possibility was the secretion of adhesive proteins from platelet a- 
granules and their subsequent localisation on immobilised FXIII. However, effective inhibition 
of platelet secretion failed to affect platelet binding (Figure 3.14). Taken together, these data 
strongly suggest that platelet binding to FXIII can occur independently of other plasma 
proteins. Moreover, such adhesion is stimulatory, resulting in spreading (Figure 3.7) and 
degranulation responses (Figure 3.14A).
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Platelet stimulation appears to be a unique property of immobilised FXIII since it failed to
stimulate platelet shape change or aggregation when added to platelets in suspension 
(Figure 3.4A). This may ensure that FXIII-mediated platelet recruitment and activation are 
restricted to sites of vascular injury where FXIII may become localised (Kikuchi et al., 1986).
Consistent with the report from Dardik et al., (2002b) adhesion experiments revealed that 
under static conditions, both FXIII and FXIIIa supported equal platelet adhesion. This was 
confirmed using two different techniques; a microplate-based method from Bellavite et al., 
(1994) (Figure 3.5) and a fluorescence microscopy-based adhesion assay (Figure 3.6). The 
immediate implication from these data was the redundancy of transglutaminase activity in 
FXIII-mediated platelet binding. This was confirmed by unchanged levels of platelet adhesion 
to rFXIIIa following direct inhibition of its transglutaminase activity with iodoacetamide 
(Figure 3.11). These data therefore suggest that different mechanisms control platelet and 
fibroblast binding to immobilised FXIII since a strict dependence on transglutaminase activity 
was demonstrated for the latter (Ueki et al., 1996). However, consistent with the present 
platelet data, endothelial cells were shown to adhere to immobilised FXIIIa independently of 
its transglutaminase activity (Dallabrida et al., 2000).
If the platelet-binding site(s) on FXIIIa is indeed separate from its catalytic site, it is tempting 
to speculate that platelet-bound FXIIIa remains free to catalyse cross-linkages among its 
substrates on the platelet surface. In fact, FXIIIa was attributed a critical role in the 
development of procoagulant "coated" platelets by cross-linking secreted a-granule
proteins such as vWF, thrombospondin, factor V, vitronectin and fibronectin to serotonin on
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platelet surfaces (Dale et al., 2002). Although the PDI activity of FXIII is also not required for
platelet adhesion (Figure 3.12), it may have a potential haemostatic role since PDI-mediated 
alteration of disulphide bonds in anb33 integrins can induce platelet aggregation (O'Neill et 
al., 2000). However, the physiological consequences of these events and their feasibility in 
vivo are yet to be fully determined.
Platelet binding to FXIII correlated positively with enzyme concentration (Figure 3.8) and 
time (Figure 3.9). Similar dependence on time and concentration was observed for platelet 
adhesion to both FXIII and FXIIIa. This suggests that the platelet-binding site(s) on both 
enzyme forms are equally accessible to platelets. Their availability to platelets is dependent 
on correct protein conformation since platelets failed to bind to denatured FXIII (Figure 3.13). 
The importance of these observations derives from recent reports that elevated FXIII plasma 
levels are associated with predisposition to chronic cardiovascular diseases such as Ml 
(Bereczky et al., 2007) and PVD (Shemirani et al., 2008, Kloczko et al., 1988). Considering that 
more platelets are recruited to surfaces coated with increasing amounts of FXIII (Figure 3.8), 
it is likely that platelet-FXIII interactions may play a role in events leading to these 
pathologies. Such a paradigm is supported by evidence that when in vivo FXIII concentrations 
are raised, platelets more readily bind to activated endothelium typically found in 
atherosclerotic regions of the vasculature (Dardik et al., 2002b). Furthermore, patients with 
PVD have platelets which circulate bound to more FXIII than those of matched controls 
without the disease (Devine et al., 1993).
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In conclusion, the data presented in this chapter have broadly outlined the basic
observations supporting a hypothesised interaction between platelets and immobilised FXIII 
which may have a pathophysiological preponderance. Successive chapters will build upon 
these findings by describing them in finer molecular detail and assessing the practicality of 
their occurrence.
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CHAPTER 4 - INTEGRIN-MEDIATED PLATELET ADHESION TO FXIII 
ENHANCES THROMBUS FORMATION BY EXTRACELLULAR MATRIX 
PROTEINS UNDER FLOW.
4.1 Introduction
The integrin ctnbPs is believed to facilitate platelet-FXIII binding (Cox and Devine, 1994). 
However, platelets from patients with GT retained an ability to bind FXIII despite lacking 
functional a^Ps (Greenberg and Shuman, 1984), suggesting the involvement of additional 
platelet receptor(s).
Physiologically, platelets are exposed to an array of blood flow conditions. In veins where 
blood velocity is low, typical wall shear rates are less than 500 s"1 whereas in small arterioles, 
shear rates can reach 5000 s'1 (Tangelder et al., 1988). Moreover, under pathological 
conditions such as those found in stenosed arteries, shear rates as high as 40 000 s"1 have 
been reported (Bluestein et al., 1997). During thrombus formation, primary platelet adhesion 
occurs on exposed subendothelial ECM proteins, primarily collagen, resulting in the 
deposition of a platelet monolayer (Farndale et al., 2004). Both primary platelet adhesion 
and aggregation are influenced by prevailing haemodynamic conditions (Ruggeri and 
Mendolicchio, 2007). Platelets are able to form adhesive contacts under all shear conditions. 
However, at shear rates higher than 800s"1, platelet interaction with vWF becomes critical for
both primary adhesion and aggregation which drives increase in thrombus volume (Weiss et
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al., 1978b). It is noteworthy that this important role for vWF in platelet thrombus formation
is not immediately apparent when measuring platelet function using optical aggregometry. 
This is because platelets are able to aggregate by binding fibrinogen in the absence of vWF 
under the low shear rates generated in this technique (Jackson, 2007).
Previous studies have demonstrated the ability of platelets to bind FXIII in suspension 
(Greenberg and Shuman, 1984, Cox and Devine, 1994). Dardik et al., (2002b) also reported 
that immobilised FXIII could mediate platelet accrual on activated endothelium. However, 
the occurrence and stability of platelet-FXIII associations with the immobilised enzyme under 
physiological shear have largely remained uncharacterised and their relevance with respect 
to platelet adhesion to the ECM has not been investigated. Due to normal platelet responses 
under optical aggregometry in FXIII-deficient platelets (Ozsoylu and Hicsonmez, 1976), FXIII 
was considered a minor contributor to haemostatic platelet function. However, in light of 
observations which revealed the importance of vWF to platelet thrombus formation (Savage 
et al., 1998), it is important that platelet-FXIII interactions are also examined under 
physiological flow conditions
The ability of FXIII to support platelet adhesion under static conditions was described in 
Chapter 3. Analyses of adhesion events under these conditions were useful for characterising 
responses stimulated in a primary adherent monolayer, particularly spreading events 
(section 3.6). However, since blood flow exerts considerable influence on platelet function, it 
was important that observations made under static conditions were revaluated for
stringency under physiological haemodynamic conditions.
Page | 125
Chapter 4
Aims:
• To identify potential platelet receptors that mediate adhesion to immobilised FXIII.
• To characterise the functional roles of each receptor type in the adhesion process.
• To determine whether adhesive contacts between platelets and FXIII occur in flowing 
blood.
• To examine how such contacts are influenced by differential shear rates that 
accompany the range of blood velocities found physiologically in different vascular 
regions.
• To test whether FXIII influences platelet thrombus formation on established platelet 
adhesive ligands under flow conditions.
4.2 The role of integrins in platelet adhesion to immobilised FXIIIa
4.2.1 Platelet adhesion to FXIIIa is integrin-mediated
Since previous reports had alluded to integrin involvement in platelet adhesion to suspended 
FXIIIa (Cox and Devine, 1994, Nagy et al., 2009), experiments were performed to examine 
whether platelet adhesion to immobilised FXIIIa was also integrin dependent. Washed 
platelets (5xl07 platelets/mL) were incubated with RGDS (500u.M), an integrin-blocking 
peptide that competitively inhibits multiple integrins (Ruoslahti, 1996), prior to adhesion to 
FXIIIa. RGDS diminished platelet adhesion from 923+128 to 102±45 platelets/0.1mm2 
(P<0.01) (Figure 4.1). Importantly, platelet treatment with RGDS reduced platelet adhesion to 
levels similar to those occurring residually on human serum-coated surfaces (36±13 
platelets/0.1mm2, P>0.05 vs RGDS). These data showed that integrins were indispensable for 
adhesion to immobilised FXIIIa.
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Figure 4.1: Platelet adhesion to FXIIIa is integrin dependent. Wells on glass slides were 
coated overnight with heat-inactivated human serum (HS, 5%) or activated FXIII (FXIIIa, 
200u,g/mL). Uncoated surfaces were blocked by overlay with HS (5%) for 30min at room 
temperature. Washed platelets (5xl07 platelets/mL) were preincubated with RGDS (SOOuM) 
or modified Tyrode's buffer (control) for 20min at 37°C then allowed to adhere to the 
indicated surface for 1 hour at 37°C. Adherent platelets were stained with TRITC-phalloidin 
and viewed under the x60 objective of an 1X71 fluorescence microscope (Olympus, Japan). 
Platelets from random visual fields with a total area of O.lmm2 were counted. Data shown 
are means ± SD and are from 4 independent experiments with separate blood donors. **: 
P<0.01, NS: not significant.
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4.2.2 Platelet-FXIIIa binding is mediated bv ctm^ and 0,6,
After establishing the general involvement of integrins in binding immobilised FXIIIa, the 
specific integrin subtypes involved were identified. Platelets were incubated with tirofiban 
(2u,M); a specific aii b(33 antagonist prior to adhesion to FXIIIa. Tirofiban at a concentration of 
2u.M has been shown to completely inhibit ctnbPs integrins (Tanaka et al., 2004, Serebruany et 
al., 2007). Treatment with tirofiban partially reduced platelet adhesion to FXIIIa from 941±42 
to 566172 platelets/0. 1mm2 (P<0.05) (Figure 4.2), demonstrating a role for ctnbPa in this 
process. However, since the inhibitory effect with tirofiban was significantly less than that 
obtained with RGDS (103±90 platelets/O.lmm2; PO.05), it suggested the involvement of 
other integrin receptors. Moreover, inhibition of platelet adhesion to FXIIIa with tirofiban 
differed from that of adhesion to fibrinogen since tirofiban almost abolished platelet 
adhesion to the latter (17111134 to 156±25 platelets/O.lmm2 for the absence and presence 
of tirofiban respectively, P<0.01) (Figure 4.3).
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Figure 4.2: Platelet adhesion to FXIIIa is partially dependent on anhtMnteerins. Wells on 
glass slides were coated overnight with heat-inactivated human serum (HS, 5%) or activated 
factor XIII (FXIIIa, 200ng/mL). Uncoated surfaces were blocked by overlay with HS (5%) for 
30min at room temperature. Washed platelets (5xl07 platelets/mL) were preincubated with 
tirofiban (2uJvl), RGDS (500u,M) or modified Tyrode's buffer (control) for 20min at 37°C then 
allowed to adhere to each surface for Ih at 37°C. Adherent platelets were stained with 
TRITC-phalloidin and viewed under the x60 objective of an 1X71 fluorescence microscope 
(Olympus, Japan). Platelets from random visual fields with a total area of O.lmm2 were 
counted. Data shown are means ± SD and are from 4 independent experiments with separate 
blood donors. *: P<0.05.
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Figure 4.3: Tirofiban ablates platelet adhesion to fibrinogen. but not FXIIIa. Wells on glass 
slides were coated overnight with fibrinogen (200\ig/ml, grey bars) or activated factor XIII 
(FXIIIa) (200u.g/mL, white bars). Uncoated surfaces were blocked by overlay with heat- 
inactivated human serum (5%) for SOmin at room temperature. Washed platelets (5xi07 
platelets/mL) were preincubated with tirofiban (2u.M) or modified Tyrode's buffer for 20min 
at 37°C then allowed to adhere to each surface for 1 hour at 37°C. Adherent platelets were 
stained with TRITC-phalloidin and viewed under the *60 objective of an 1X71 fluorescence 
microscope (Olympus, Japan). Platelets from random visual fields with a total area of O.lmm2 
were counted. Data shown are means ± SD and are from 3 independent experiments with 
different blood donors. **: P<0.01, *: P<0.05.
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The integrin av|}3 mediates monocyte and endothelial cell adhesion to FXIIIa (Ueki et al., 
1996, Dallabrida et al., 2000, Dardik et al., 2002b). It was likely that it also plays a similar role 
in platelets since they also express avp3 (Lam et al., 1989). Platelets were therefore incubated 
with LM609 (20|ig/mL); a specific avp3-blocking antibody (Cheresh and Spiro, 1987, Brooks et 
al., 1994). LM609 at a concentration of 20u,g/mL has previously been shown to fully inhibit 
av |53 integrins (Soldi et al., 1999, May et al., 2002). Treatment with LM609 significantly 
diminished platelet adhesion to FXIIIa from 941±42 to 480191 platelets/O.lmm2 (P<0.01) 
(Figure 4.4). However, similar to inhibition by tirofiban, the effect was less than that 
observed with RGDS (103±90 platelets/O.lmm2, P<0.05 vs LM609). Importantly, no inhibition 
of platelet adhesion was observed when platelets were incubated with a control antibody 
that was non-reactive against avp3 and isotype-matched with LM609 (886±66 
platelets/O.lmm2 P>0.05 vs control). Hence the effects observed with LM609 were not due 
non-specific platelet-antibody interactions. LM609 did not affect platelet adhesion to 
fibrinogen (1769144 vs 1960142 for the absence and presence of LM609 respectively, 
P>0.05) (Figure 4.5). Together with data obtained using tirofiban (Figure 4.3), this further 
distinguished the roles of platelet a^Pa and avp3 integrins in mediating adhesion to 
fibrinogen and FXIIIa.
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Figure 4.4: Platelet adhesion to FXIIIa is partially dependent on oJkjntegrins. Wells on 
glass slides were coated overnight with heat-inactivated human serum (HS, 5%) or activated 
factor XIII (FXIIIa, 200u,g/mL). Uncoated surfaces were blocked by overlay with HS (5%) for 
SOmin at room temperature. Washed platelets (5xl07 platelets/mL) were preincubated with 
LM609 (20u,g/mL), normal mouse IgG (20u.g/mL), RGDS (500u,M) or modified Tyrode's buffer 
(control) for 20min at 37°C then allowed to adhere on the indicated surface for Ihr at 37°C. 
Adherent platelets were stained with TRITC-phalloidin and viewed under the x60 objective of 
an 1X71 fluorescence microscope (Olympus, Japan). Platelets from random visual fields with a 
total area of O.lmm2 were counted. Data shown are means ± SD and are from 3 independent 
experiments with different blood donors. **: P<0.01, *: P<0.05, NS: not significant.
Page | 132
Chapter 4
2500 -i
NS
HS Control LM609
Fibrinogen
Figure 4.5: LM609 does not affect platelet adhesion to fibrinoeen. Wells on glass slides were 
coated overnight with heat-inactivated human serum (HS, 5%) or fibrinogen (200u.g/mL). 
Uncoated surfaces were blocked by overlay with HS (5%) for 30min at room temperature. 
Washed platelets (5xl07 platelets/mL) were incubated with LM609 (20|ig/mL) or modified 
Tyrode's buffer (control) for 20min at 37°C then allowed to adhere for In at 37°C. Adherent 
platelets were stained with TRITC-phalloidin and viewed under the *60 objective of an 1X71 
fluorescence microscope (Olympus, Japan). Platelets from random visual fields with a total 
area of O.lmm2 were counted. Data shown are means ± SD and are from 3 independent 
experiments with different blood donors. NS: not significant.
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Since both a^Ps and av3a demonstrated partial involvement in mediating platelet adhesion 
to FXIIIa, their combined roles in the process were next investigated. Platelets were 
incubated with both tirofiban and LM609 prior to adhesion to FXIIIa. Combined inhibition of 
anbPs and ctv33 abolished platelet adhesion from 941±42 to 68±116 platelets/0.1mm2 
(P<0.01), reducing it to levels similar to those obtained with RGDS (103±90 platelets/0.1mm2, 
P>0.05) (Figure 4.6). Substituting a non-reactive IgG control antibody for LM609 failed to 
enhance the inhibitory effects of tirofiban (6191115 vs 527±7 platelets/O.lmm2 for tirofiban 
in the absence and presence of IgG respectively, P>0.05). This confirmed that the effects with 
LM609 were not due to non-specific antibody interactions with tirofiban or platelets. 
Together, these data suggest that maximal platelet adhesion to FXIIIa requires both allb33 and 
ctvPs integrins.
4.3 Platelet spreading on FXIIIa is dependent on aMbp3, but not avp3
Although both anb33 and av3s mediated platelet adhesion to FXIIIa (Figures 4.2 and 4.4), 
adherent platelets displayed different morphologies when each receptor was blocked in 
isolation. Inhibition of ctnb33 ablated spreading responses in adherent platelets from 31±lu,m2 
to 8±2u,m2 (P<0.01). In contrast, inhibition of av3s did not affect platelet spreading (27±4u,m2 
compared to 31±lu,m2 for the presence and absence of LM609 respectively, P>0.05) (Figure 
4.7). Thus, platelet adhesion and spreading on FXIIIa are differentially mediated by anb33 and 
av33 . While both receptors are required for adhesion, only aMb33 is involved in the stimulation 
of spreading responses.
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Figure 4.6: Platelet adhesion to FXIIIa is dually dependent on ctiibBa and cUigjnteerins. Wells 
on glass slides were coated overnight with heat-inactivated human serum (HS, 5%) or 
activated factor XIII (FXIIIa, 200u.g/mL). Uncoated surfaces were blocked by overlay with HS 
(5%) for 30min at room temperature. Washed platelets (5xi07 platelets/mL) were incubated 
with tirofiban (2u.M), LM609 (20u.g/mL), normal mouse IgG (20u.g/mL), RGDS (500u.M) or 
modified Tyrode's buffer (control) for 20min at 37°C then allowed to adhere for Ih at 37°C. 
Adherent platelets were stained with TRITC-phalloidin and viewed under the x60 objective of 
an 1X71 fluorescence microscope (Olympus, Japan). Platelets from random visual fields with a 
total area of O.lmm2 were counted. Data shown are means ± SD and are from 3 independent 
experiments with different blood donors. NS: not significant, **: P<0.01.
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Figure 4.7: Platelet spreading on FXIIIa is mediated by anhBa. but not a^Bg. Wells on glass 
slides were coated overnight with heat-inactivated human serum (HS, 5%) or activated factor 
XIII (FXIIIa, 200u.g/mL). Uncoated surfaces were blocked by overlay with HS (5%) for 30min at 
room temperature. Washed platelets (5xl07 platelets/mL) were incubated with tirofiban 
(2u.M), LM609 (20u.g/mL), normal mouse IgG (20u.g/mL) or modified Tyrode's buffer (control) 
for 20min at 37°C then allowed to adhere for Ih at 37°C. Adherent platelets were stained 
with TRITC-phalloidin and viewed under the x60 objective of an 1X71 fluorescence 
microscope equipped with an XM10 CCD camera (Olympus, Japan), (i) Shown are 
representative images of adherent platelets captured under fluorescence. Scale Bar = 20u.m. 
(ii) Surface areas covered by individual adherent platelets from random visual fields with a 
total area of O.lmm2 were measured using ImageJ software (NIH, USA). Data shown are 
means ± SD from 3 independent experiments with different blood donors. NS: not significant, 
**: P<0.01.
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4.4 Platelets adhere to FXIIIa under flow
The method of Cooke et al., (1993), was adapted to examine adhesive interactions between 
platelets and immobilised FXIII under physiological flow. Under this method, fluorescently 
stained washed platelets were reconstituted with autologous red blood cells and perfused 
through FXIII-coated glass microslide capillary tubes at various shear rates. Platelet adhesion 
and thrombus formation under these conditions were observed under fluorescent 
videomicroscopy and images of stably adherent platelets captured using a digital camera. 
Images were then used to calculate surface area coverage by adherent platelets as a 
measure of platelet adhesion.
4.4.1 Platelet adhesion to FXIII is shear-dependent
In the first instance, the ability of immobilised FXIII to support platelet adhesion under flow 
was assessed at 300s"1, a shear rate reported to represent venous blood flow using this 
methodology (Wu et al., 1997, Nesbitt et al., 2009). Under these conditions, video analysis 
revealed that platelet adhesion was characterised by rapid, immediate attachment with brief 
rolling in some instances to form an adherent platelet monolayer. Additional platelets were 
subsequently deposited over the monolayer leading to aggregate formation (Figure 4.8A and 
Video 1), suggesting activation and release of secondary agonists (ADP and TXA2) by platelets 
in the monolayer (Ruggeri and Mendolicchio, 2007). Consistent with data obtained under 
static conditions (section 3.6.1), image analysis of platelets adherent under flow revealed
similar surface coverage on zymogen and activated FXIII (6.2±0.4% vs 5.9±0.4% for FXIII and
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FXIIIa respectively P>0.05) (Figure 4.8A). Importantly, no adhesion was observed on BSA used
to block platelet binding to uncoated glass, indicating that adhesive events were mediated by 
FXIII (Figure 4.8A).
Flow velocity was increased to generate an arterial shear rate of 800s"1, reported to be the 
threshold above which the presence of vWF is absolutely crucial for platelet adhesion to 
immobilised proteins under flow (Weiss et al., 1978b, Ruggeri, 2004, Ruggeri, 2007b). 
Although equal platelet arrest still occurred on both FXIII and FXIIIa (0.8±0.1% vs 0.9±0.1% 
surface coverage for FXIII and FXIIIIa respectively, P>0.05), in each case it was significantly 
less than at 300s 1 (P<0.05 for either FXIII or FXIIIa at 800s 1 vs 300s 1 ). However, it still caused 
significantly more surface coverage than BSA (P<0.05 vs FXIII and FXIIIa at 800s"1, ANOVA) 
(Figure 4.8A). Video analysis revealed that while many platelets tethered on the FXIII/FXIIIa 
surface at a shear rate of 800s"1, such associations were often weak and brief resulting in few 
stably adherent platelets with the majority being washed away in the direction of flow 
(Figure 4.8A and Video 2). No adhesive interactions were observable at shear rates above 
1000s"1 (Figure 4.8A). Thus, immobilised FXIII and FXIIIa support equal platelet adhesion in a 
shear-dependent manner under physiological conditions of flow.
Since FXIII is a plasma transglutaminase, it associates with numerous plasma proteins 
(Muszbek et al., 1999). It was essential to ensure that the observed platelet adhesive 
interactions were indeed mediated by FXIII rather than an associated plasma protein. Hence, 
flow experiments were conducted with washed platelets and red blood cells for specific
investigation (Figure 4.8A). However, it was important to ascertain whether the association
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of platelets with FXIII was feasible in a more physiological environment of whole blood under 
flow. Therefore, whole blood was perfused through capillary tubes coated with either 
zymogen or activated rFXIII-A. In these experiments, rFXIII-A was used in order to exclude 
FXIII-B, which mediates FXIII-binding to fibrinogen (Siebenlist et al., 1996). Using whole 
blood, platelet adhesion to the enzyme was also observable under flow. Moreover, similar to 
data with washed platelets, adhesion proceeded equally on native and activated enzyme 
forms (6.1±0.3% and 6.5±0.6% surface coverage for rFXIII-A and rFXIIIa respectively, P>0.05) 
(Figure 4.8B). Nevertheless, these experiments could not be pursued due to the 
aforementioned difficulty of eliminating potential confounding effects of plasma proteins 
and the limited availability of rFXIII-A during the study.
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Figure 4.8: Platelets adhere equally to FXIII and FXIIIa under flow in a shear dependent 
manner. (A) Glass microslide capillary tubes were coated for 12 hours at 4°C with bovine 
serum albumin (BSA, lOmg/mL), zymogen factor XIII (FXIII, 200u,g/mL) or activated factor XIII 
(FXIIIa, 200u,g/mL). Uncoated surfaces were blocked by overlay with BSA (lOmg/mL) for Ih at 
20°C. Washed platelets were stained with DiOC6 (lu,M) and reconstituted with autologous 
red blood cells to final concentrations of 2xl08 platelets/mL and 50% (v/v) respectively, then 
perfused through coated tubes for 4min at the indicated shear rate and platelet deposition 
viewed by fluorescence microscopy. Images from random visual fields with a total area of 
O.lmm2 were captured under fluorescence using cell A P imaging software (Olympus, Japan). 
Magnification = x60. (i) Shown are representative images. Scale bar = 20u,m. (ii) Data are 
shown as percentage area coverage and are means ± SD of 5 independent experiments with 
separate blood donors. White bars (FXIII) and grey bars (FXIIIa). (B) As in (A), except platelets 
were stained with DiOC6 (lu,M) in whole blood which was then perfused through capillary 
tubes that had been coated with either (BSA, lOmg/mL), zymogen recombinant factor XIII A- 
subunit (rFXIII-A, 200u.g/mL) or activated rFXIII-A (rFXIIIa, 200u.g/mL). **: P<0.01, *: P<0.05, 
NS: not significant.
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4.4.2 Structure of FXIIIa influences platelet adhesion under flow
Under static conditions, the conformation of FXIII was observed to be crucial for platelet 
adhesion as evidenced by loss of platelet binding following heat-denaturation of the enzyme 
(section 3.8). To examine whether platelet adhesion similarly depended on protein structure 
under flow, FXIII was heat-denatured prior to immobilisation on microslide capillary tubes. 
Heat-treatment completely abolished platelet accrual on FXIII under flow (P<0.01). Similarly, 
no platelet adhesion could be observed on heat-denatured FXIIIa (Figure 4.9).
Under flow conditions, negligible platelet adhesion was observed on uncoated tubes which 
was significantly less than that occurring on FXIII-coated tubes (0.3±0.1 vs 6.2±0.4% surface 
coverage respectively, P<0.05). This provided evidence that observations attributed to 
platelet-FXIII interactions were not due to platelet adhesion on glass (Figure 4.9).
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Figure 4.9; Protein structure of FXIII influences platelet adhesion under flow. (A) Factor XIII 
(FXIII, 200ng/mL) was used to coat glass microslide capillary tubes for 12hours at 4°C. In 
some cases, FXIII and activated FXIII (FXIIIa) were heat-denatured by incubation at 60°C for 
Ih to produce dFXIII (200ng/mL) and dFXIIIa (200u.g/mL) respectively, which were also used 
for coating tubes. Uncoated surfaces were blocked with bovine serum albumin (lOmg/mL) 
for Ih at room temperature. Washed platelets were stained with DiOCe (lu.M) and 
reconstituted to a final concentration of 2xi08 platelets/mL in autologous red blood cells 
(50%, v/v), then perfused through coated and uncoated glass tubes at a shear rate of 300s"1 
for 4min and viewed by fluorescent microscopy, (i) Images from random visual fields with a 
total area of O.lmm2 were captured under fluorescence using cell A P imaging software 
(Olympus, Japan). Magnification = x60, scale bar = 20u.m. (ii) Data are shown as percentage 
area coverage and are mean ± SD of 5 independent experiments with separate blood donors. 
**: P<0.01, *: P<0.05, NS: not significant.
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4.4.3 Platelet adhesion to FXIII under flow is dependent on inteerins 
an
Data presented in section 4.2.2 suggested that FXIII-mediated platelet adhesion is dually 
dependent on a\\t,fa and av33 integrins, with the two potentially playing complementary, non- 
redundant roles. The contributions of each receptor to adhesive interactions with FXIII were 
next examined under flow. Since activated FXIII predominates at sites of vascular injury due 
to high local thrombin concentrations (Troy, 1988, Narayanan, 1999), these experiments 
were performed with FXIIIa.
Consistent with experiments performed under static conditions (section 4.2.1), platelet 
adhesion under flow was abolished by RGDS (SOOuM) (5.7±0.6% vs 0.8±0.2% surface 
coverage for the absence and presence of RGDS respectively, P<0.01) (Figure 4.10).
Having confirmed the role of integrins under flow, receptor-specific inhibitors were then 
used to dissect the roles of aMb33 and avp3 . Incubation of platelets with tirofiban (2[iM) 
significantly reduced platelet adhesion to FXIIIa under flow from 5.7±0.6% to 1.4±0.5% 
surface coverage (for the absence and presence of tirofiban respectively, P<0.01) (Figure 
4.11). Similarly, when platelets were treated with LM609 (20u,g/mL), surface coverage was 
reduced from 5.7±0.6% to 2.4±1.2% (for the absence and presence of LM609 respectively 
P<0.01). These data suggest that ai^and civPs play important roles in mediating adhesion to 
FXIIIa under flow.
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Figure 4.10: Platelet adhesion to FXIIIa under flow is integrin-dependent. Washed platelets 
were treated with RGDS (500u,M) to block integrins or modified Tyrode's buffer (control) for 
20min at 37°C. They were stained with DiOC6 (lu,M) then reconstituted with autologous red 
blood cells to final concentrations of 2xio8 platelets/mL and 50% (v/v) respectively and 
perfused through FXIIIa (200u.g/mL)-coated capillary tubes for 4min at a shear rate of 300s"1 . 
Thrombus formation was viewed using the x60 oil-immersion lens of an 1X71 fluorescence 
microscope equipped with an XM10 CCD digital camera (Olympus, Japan), (i) Shown are 
representative images of adherent platelets. Scale bar = 20u.m. (ii) Images from random view 
fields with a total area of O.lmm2 were used to calculate platelet surface area coverage (%) 
using ImageJ software (NIH, USA). Data are means ±SD from 4 separate experiments with 
different blood donors. *: P<0.05. BSA: bovine serum albumin.
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Blocking both 0,^3 and avp3 simultaneously with tirofiban and LM609 ablated FXIIIa- 
mediated platelet adhesion reducing surface coverage from 5.7±0.6% to 0.3±0.2% (P<0.01) 
(Figure 4.11). Observations with LM609 could not be reproduced with a normal, isotype- 
matched IgG control antibody, thereby excluding potential non-specific antibody effects. 
Inhibition of a^Ps reduced platelet adhesion significantly more than inhibition of av3s 
(1.4±0.5% vs 2.4±1.2% for tirofiban and LM609 respectively, P<0.05), suggesting a more 
critical role for the former in mediating platelet adhesion under flow (Figure 4.11). Indeed, 
video analysis revealed that although platelet surface coverage was significantly diminished 
by separate inhibition of each integrin, tethering leading to stable contacts and aggregate 
formation was more dramatically reduced by otnbPs blockade (Video 4). These findings 
reinforce data showing that platelet adhesion to FXIIIa is dually dependent on ctnbPs and <xvp3 
while spreading that leads to stable adhesion is uniquely driven by aMb33 (Section 4.3). In 
addition, while only single adherent platelets were observed following blockade of ctnbPs, 
small platelet aggregates could still be seen when avp3 was inhibited in isolation (Figure 
4.11AJ and Video 5). This is consistent with a recognised minor involvement of av3s in 
platelet aggregation (Smith et al., 1990).
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Figure 4.11: Platelet adhesion to FXIIIa under flow is duallv dependent on aiihjk and q,Bg.
Washed platelets were treated with tirofiban (2u,M), LM609 (20u,g/mL), IgG control antibody 
(20ng/mL) or modified Tyrode's buffer (control) for 20min at 37°C. They were stained with 
DiOCs (lu,M) then reconstituted with autologous red blood cells to final concentrations of 
2xl08 platelets/mL and 50% (v/v) respectively and perfused over immobilised FXIIIa 
(200u,g/mL) for 4 minutes at a shear rate of 300s"1 . Thrombus formation was viewed by 
fluorescence videomicroscopy. (i) Shown are representative images taken under x60 
magnification. Bar = 20u,m (ii) Images from random fields of view with an area totalling 
O.lmm2 were used to calculate platelet surface area coverage (%) using ImageJ software 
(NIH, USA). Data are means ± SD from 3 independent experiments with separate blood 
donors. **: P<0.01, *: P<0.05, NS: not significant, BSA: bovine serum albumin.
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4.5 FXIII enhances platelet accrual by major thrombogenic platelet 
ligands under flow
At sites of vascular injury platelets bind to a plethora of adhesive proteins which influence 
their ability to form thrombi under flow (Ruggeri, 2002). Having observed that FXIII could 
recruit flowing platelets, the significance of these events in the context of adhesion to major 
platelet adhesive ligands was examined.
4.5.1 FXIII enhances platelet adhesion to fibrinogen under flow
FXIII can bind to fibrinogen in plasma where the two circulate in association (Greenberg and 
Shuman, 1982, Siebenlist et al., 1996). Since FXIII also binds platelets, its ability to influence 
platelet-adhesive properties of fibrinogen was investigated. To allow binding to fibrinogen, 
increasing concentrations of FXIII (0-200u.g/mL) were incubated with a fixed concentration of 
fibrinogen (Img/ml) prior to immobilisation and examination of platelet interactions under 
flow. Platelets were then either perfused over fibrinogen alone or in complex with FXIII.
Fibrinogen alone supported the deposition of flowing platelets under an arterial shear rate of 
800s * (9.6±0.9% surface coverage). However, preincubation with FXIII (100u.g/mL) increased 
platelet recruitment by fibrinogen to 12.1±0.8% surface coverage (P<0.05) (Figure 4.12). This 
effect was not saturated at 200|ig/mL of FXIII, the highest FXIII concentration used in these 
studies, since adhesion was further increased to 15.0±0.46% surface coverage (P<0.01 vs 
lOOug/mL FXIII). To exclude possible non-specific effects resulting from incubating fibrinogen 
with another protein, fibrinogen was incubated with heat-denatured FXIII (dFXIII, 200u-g/mL)
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prior to immobilisation. In contrast to findings with FXIII, dFXIII failed to enhance fibrinogen-
mediated platelet adhesion (Figure 4.12). Effects of FXIIIa on fibrinogen-mediated platelet 
accrual could not be investigated since incubation of the two resulted in clotting by FXIIIa- 
mediated fibrinogen-chain cross-linking.
4.5.2 FXIIIa. but not FXIII binds to collagen and enhances collagen-mediated 
thrombus formation
FXIII is known to localise on collagen (Kikuchi et al., 1986, Blanchy et al., 1986). Moreover, it 
was reported to potentially mediate adhesion of bovine platelets to collagen (Kasahara et al., 
1988). However, distinct abilities of FXIII and FXIIIa to bind collagen and influence collagen- 
mediated thrombus formation have not been assessed. FXIII and FXIIIa were suspended over 
collagen-coated glass surfaces. In each case, binding to collagen was examined using a 
primary antibody against FXIII-A and a fluorescent secondary antibody (section 2.5.2.3). The 
primary antibody's sensitivity for FXIII-A was demonstrated by its detection of immobilised 
FXIII (Figure 4.13), and rFXIII-A (Figure 3.2). Under these conditions, FXIIIa, but not FXIII 
bound to collagen (Figure 4.13). No signal was obtained from collagen or BSA used to block 
uncovered glass surfaces indicating that the primary antibody was specific for FXIII-A. Also, 
no signal was obtained from the secondary antibody in the absence of the primary antibody 
indicating that under these conditions, the former did not give false positive results by 
binding proteins non-specifically (Figure 4.13).
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Figure 4.12: Fibrinoeen-bound FXIII enhances platelet binding to fibrinogen under flow.
Zymogen factor XIII (FXIII, 0-200u.g/mL) was allowed to bind to fibrinogen (Fbg, Img/mL) by 
15min preincubation at 37°C prior to coating microslide capillary tubes. In some cases, FXIII 
was heat-denatured (dFXIII) by incubation at 60°C for Ih. Uncoated surfaces were blocked by 
overlay with bovine serum albumin (BSA, lOmg/mL) for Ih at 20°C. Washed platelets were 
stained with DiOC6 (lu,M) and reconstituted with autologous red blood cells to final 
respective concentrations of 2xl08 platelets/mL and 50% (v/v) then perfused over the 
indicated surfaces at 800s"1 for 4min. (i) Shown are representative images captured under 
fluorescence videomicroscopy with the *60 oil immersion lens of an 1X71 fluorescence 
microscope (Olympus, Japan). Scale bar = 20u.m. (ii) Images were used to calculate platelet 
surface area coverage. N=3 with separate blood donors. **: P<0.01, *: P<0.05, NS: not 
significant.
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BSA Collagen FXIII
Collagen + FXIII Collagen + FXIIIa Collagen + FXIIIa (No l°Ab)
Figure 4.13: FXIIIa. but not FXIII immobilises on collagen. Wells on glass slides were coated 
overnight at 4°C with collagen (100|ag/mL), bovine serum albumin (BSA, lOmg/mL) or factor 
XIII (FXIII, 200u.g/mL). Uncoated surfaces were blocked with BSA (lOmg/mL). Wells were then 
overlaid with zymogen FXIII (200u,g/mL) or activated factor XIII (FXIIIa, 200u.g/mL) for 15min 
at 37°C. Collagen-bound FXIII and FXIIIa were then detected by probing with a primary mouse 
antibody (1° Ab) against the A-subunit of factor XIII (FXIII-A). This was followed by incubation 
with a FITC-conjugated secondary goat anti-mouse antibody. Images were captured using the 
xlOO oil immersion lens of an 1X71 fluorescence microscope (Olympus, Japan). Images are 
representative of 3 independent experiments. Bar = 20nm.
Page | 156
_______ _______ ___ ___________________ Chapter 4 
After establishing that FXIIIa was able to bind to collagen (Figure 4.13), and considering its 
platelet adhesive effects under flow (Figure 4.8), its role in collagen-mediated platelet accrual 
was next investigated. Washed platelets reconstituted with autologous red blood cells were 
perfused at 800s"1 over native collagen (100ug/mL) or collagen that had been preincubated 
with FXIIIa (200ng/mL) or dFXIIIa (200u,g/mL) to allow binding. Under these conditions, 
collagen alone supported the deposition of robust platelet-rich thrombi which covered 
24.0±0.2% of the surface. FXIIIa did not influence collagen-mediated platelet surface 
coverage which was maintained at 27.6±2.3% (P>0.05 vs collagen alone) (Figure 4.14ii).
However, visual image inspection revealed that thrombi formed in the presence of FXIIIa 
were more fluorescently intense (Figure 4.14i). Since fluorescence intensity can be used to 
determine thrombus volume (Ross et al., 1995), it was therefore measured. Using this 
approach (section 2.6.1), the mean thrombus volume on collagen alone (3.7±0.1xi05 
arbitrary units) was significantly increased by the presence of FXIIIa (6.7±0.5xi05 arbitrary 
units, P<0.05 vs collagen alone) (Figure 4.14iii). Importantly, this required correct FXIIIa 
protein structure, since heat-denatured FXIIIa could not enhance the effects of collagen 
(4.2±0.1xl05 arbitrary units P>0.05 vs collagen alone).
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Figure 4.14; Collagen-bound FXIlia accentuates platelet thrombus formation on collagen.
Glass microslide capillary tubes were coated for 12 hours at 4°C with collagen (100u,g/mL). In 
some cases FXIlia (200u.g/mL) or heat-denatured FXIlia (dFXIIIa, 200u,g /mL) were allowed to 
bind to collagen (100ng/mL) through 15min preincubation at 37°C prior to coating tubes. 
Uncoated surfaces were blocked by overlay with bovine serum albumin (BSA, lOmg/mL) for 
Ih at 20°C. Washed platelets were stained with DiOCe (lu.M) and reconstituted with 
autologous red blood cells to final concentrations of (2xl08 platelets/mL) and 50% (v/v) 
respectively, then perfused through coated tubes for 4min at a shear rate of 800s" . 
Thrombus formation was viewed by fluorescence microscopy, (i) Shown are representative 
images of stable thrombi formed on each surface. Bar = 20|am (ii) ImageJ software (NIH, USA) 
was used to measure percentage surface area coverage, (iii) Volumes of thrombi formed on 
each surface were measured as previously described (Ross et al., 1995). All data shown are 
means ± SD from 4 separate experiments with different blood donors. *: P<0.05, NS: not 
significant.
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4.5.3 FXIIIa accentuates platelet recruitment bv vWF at high shear
vWF is critical for platelet recruitment to vascular injury sites at elevated shear (Ruggeri and 
Ware, 1993). However its interaction with platelets through GPlb/IX/V is transient and 
platelets require integrin-mediated ligand engagement for stable adhesion (Jackson, 2007). 
Since FXIIIa adhered to platelet integrins under flow (section 4.4.3), its ability to supplement 
platelet recruitment by vWF was investigated.
At a shear rate of 800s"1 , immobilised vWF (20u,g/mL) supported transient tethering and 
rolling of flowing platelets with only single platelets adhering stably to cover 8.9±0.1% of the 
vWF-coated surface (Figure 4.15). However, platelet surface coverage was significantly 
increased when vWF was co-immobilised with FXIIIa (100u.g/mL) (14.3±3.8%, P<0.05 vs vWF 
alone) (Figure 4.15ii). Increasing the concentration of FXIIIa to 200u.g/mL did not further 
enhance platelet recruitment since surface coverage was insignificantly changed (15.0±1.6%, 
P>0.05 vs FXIIIa at 100u,g/mL). Importantly, there was clear contrast between single platelets 
adherent on vWF and platelet aggregates observed on vWF/FXIIIa (Figure 4.15i). These data 
indicate that FXIIIa can enhance vWF-mediated platelet accrual at high shear. Furthermore, 
the presence of vWF facilitates greater platelet deposition on immobilised FXIIIa at arterial 
shear since platelet surface coverage was increased from 0.9±0.1% to 15.0±1.6% (P<0.01 for 
the absence and presence of vWF respectively) (Figure 4.15ii).
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Figure 4.15: FXIIIa enhances platelet accrual by vWF at arterial shear. Washed platelets 
were stained with DiOC6 (lumol/L) and reconstituted with autologous red blood cells to final 
concentrations of 2 x 108 platelets/mL and 50% (v/v) respectively. This was perfused over 
immobilised FXIIIa (lOU/mL) or vWF (20u.g/mL) either alone or co-immobilised with 
increasing concentrations of FXIIIa (20-200u.g/mL) for 4 minutes at a shear rate of 800s J and 
viewed by fluorescence microscopy. Images from random fields of view covering a total area 
of O.lmm2 were captured under fluorescence using cell A P imaging software from Olympus 
(magnification = x60). (i) Shown are representative images. Scale bar = 20u,m (ii) Data shown 
are means ± SD of 3 separate experiments with different blood donors. **: P<0.01. *: P<0.05.
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4.6 Discussion
The present study concentrated on examining platelet adhesion to immobilised FXIII and 
investigating the ensuing effects on platelet function. Having confirmed the purity of the 
source of FXIII used in these studies from contaminating platelet adhesive plasma proteins 
(section 3.2), characterisation of the platelet receptors mediating adhesion to FXIII was 
performed.
The essential role of integrin receptors in platelet adhesion to immobilised FXIII was 
demonstrated by its abolition when platelet integrins were broadly inhibited by RGDS (Figure 
4.1). Given that previous studies had reported a role for a^Pa in mediating platelet adhesion 
to suspended FXIII (Cox and Devine, 1994, Dardik et al., 2002b), its role in binding the 
immobilised enzyme was assessed. Specific inhibition of ctnbPs with tirofiban partially, but 
significantly reduced platelet adhesion (Figure 4.2). This was indicative of its importance in 
these events, but suggested the involvement of other integrin receptors. Partial inhibition of 
platelet adhesion to FXIII under these conditions was not due to incomplete receptor 
inhibition since tirofiban at the same concentration ablated adhesion to fibrinogen (Figure 
4.3), which is known to be critically dependent on anb33 integrins (Bennett et al., 1983, French 
and Seligsohn, 2000).
Further investigation revealed that avp3 supplemented aubp3-mediated platelet adhesion to 
FXIII. Adhesion was also partially, but significantly dependent on ctvp3 and was abolished only
when both receptors were blocked (Figure 4.6), indicating that they collaborated in these
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events. This ablation of adhesion suggests that platelets do not possess additional receptors 
for FXIII.
In attempt to specifically demonstrate the crucial role of ai,bp3 in mediating platelet adhesion 
to FXIII, previous studies used the antibody 7E3 (Cox and Devine, 1994), its humanised 
derivative abciximab (Dardik et al., 2002b) or eptifibatide (Nagy et al., 2009). However, all 
three inhibitors also block av33, unlike tirofiban which is strictly selective for anbp3 (Nurden et 
al., 1999, Lele et al., 2001). Thus, these studies overlooked the potential involvement of ctv33 
in adhesive events. Identification of avp3 involvement in FXIIf-mediated platelet binding 
therefore constitutes a novel finding of a potential platelet FXIII-receptor.
Estimates of av|J3 copy number on the platelet surface range from 1485 ± 780 (mean ± SD) 
(Lawler and Hynes, 1989) to 50-100 (Coller et al., 1991). This makes its surface expression 
considerably lower than that of aMb33 which is estimated to be about 80000 per platelet 
(Wagner et al., 1996). However, it is noteworthy that platelet <xvp3 has been shown to possess 
an affinity 150 times greater than aMb33 for RGD sequences (Smith et al., 1990). In fact, 
although platelet adhesion to vitronectin is jointly mediated by aMb33 and avp3 integrins, av33 
is responsible for as much as 26% of the adhesive interactions (Coller et al., 1991). Thus, 
despite its lower copy number Ov33 is an important mediator of platelet adhesive events.
Interestingly, separate studies using platelets from patients with GT gave conflicting results 
regarding the role of aMb33 in platelet-FXIIIa interactions. Using platelets from a single
patient. Cox and Devine (1994) reported severely diminished FXIIIa-binding whereas
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Greenberg and Shuman (1984) observed normal platelet-FXIIIa binding by platelets from two 
patients. While the two studies are not directly comparable due to differences in 
methodology, the conflicting findings may also be due to differences in receptor defects 
among patients with GT. For instance, it is known that in GT sufferers with mutations in (33 
chains, both a.\\$3 and av3s have functional defects, whereas when ct|| b chains are affected; 
dvPs, but not ctnbPs may retain normal function (Nurden, 2006). In order to resolve 
discrepancies among reports, future studies with well-characterised platelets with defective 
ttnb chains will need to be performed. However, the fact that platelets from patients with GT 
can still adhere to vitronectin through ctvp3 (Coller et al., 1991), and the ability of this 
receptor to also mediate FXIII(a)-binding by endothelial cells (Dallabrida et al., 2000, Dardik 
et al., 2002a), monocytes (Dardik et al., 2007) and fibroblasts (Ueki et al., 1996) together 
support its involvement in the platelet-FXIII(a) interactions reported in the present study.
Visual microscopic analysis of FXIIIa-adherent platelets revealed that although separate 
inhibition of ttabPs and av3s integrins reduced platelet adhesion (Figures 4.2 and 4.4), the 
treatments had different effects on adherent-platelet morphology. While unaffected by 
inhibition of OVP3, platelet spreading responses were abolished following at , b fa blockade 
(Figure 4.7). This suggests that the two receptors mediate different, non-redundant 
functional effects in adherent platelets. Together, these data suggest a model where anbp3 
complements ctvPa-mediated platelet adhesion to FXMIa through stimulation of platelet 
spreading. Indeed, spreading is an activation-dependent response that allows adherent 
platelets to cover larger surface areas and adhere more stably (Jen et al., 1996, Kuwahara et
al., 2002).
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Although adhesive interactions between platelets and suspended FXIII are recognised 
(Greenberg and Shuman, 1984, Devine et al., 1993, Cox and Devine, 1994, Nagy et al., 2009), 
they have not been studied under physiological flow conditions nor have their potential 
contributions to platelet accrual by extracellular matrix proteins exposed at vascular injury 
sites been investigated. Both immobilised FXIII and FXIIIa were observed to equally support 
platelet adhesion under flow at venous and arterial shear rates (Figure 4.8). This was 
consistent with data obtained under static conditions where platelet adhesion occurred 
independently of transglutaminase activity (section 3.7.1). However, platelet adhesion to 
both FXIII and FXIIIa was influenced by prevailing flow conditions. At venous shear, platelets 
were readily recruited and adhered stably to form aggregates, while at arterial shear, platelet 
adhesion was markedly reduced, but not abolished (Figure 4.8). This was in line with the 
formation of integrin-mediated platelet contacts which are known to occur too slowly to 
facilitate platelet-binding to integrin ligands including fibrinogen, fibronectin and vitronectin 
under rapid arterial flow in the absence of vWF (Zaidi et al., 1996). Indeed, platelet adhesion 
to FXIIIa at arterial shear was significantly increased in the presence of vWF (Figure 4.15ii). 
Thus, similar to other integrin ligands, platelet adhesion to FXIIIa under flow is shear- 
dependent, diminished at high shear where it is critically dependent on vWF which retards 
platelets to allow stable adhesive contacts to form.
Under flow, platelet adhesion to FXIIIa was also observed to be dually dependent on
and dvPa integrins since it was only effectively abolished when both integrins were blocked
(Figure 4.11). Consistent with data obtained under static conditions (Figure 4.7), separate
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inhibition of each integrin had different effects on adhesion under flow. Although blockade
of avPa significantly reduced adhesion, analysis of platelets flowing at venous shear revealed 
that they were still able to form stable contacts with no increase in transient tethering and 
rolling observed (Figure 4.8i and Video 5). In contrast, blockade of anbfa more severely 
limited the ability of platelets to form stable contacts or aggregate resulting in a greater 
tendency to disengage from FXIIIa and wash away in the direction of flow (Figure 4.8i and 
Video 4). This suggests that spreading occurring downstream of aMbP3 was required to 
stabilise adhesive contacts with FXIIIa. Therefore, while both avp3 and aHbfa integrins are 
involved in facilitating the initial platelet engagement with FXIII, stable adhesion is critically 
dependent on
FXIII associates with multiple thrombogenic platelet ligands (Muszbek et al., 1999). Since FXIII 
also supported platelet recruitment under flow, it was possible that it could increase 
thrombus formation by key platelet ligands. Collagen-bound vWF mediates platelet 
tethering, retarding flowing platelets and allowing their activation in response to exposed 
matrix proteins at high shear (Ruggeri and Ware, 1993). Firm platelet adhesion then takes 
place which is strengthened by spreading following integrin-mediated binding of various 
plasma proteins (Shattil and Newman, 2004). Although solely immobilised vWF captured 
single platelets at high shear, the presence of FXIIIa increased platelet accrual as evidenced 
by enhanced platelet surface coverage and aggregate formation, which was unobservable on 
vWF alone (Figure 4.15i). Hence, FXIIIa may act in concert with vWF to arrest platelets 
flowing at high shear.
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FXIIIa, but not FXIII bound to collagen and enhanced the ability of this key matrix protein to
form platelet-rich thrombi (Figures 4.13 and 4.14). Thus, although activation of the enzyme is 
not essential for its adhesive interactions with platelets (section 3.7.1), activation allows 
FXIIIa to localise on exposed collagen fibres. This may specifically recruit FXIIIa to the ECM 
where through its cross-linking reactions that reorganise matrix proteins, it facilitates 
fibroblast migration and wound healing (Brown et al., 1993, Inbal et al., 2005). Despite 
collagen being the most potent platelet agonist in the ECM, its ability to bind platelets 
through GPVI and a23i receptors is limited by the low affinity of GPVI and low copy number 
of a23i (Watson et al., 2005). Hence, by binding collagen exposed at vascular injury sites; 
FXIIIa like vWF may increase platelet recruitment by supplementing platelet-binding sites 
available per collagen fibre. This may explain why platelet surface coverage was not 
increased by collagen-bound FXIIIa (Figure 4.14M), since its adhesive interactions with 
platelets were likely confined to where it was physically associated with each collagen fibre.
Fibrinogen becomes localised on the ECM following vascular injury where it is thrombin- 
cleaved to form fibrin clots (Duckert and Nyman, 1978). In plasma, FXIII can associate with 
fibrinogen (Siebenlist et al., 1996), a ligand for ctnbpa and a vital mediator of platelet 
aggregation (Jackson, 2007). Since fibrinogen is present in excess of FXIII in plasma, much of 
the enzyme potentially circulates bound to fibrinogen (Greenberg and Shuman, 1982). 
Platelet adhesion to plasma protein-free recombinant FXIII-A (Figure 3.6) and the absence of 
fibrinogen from Fibrogammin P (section 3.2) strongly suggested that platelets were able to 
adhere to FXIII independently of fibrinogen. Consistent with a previous report (Smith et al.,
1990), sole blockade of avp3 had no measurable effect on platelet adhesion to fibrinogen
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(Figure 4.5). This supported data showing fibrinogen-independent adhesion since platelet 
adhesion to FXIII would not have been expected to decrease following treatment with LM609 
(Figure 4.4), if it were mediated by fibrinogen. Crucially, it also suggested that different, non- 
redundant mechanisms controlled platelet-binding to the two proteins. Indeed, when bound 
to immobilised fibrinogen, FXIII dose-dependently increased fibrinogen-mediated platelet 
recruitment under flow (Figure 4.12), suggesting that it may collaborate with fibrinogen in 
mediating platelet accrual.
These data appear to contradict a recent report suggesting that FXIII does not bind platelets 
directly, but instead relies on its association with fibrinogen to interact with platelets (Nagy 
et al., 2009). However, the data are supported by findings from Cox and Devine (1994) who 
demonstrated FXIII-binding by washed platelets and isolated a\\bfa integrins in the absence of 
fibrinogen which enhanced the process when present. In any case, both studies examined 
platelet-FXIII associations occurring in suspenstion using flow cytometry while platelet 
interactions with the immobilised enzyme were considered in the present work. Thus 
methodological differences limit comparability of results.
Intravital and in vitro perfusion studies examining thrombus formation in genetically 
modified mice have revealed important roles for plasma proteins outside the recognised 
major platelet adhesive ligands in thrombus formation. Using mice deficient in vWF and 
fibrinogen, Ni et al., (2000) demonstrated that although considerably incapacitated, the mice 
were still able to form occlusive platelet thrombi in response to vascular injury, even at
elevated shear. As a result, an important role for fibronectin in thrombus formation under in
Page | 169
Chapter 4
vivo flow was established (Ni et al., 2003). More recently, mice deficient in all three proteins 
(vWF, fibrinogen and fibronectin) were also observed to retain an ability to form platelet 
thrombi under flow (Reheman et al., 2009). Thus, in vivo thrombus formation involves 
complex interactions between platelets and multiple plasma proteins potentially including 
FXIII. Indeed, FXIII-deficient mice exhibit elongated tail bleeding times (Lauer et al., 2002) and 
markedly diminished clot retraction (Kasahara et al., 2010), suggesting a potential role for 
FXIII in platelet-dependent thrombosis. Hence, the present data add FXIII to the growing list 
of proteins known to localise at sites of vascular damage and synergistically activating blood 
platelets through manifold integrated signalling pathways.
In summary, this chapter has further clarified the nature of physical interactions between 
platelets and FXIII by characterising the roles of individual receptors involved. Moreover, the 
potential implications of adhesion events with respect to other platelet adhesive proteins 
under physiological conditions of flowing blood have been discussed. This provides a 
platform to understand the signalling events initiated downstream of receptor occupation 
and how they lead to platelet functional responses which will be addressed in the next 
chapter.
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CHAPTER 5 - ADHESION TO FXIII ACTIVATES AN INTEGRIN- 
MEDIATED SIGNALLING CASCADE IN PLATELETS.
5.1 Introduction
Blood platelets circulate in quiescent states and fulfil their haemostatic roles following 
restricted activation at sites of vascular injury. Platelet activation is induced by an array of 
agonists which stimulate signal transduction after binding to specific platelet-surface 
receptors (Rivera et al., 2009). The ensuing signalling events transform physical receptor 
occupation at the platelet surface to functional responses by relaying activatory information 
through intracellular biochemical signalling networks.
Although activatory signals may lead to platelet responses including spreading, secretion and 
expression of procoagulant phosphatidylserine on the membrane surface (Zucker and 
Nachmias, 1985), the transformation of platelet integrin receptors to their high affinity states 
is perhaps most important for platelet clot formation. Indeed, this "final common pathway" 
of platelet activation facilitates platelet thrombus formation through fibrinogen binding by 
onbfe integrins (Ruggeri, 2002). However, far from being passive mediators in clot formation, 
integrins also transmit activatory signals upon binding their ligands (Giancotti and Ruoslahti, 
1999). This "outside-in" signalling perpetuates and reinforces clot formation, essentially 
making platelet activation a process dependent on bidirectional signalling (Shattil et al.,
1998).
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In Chapter 3, data demonstrating spreading and secretory responses by FXIII-adherent 
platelets were presented. The characteristic display of such responses by activated platelets 
and the known involvement of ct^s in mediating platelet adhesion to FXIII guided a 
hypothesis that FXIII stimulates activatory signalling in adherent platelets.
Aims:
To examine whether biochemical signal-transduction occurs in FXIII-adherent 
platelets and if so, to identify some of the signalling molecules involved.
To establish the relative roles of a«b33 and avp3 in mediating the signalling events. 
To determine how platelet activation influences adhesive contacts with FXIII.
5.2 Platelet-FXIIIa interactions require Src-family tyrosine-kinases
Src-family kinases are crucially involved in initiating signal transduction downstream of dubPs 
integrins following occupancy by their ligands (Gao et al., 1997, Obergfell et al., 2002). Since 
ctnbPs integrins facilitated FXIIIa-mediated platelet adhesion and spreading (section 4.3), the 
involvement of Src-family kinases in these events was assessed. Incubating platelets with PP1 
(20u.M), a selective Src-family kinase inhibitor (Hanke et al., 1996), significantly attenuated 
spreading on FXIMa (27±1 to ll±3u,m2 for the absence and presence of PP1 respectively, 
P<0.01). Furthermore, stable platelet adhesion was also diminished (762140 to 143177 
platelets/0.1mm2 for the absence and presence of PP1 respectively, P<0.05) (Figure 5.1).
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Figure 5.1: Platelet adhesion and spreading on FXHIa is tvrosine-kinase dependent. Wells on 
glass slides were coated overnight with heat-inactivated human serum (HS, 5%) or activated 
factor XIII (FXIIIa, 200u,g/mL). Uncoated surfaces were blocked by overlay with HS (5%) for 
30min at room temperature. Washed platelets (5xi07 platelets/mL) were treated with PP1 
(20u.M) or DMSO (0.01%, vehicle control) for 20min at 37°C then adhered for Ih at 37"C. 
Adherent platelets were viewed using an 1X71 fluorescence microscope equipped with an 
XM10 CCD camera (Olympus, Japan), (i) Shown are representative images taken under x60 
magnification. Scale bar = 20u,m. (ii) Adherent platelets were counted from random visual 
fields with a total area of O.lmm2. (iii) Images of adherent platelets were used to evaluate 
platelet surface area using ImageJ software (NIH, USA). Data are from 4 independent 
experiments with separate blood donors and are means ± SD. *: P<0.05, **: P<0.01.
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5.3 Tyrosine phosphorylation occurs in platelets adherent to FXIIIa
The effects observed from Src-family kinase inhibition suggested that protein tyrosine- 
phosphorylation events were induced in FXIIIa adherent platelets. To examine this, adherent 
platelets were lysed and inspected for proteins phosphorylated on tyrosine residues using 
SDS-PAGE and immunoblotting (section 2.8). Platelets were adhered in the presence of 
apyrase (lU/mL) and indomethacin {10u,M) to preclude activation induced by secreted ADP 
and TXA2 respectively. Adhesion to FXIIIa resulted in the phosphorylation of multiple proteins 
with those most prominently phosphorylated appearing at molecular weights of 27, 36, 40, 
48, 55, 72 and 130kDa under SDS-PAGE (Figure 5.2A). The profile of tyrosine-phosphorylated 
proteins matched that from fibrinogen-adherent platelets and in both cases, tyrosine 
phosphorylation was restricted to resting levels when platelet integrins were blocked with 
RGDS (Figure 5.2A). These data suggested that FXIIIa triggers integrin-mediated signalling in 
adherent platelets which is similar to that stimulated by fibrinogen. Signalling induced by 
FXIIIa was reproducible in platelets adherent on zymogen FXIII (Figure 5.2B), suggesting that 
transglutaminase activity was not involved in the induction of signalling.
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Figure 5.2: Adhesion to immobilised FXIII and FXIHa triggers protein tvrosine- 
phosphorylation in adherent platelets. (A) Wells of a 6-well culture plate were coated 
overnight at 4°C with activated factor XIII (FXIHa, 200u.g/mL) or heat-inactivated human 
serum (HS, 5%). Uncoated surfaces were blocked by overlay with HS (5%) for 30min at room 
temperature. Washed platelets (5xio8 platelets/mL) were allowed to adhere in the presence 
of apyrase (lU/mL) and indomethacin (10u.M) for 45min at 37°C. In some cases, platelets 
were pretreated with RGDS (500u.M). Adherent-platelet lysates were subjected to SDS-PAGE 
on a 10-18% gradient gel for 2.5h at 120V under reducing conditions. Separated proteins 
were then transferred to polyvinylidene fluoride (PVDF) membranes for 2.5h at 100V, 
immunoblotted (IB) for phosphotyrosine (pTyr) and visualised by enhanced 
chemiluminescence. Membranes were then stripped and immunoblotted for (J-tubulin to 
assess equal protein loading. The blot is representative of 4 separate experiments with 
different blood donors. (B) As in (A) except platelets were also adhered to wells coated with 
inactive factor XIII (FXIII, 200u.g/mL) in the absence of RGDS. MW: molecular weight.
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5.4 FXIIIa stimulates platelet signalling through aMbp3, but not av(53
Since aMbp3 and avp3 were involved in mediating platelet binding to FXIIIa (section 4.2.2), it 
was possible that the observed signalling events occurred downstream of either or both 
receptors. To specifically determine whether each receptor transmitted signals, platelets 
were treated with either LM609 (20u.M) or tirofiban (2u.M), adhered to FXIIIa, and then their 
lysates examined by immunoblotting. Blockade of aMbp3 with tirofiban restricted protein 
tyrosine-phosphorylation to basal levels which was unrestrained following specific inhibition 
of avp3 with LM609 (Figure 5.3). These data were consistent with those from spreading 
measurements where anbp3, but not avp3 mediated platelet spreading (Figure 4.7). Taken 
together, these data suggest that aMbp3, but not avp3 triggers activatory platelet signalling 
which leads to spreading responses in FXIIIa-adherent platelets.
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Figure 5.3: FXIIIa stimulates protein tvrosine-phosphorvlation through anhBa. but not 
adherent platelets. Wells of a 6-well culture plate were coated overnight at 4°C with 
activated factor XIII (FXIIIa, 200u.g/mL) or heat-inactivated human serum (HS, 5%). Uncoated 
surfaces were blocked by overlay with HS (5%) for 30min at room temperature. Washed 
platelets (5xl08 platelets/mL) were allowed to adhere in the presence of apyrase (ILJ/mL) 
and indomethacin (10|aM) for 45min at 37°C. In some cases, platelets were pretreated with 
tirofiban (2u,M), LM609 (20u.g/mL), IgG control antibody (20u,g/mL) or modified Tyrode's 
buffer (control) for 20min at 37°C. Adherent-platelet lysates were subjected to SDS-PAGE on 
a 10-18% gradient gel for 2.5h at 120V under reducing conditions. Separated proteins were 
then transferred to polyvinylidene fluoride (PVDF) membranes for 2.5h at 100V, 
immunoblotted (IB) for phosphotyrosine (pTyr) and visualised by enhanced 
chemiluminescence. Membranes were then stripped and immunoblotted for 3-tubulin to 
assess equal protein loading. The blot is representative of 3 separate experiments with 
different blood donors. MW: molecular weight.
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5.5 Specific identification of tyrosine-phosphorylated proteins in 
FXIIIa-adherent platelets
Having established that FXIIIa could stimulate platelet signalling uniquely through anb33, 
some of the intracellular proteins involved were identified. Signalling downstream of dnbPs is 
characterised by Src-mediated phosphorylation and activation of Syk which sequentially 
phosphorylates the adaptor protein SLP-76 and PLCyZ (Obergfell et al., 2002). Similar events 
occur downstream of glycoprotein VI (GPVI); another crucial platelet receptor, but are 
distinguishable by Syk-mediated phosphorylation of the adaptor protein LAT which does not 
occur downstream of a^Ps (Watson et al., 2005). Thus, in order to isolate the tyrosine 
kinase-dependent signalling pathway activated in FXIIIa-adherent platelets, tyrosine- 
phosphorylation of Syk, SLP-76, PLCy2 and LAT were examined using immunoprecipitation 
and western blotting techniques.
5.5.1 Optimisation of protein-immunoprecipitation from adherent platelets
In order to efficiently immunoprecipitate each protein, the technique required optimisation 
with respect to quantity of antibody and type of beads used as a solid-phase for antibody- 
binding. Increasing amounts of antibodies specific for each target protein were bound to 
fixed amounts of either protein-A or protein-G beads. Antibody-conjugated beads were then 
incubated with unstimulated platelet-lysates to establish the amount of each antibody that 
could immunoprecipitate detectable protein levels most economically. Immunoprecipitated 
proteins were then subjected to SDS-PAGE, transferred to PVDF membranes and identified 
by immunoblotting (section 2.8.2.1).
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Data obtained using an anti-PLCy2 antibody revealed that PLCy2 could be detected by 0.5u.g 
of antibody and increasing the amount of antibody beyond 5ug failed to increase the yield of 
immunoprecipitated PLCv2 with protein-A beads (Figure 5.4A). Comparable PLCv2 levels 
were obtained using protein-G beads with 5u,g of antibody, indicating no superior advantage 
over protein-A beads. Importantly, PLCy2 was undetectable following incubation of platelet 
lysates with protein-A beads coated with a control IgG antibody that was non-reactive 
against PLCv2, indicating the absence of non-specific binding of PLCv2 by added antibodies. 
Furthermore, protein-A beads alone failed to pull down PLCv2, also indicating that they did 
not bind it non-specifically.
For immunoprecipitation experiments, a fixed amount of bead-slurry (25ul) was used to bind 
antibodies. To investigate whether this amount of beads limited the surface available for 
antibody-conjugation and the resulting protein yield, greater amounts of Protein-A bead- 
slurry up to 75ul were incubated with 5ug of anti-PLCy2 antibody. Increasing the amount of 
slurry over 25ul failed to increase the yield of immunoprecipitated PLCv2, indicating that it 
was not limiting (Figure 5.4). From these data, it was concluded that using 5u,g of anti-PLCy2 
antibody with 25ul of protein-A beads would suffice for subsequent experiments.
Using a similar approach to that described in detail for PLCv2, inference from data in Figure 
5.5 led to the use of anti-SLP-76 (5ug) and of anti-LAT (5ug) antibodies with protein-G beads. 
Syk was immunoprecipitated with anti-Syk antibody (5u.g) with protein-A beads in
accordance with optimisation previously performed in the lab (Riba et al., 2008).
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Figure 5.4: Optimisation of amounts of antibody and bead slurry required for PLCvZ 
immunoprecipitation. A suspension of either protein-A or protein-G sepharose beads (50%, 
w/v in TBS-T) was prepared (slurry). (A) Anti-PLCy2 antibody (0.5-lOu.g) or non-reactive IgG 
(5u,g) were incubated with slurry (25ul) for Ih at 4°C to allow conjugation with beads. 
Antibody-bead conjugates were then incubated with precleared lysates of unstimulated 
platelets (5xl08 platelets/mL) overnight at 4°C to immunoprecipitate PLCy2. In some cases, 
unconjugated slurry was incubated with platelet lysates to assess non-specific protein 
binding. Beads were then pelleted by centrifugation at 8500g for Imin, washed sequentially 
with lysis buffer and IBS then boiled in Laemmli buffer to liberate antibody-PLCy2 
complexes. Immunoprecipitates were separated by SDS-PAGE, transferred to polyvinylidene 
fluoride (PVDF) membranes, immunoblotted for PLCy2 with anti-PLCy2 antibody (1:1000) and 
visualised by enhanced chemiluminescence. (B) As in (A), except anti-PLCy2 antibody (Spg) or 
non-reactive rabbit IgG (5u.g) were incubated with increasing amounts of slurry (25-75ul). 
Blots are from single experiments performed in duplicate.
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Figure 5.5: Optimisation of amounts of antibody and bead slurry required for SLP-76 and 
LAT immunoprecipitation. Suspensions of either protein-A or protein-G sepharose beads 
(50%, w/v in TBS-T) were prepared (slurry). (A) Anti-SLP-76 (0.5-lOu.g) or non-reactive IgG 
(5u.g) antibodies were incubated with slurry (25ul) for Ih at 4°C to allow conjugation with 
beads. Antibody-bead conjugates were then incubated with precleared lysates of 
unstimulated platelets (5xl08 platelets/mL) overnight at 4°C to immunoprecipitate each 
protein. In some cases, slurry alone was incubated with platelet lysates to assess non-specific 
protein binding. Beads were then pelleted by centrifugation at 8500g for Imin, washed 
sequentially with lysis buffer and IBS then boiled in Laemmli buffer to liberate antibody- 
antigen complexes. Immunoprecipitates were separated by SDS-PAGE, transferred to 
polyvinylidene fluoride (PVDF) membranes then immunoblotted for SLP-76 using anti-SLP-76 
(1:1000) and visualised by enhanced chemiluminescence. (B) As in (A), except lysates were 
immunoprecipitated for LAT by conjugating increasing amounts of anti-LAT antibody (0.5- 
10u,g) to bead slurry (25ul) and membranes immunoblotted with anti-LAT (1:1000). Blots are 
from single experiments performed in duplicate.
Page | 183
____ Chapter 5
5.5.2 Svk. PLCvZ. SIP-76, but not LAT are tvrosine-phosphorvlated in FXIIia- 
adherent platelets.
Having optimised the immunoprecipitation technique, it was applied to FXIIIa-adherent 
platelets. Each of the targeted proteins was immunoprecipitated sequentially from the same 
lysates to ensure that all phosphorylation events occurred in the same platelets. 
Immunoprecipitates were subjected to SDS-PAGE, transferred to PVDF membranes and 
immunoblotted initially with an anti-phosphotyrosine antibody then with antibodies against 
each target protein to ensure equal loading in each lane of the gel.
Syk (72kDa molecular weight) was tyrosine-phosphorylated in FXIIIa and fibrinogen-adherent 
platelets, but not those suspended over human serum (Figure 5.6A). Importantly, the IgG 
control antibody failed to immunoprecipitate Syk, indicating the absence of non-specific 
antibody binding. Immunoblotting with an anti-Syk antibody showed that equal amounts of 
immunoprecipitated Syk were present in each lane. Similarly, PLCvZ (155kDa) (Figure 5.6B) 
and SLP-76 (76kDa) (Figure 5.6C) were tyrosine-phosphorylated in FXIIIa and fibrinogen- 
adherent platelets indicating their involvement in tyrosine kinase-mediated signalling. Also 
observable in the blots were the heavy chains (55kDa) and light chains (25kDa) of antibodies 
used to immunoprecipitate each protein (Figure 5.6).
To isolate the tyrosine-kinase signalling pathway occurring in FXIIIa-adherent platelets, LAT 
was immunoprecipitated and its tyrosine-phosphorylation assessed. LAT remained 
unphosphorylated in both FXIIIa and fibrinogen-adherent platelets (Figure 5.7A). In contrast,
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its tyrosine-phosphorylation was stimulated by collagen (Figure 5.7B). Taken together with
data in Figure 5.3, these data suggest that FXIIIa stimulates tyrosine kinase-mediated 
signalling through anbP3 which is similar to that stimulated by fibrinogen, but not collagen.
5.6 FXIIIa does not stimulate tyrosine-phosphorylation in 
suspended platelets
FXIII circulates in plasma where it can also bind suspended platelets (Devine et al., 1993, Cox 
and Devine, 1994). Having established that FXIII stimulated signal-transduction in adherent 
platelets when immobilised, its ability to do the same in suspension was also investigated. 
Washed platelets (5xl08 platelets/mL) were incubated with FXIIIa for up to 60min under 
constant stirring conditions. Manganese ions (ImM) were added to artificially give integrins 
high affinity conformations without stimulating "inside-out" signalling (Mould et al., 2002, 
Chen et al., 2003). Platelets were subsequently lysed and the lysates separated by SDS-PAGE 
then immunoblotted with an anti-phosphotyrosine antibody. In contrast to platelets that had 
been incubated with collagen, no significant increase in tyrosine-phosphorylation was 
observed with suspended FXIIIa (Figure 5.8).
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Figure 5.6: Svk. PLCv2 and SLP-76 are tyrosine-phosphorylated in platelets adherent on 
FXIIIa. Wells of a 6-well culture plate were coated overnight at 4°C with heat-inactivated 
human serum (HS, 5%), activated factor XIII (FXIIIa, 200u.g/mL) or fibrinogen (Fib, 200ug/mL). 
Uncoated surfaces were blocked by overlay with HS (5%) for SOmin at room temperature. 
Washed platelets (5xio8 platelets/mL) were allowed to adhere in the presence of apyrase 
(lU/mL) and indomethacin (lOuM) for 45min at 37°C. Syk: (A), PLCv2: (B) and SLP-76: (C) 
were sequentially immunoprecipitated from adherent platelet lysates using specific 
antibodies (all 5u,g with 25ul bead slurry) overnight at 4°C. Protein-A beads were used for 
Syk and PLCy2 while protein-G beads were used for SLP-76. Immunoprecipitation with non- 
reactive antibody (IgG, 5u,g) was a control against non-specific antibody interactions. 
Immunoprecipitates were subjected to SDS-PAGE on a 10-18% gradient gel for 2.5h at 120V 
under reducing conditions. Separated proteins were then transferred to polyvinylidene 
fluoride (PVDF) membranes for 2.5h at 100V, immunoblotted against the indicated proteins 
using specific antibodies (all 1:1000) and visualised by enhanced chemiluminescence. Blots 
represent 3 independent experiments with platelets from separate blood donors. IB: 
immunoblotting, MW: molecular weight, pTyr: phosphotyrosine.
Page | 187
Chapters
A)
HS FXIIIa Fib IgG HS FXIIIo Fib
MW (kDa) 220 
80- 
60- 
50- 
40-
20 — 20 —
IP: LAT 
IB: pTyr
IP: LAT 
IB: LAT
B)
Basal Coll Basal Coll IgC
MW (kDa) 140 
SO
60
50
40
30 —
20 —
MW (kDa) 140 . 
80
60 . 
50.
40.
30 —
20 —
LAT
IP: LAT 
IB: pTyr
IP: LAT 
IB: LAT
Page I 188
__________________________________________________Chapter 5
Figure 5.7: LAT is not tvrosine-phosphorylated in FXIIIa-adherent platelets. (A) Wells of a 6- 
well culture plate were coated overnight at 4°C with heat-inactivated human serum (HS, 5%), 
activated factor XIII (FXIIIa, 200u.g/mL) or fibrinogen (Fib, 200u,g/mL). Uncoated surfaces 
were blocked by overlay with HS (5%) for 30min at room temperature. Washed platelets 
(5xi08 platelets/mL) were allowed to adhere in the presence of apyrase (lU/mL) and 
indomethacin (10u,M) for 45min at 37°C. LAT was immunoprecipitated from adherent 
platelet lysates using anti-LAT antibody (5u,g with 25ul protein-G bead slurry) overnight at 
4°C. Immunoprecipitation with non-reactive antibody (IgG, 5|ig) was a control against non­ 
specific antibody interactions. Immunoprecipitates were subjected to SDS-PAGE on a 10-18% 
gradient gel for 2.5h at 120V under reducing conditions. Separated proteins were then 
transferred to polyvinylidene fluoride (PVDF) membranes for 2.5h at 100V, immunoblotted 
against the indicated proteins using specific antibodies (all 1:1000) and visualised by 
enhanced chemiluminescence. (B) As in (A), except platelets were adhered to collagen 
(10u.g/mL) in the presence of EGTA (ImM), apyrase (lU/mL) and indomethacin (10umol/L). 
Blots are representative of 3 independent experiments with platelets from separate donors. 
IB: immunoblotting, MW: molecular weight. pTyr: phosphotyrosine.
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Figure 5.8: FXIIIa does not stimulate protein tyrosine phosphorylation in suspended 
platelets. (A) Washed platelets (5xl08 platelets/mL) were incubated with activated factor XIII 
(FXIIIa, 200u.g/mL) in the presence of manganese ions (ImM), apyrase (lU/mL) and 
indomethacin (10u,M) for various times (0.5-60min) under constant stirring (lOOOrpm) at 
37°C. Platelets were lysed and subjected to SDS-PAGE on a 10-18% gradient gel for 2.5h at 
120V under reducing conditions. Separated proteins were then transferred to polyvinylidene 
fluoride (PVDF) membranes for 2.5h at 100V, immunoblotted against the indicated proteins 
using specific antibodies (all 1:1000) and visualised by enhanced chemiluminescence. (B) As 
in (A), except suspended platelets were incubated with collagen (50u.g/mL) for various 
durations (0.5-15min) in the presence of EGTA (ImM), apyrase (lU/mL) and indomethacin 
(10u,M). Blots are representative of 3 independent experiments with platelets from separate 
donors. IB: immunoblotting, MW: molecular weight. pTyr: phosphotyrosine.
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5.7 Stable platelet adhesion and spreading on FXIIIa are 
dependent on intracellular calcium mobilisation.
Signalling downstream of aMb33 causes activation of PLCy2 which leads to the mobilisation of 
intracellular calcium stores and platelet activation (Wonerow et al., 2003). Since PLCy2 was 
tyrosine-phosphorylated in FXIIIa-adherent platelets (Figure 5.6), which is associated with its 
activation (Daniel et al., 1994), the role of intracellular calcium elevation in platelet adhesion 
to FXIIIa was investigated. Preincubating platelets with BAPTA-AM (20uM), an intracellular 
calcium chelator (Harrison and Bers, 1987), significantly diminished platelet adhesion to 
FXIIIa (762±40 to 123±26 platelets/0.1mm2 for the absence and presence of BAPTA-AM 
respectively, P<0.01). Moreover, U73122 (5u,M), a PLC antagonist (Bleasdale et al., 1990), 
ablated stable platelet adhesion (5±3 platelets/O.lmm2 P<0.01 vs control) (Figure 5.9). 
Together, these data suggest a crucial role for calcium mobilisation in stabilising platelet 
adhesion to FXIIIa.
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Figure 5.9: Intracellular Ca 2* mobilisation is required for stable platelet adhesion on FXIIIa.
Wells on glass slides were coated overnight with heat-inactivated human serum (HS, 5%) or 
activated factor XIII (FXIIIa, 200u.g/mL). Uncoated surfaces were blocked by overlay with HS 
(5%) for SOmin at room temperature. Washed platelets (5xi07 platelets/mL) were treated 
with l,2-bis-(o-aminophenoxy)ethane-tetra-acetic acid tetra-(acetoxymethyl)ester (BAPTA- 
AM, 20u.M), U73122 or 0.01% DMSO (vehicle control) for 20 min at 37°C then adhered to the 
indicated surface for Ih at 37°C. Adherent platelets were stained with TRITC-phalloidin and 
viewed under the x60 objective of an 1X71 fluorescence microscope (Olympus, Japan). 
Platelets from random visual fields with a total area of O.lmm2 were counted. Data shown 
are means ± SD from 4 independent experiments with separate blood donors. **: P<0.01.
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5.8 Platelet adhesion to FXIIIa is influenced by platelet activation
Following stimulation by agonists, platelet integrin receptors acquire high affinity 
conformations and bind more readily to their ligands (Shattil et al., 1998, Shattil and 
Newman, 2004). To establish the role of agonist-stimulated platelet activation in platelet 
adhesion to FXIIIa, platelets were preincubated with ADP (lu.M) which significantly increased 
numbers of adherent platelets from 9221128 to 1415±145 platelets/O.lmm2 (P<0.01) (Figure 
5.10A). Since FXIIIa-adherent platelets were observed to secrete their granular contents 
(section 3.9), the role of secreted ADP was also investigated. Addition of apyrase (lU/mL), an 
enzyme that decomposes ambient ADP (Pilla et al., 1996), reduced adherent platelet 
numbers from 9221128 to 412178 platelets/O.lmm2 (P<0.01).
In contrast to adhesion, ADP did not influence platelet spreading since it did not change from 
control values of 29.014.0 to 28.712.2u,m2 in the presence of ADP and 28.013.1 in the 
presence of apyrase (P>0.05, ANOVA) (Figure 5.10B). These data suggest that although 
adhesion to FXIIIa is enhanced by platelet activation, integrin binding to FXIIIa provides 
adequate stimulus to drive platelet spreading.
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Figure 5.10; ADP-stimulated platelet activation increases adhesion, but not spreading on 
FXIIIa. Wells on glass slides were coated overnight with heat-inactivated human serum (HS, 
5%) or activated factor XIII (FXIIIa, 200u,g/mL). Uncoated surfaces were blocked by overlay 
with HS (5%) for 30min at room temperature. Washed platelets (5xl07 platelets/mL) were 
treated with adenosine diphosphate (ADP, lu,M), apyrase (ID/ml) or modified Tyrode's 
buffer (control) for 20min at 37°C then adhered for Ih at 37°C. Adherent platelets were 
stained with TRITC-phalloidin and viewed under the x60 objective of an 1X71 fluorescence 
microscope (Olympus, Japan). (A) Platelets from random visual fields with a total area of 
O.lmm2 were counted. (B) Images of adherent platelets were used to evaluate platelet 
surface area using ImageJ software (NIH, USA). Data shown are means ± SD from 4 
independent experiments with separate blood donors. **: P<0.01, NS: not significant.
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5.9 Platelet inhibition regulates adhesion to FXIIIa
Vascular endothelial cells release NO to restrict circulating platelets to their quiescent states 
(Furchgott and Zawadzki, 1980, Palmer et al., 1988). To investigate the effects of platelet 
inhibition by NO on their ability to bind FXIIIa, platelets were preincubated with GSNO, an NO 
donor (Radomski et al., 1992), prior to adhesion to FXIIIa. Treating platelets with GSNO 
(10u,M) significantly diminished their ability to bind FXIIIa (922±128 to 187178 
platelets/O.lmm2 for the absence and presence of GSNO, P<0.01) (Figure 5.11).
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Figure 5.11: Platelet inhibition by nitric oxide diminishes FXIIIa-mediated platelet adhesion.
Wells on glass slides were coated overnight with heat-inactivated human serum (HS, 5%) or 
activated factor XIII (FXIIIa, 200u.g/mL). Uncoated surfaces were blocked by overlay with HS 
(5%) for 30min at room temperature. Washed platelets (5xi07 platelets/mL) were treated 
with GSNO (10u.M) or modified Tyrode's buffer (control) for 20min at 37°C then adhered for 
Ih at 37°C. Adherent platelets were stained with TRITC-phalloidin and viewed under the *60 
objective of an 1X71 fluorescence microscope (Olympus, Japan). Platelets from random visual 
fields with a total area of O.lmm2 were counted. Data shown are means ± SD from 4 
independent experiments with separate blood donors. **: P<0.01.
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5.10 Discussion
Biochemical signalling is central to the induction of activatory responses which accompany 
platelet adhesion to thrombogenic ligands. It is this activatory signalling which stimulates 
platelet shape changes, granular secretion, phosphatidylserine exposure, stable adhesion 
and aggregation (Ruggeri, 2002, Varga-Szabo et al., 2008, Rivera et al., 2009). The present 
study demonstrates for the first time that FXIIIa is able to initiate signalling in platelets 
thereby stimulating characteristic functional responses. In particular, FXIIIa induced signalling 
through (Xnb33 integrins which led to spreading of adherent platelets (sections 4.3 and 5.4). 
This relied on the activity of Src-family kinases, since spreading and its dependent stable 
adhesion were blocked following their inhibition (Figure 5.1). Consistent with the activation 
of tyrosine-kinases, adhesion to FXIIIa caused tyrosine phosphorylation of key platelet 
signalling proteins including Syk, SLP-76 and PLCy2 independently of platelet-derived agonists 
ADP and TxA2 (Figure 5.6). Tyrosine phosphorylation was also stimulated in platelets 
adherent to zymogen FXIII suggesting that it was independent of transglutaminase activity 
(Figure 5.2B). Thus, the signalling events initiated by FXIIIa resemble those in platelets 
adherent on fibrinogen, which also signals through aMbB3 (Gao et al., 1997, Obergfell et al., 
2001, Shattil, 2005). Although the same secondary messengers appear to be involved in 
signalling that follows adhesion to FXIIIa and fibrinogen, there are observable differences in 
the extents of their phosphorylation in platelets that have adhered for 45min. For instance, 
Syk appears to be more heavily phosphorylated in FXIIIa-adherent platelets than in those 
adherent to fibrinogen, while the converse is true for SLP-76 (Figure 5.6). This suggests that
signalling downstream of FXIIIa and fibrinogen may follow different kinetics. Since, platelet- 
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associated FXIIIa cross-links several ligands which occupy integrins (Dale et al., 2002), the 
ensuing signalling may explain the differences observed. Nevertheless, fuller appreciation of 
the nature of phosphorylation of each secondary messenger would be enabled by conducting 
time-course experiments with platelets that would have been allowed to adhere for times 
other than 45min.
"Outside-in" signalling downstream of a^Pa is characterised by activation of Src-family 
kinases which leads to the recruitment of the tyrosine kinase Syk (Gao et al., 1997, Obergfell 
et al., 2002). Sequentially, PLCv2 is activated, leading to Ca2+ mobilisation required for 
platelet activation, causing further anb33 high affinity conformational changes ("inside-out 
signalling"). Hence, integrin activation is self-propagating and influenced by platelet 
activation. Indeed, platelet adhesion to FXIIIa was enhanced by ADP-stimulated platelet 
activation (Figure 5.10A). In line with this, platelet adhesion to FXIIIa was inhibited by NO 
(Figure 5.11), a physiological endothelium-derived platelet antagonist. This suggests that 
adhesion only takes place at regions where platelet inhibition is diminished and platelet 
activation promoted such as at sites of vascular injury or where the endothelium is 
dysfunctional.
Platelets have multiple receptors for many of their ligands and some of these receptors 
mediate differential, non-redundant effects. For example, ADP stimulates platelets through 
P2Yi and P2Yi2 purinergic receptors with the former leading to PKC activation and Ca2+ 
mobilisation while the latter diminishes intracellular cAMP levels (Daniel et al., 1998). Similar
multiplicity holds true for vWF, thrombin and collagen receptors (Rivera et al., 2009). In
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particular, collagen and vWF-mediate platelet activation through mechanisms which 
resemble those by FXIIIa which triggers tyrosine kinase-dependent signalling downstream of 
aMb33, but not av33 (Figure 5.3). Firstly, collagen drives activatory signalling through GPVI 
while a2pi appears more limited to an adhesive role (Watson et al., 2005). Secondly, collagen 
stimulates protein tyrosine-phosphorylation with the involvement of Src, Syk, and SLP-76 
leading to activation of PLCv2 and cellular Ca2+ mobilisation (Watson and Gibbins, 1998). 
Immobilised vWF binds flowing platelets only transiently through GPlb/IX/V and requires 
association with aMb33 for more stable attachment to initiate spreading responses (Ruggeri, 
2007a). Thus, it is unsurprising that FXIIIa binds platelets through the dual-receptor 
mechanism described here.
Since aMb33 and avp3 share a common 3 subunit and considerable homology between their a 
subunits (Shattil and Newman, 2004) signalling by one integrin, but not the other may be 
unexpected. av3s was first discovered in melanoma cells where its ligand affinity for 
vitronectin, vWF and fibrinogen was established (Cheresh and Spiro, 1987). The receptor was 
also identified in endothelial cells where it had similar ligand affinity and its blockade 
inhibited angiogenesis as well as induced apoptosis (Brooks et al., 1994, Brooks et al., 1995). 
In these cells, av33 was reported to stimulate a signalling cascade involving FAK, calpain, NF- 
KB, and Rac (Shattil, 1995). Signalling mediated by av33 has also been well characterised in 
osteoclasts where it involves activation of Src and Syk through mechanisms similar to those 
downstream of platelet aMb33 (Zou et al., 2007). Since av33 and both tyrosine kinases are 
present in platelets, the existence of a similar signalling cascade would be tempting to
speculate. Nevertheless, although platelet studies have demonstrated that av3s can mediate
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adhesion to vitronectin, fibrinogen and thrombospondin, even by platelets from patients 
with GT (Lam et al., 1989, Lawler and Hynes, 1989, Coller et al., 1991), there is limited 
evidence regarding its signalling properties. However, McCarty et al., (2004) reported that 
adhesion of platelets from dm,7' deficient mice to fibrinogen could be inhibited by blocking 
avp3 . Importantly, although these platelets could adhere to fibrinogen, they failed to spread 
suggesting that only ttiibPa, but not avp3 is able to trigger signalling in platelets. Similar results 
were obtained with fibronectin, suggesting that platelet a5pi may be involved in adhesion, 
but not signalling and spreading on the protein (McCarty et al., 2004). These data suggest 
that signalling downstream of <zvp3 may be a phenomenon operating in other cells, but not 
platelets. A possible explanation for this may be the low copy number of avp3 on platelets 
which might restrict its cross-linking, homotypic oligomerisation and formation of focal 
adhesions which facilitate integrin-mediated "outside-in" signalling.
Although immobilised FXIIIa stimulated platelet spreading, it is noteworthy that it did not 
induce shape changes or aggregation (Figure 3.4), or tyrosine phosphorylation in platelet 
suspensions (Figure 5.8A). This explains in part why previous studies have not reported 
signalling events induced by this enzyme. Furthermore, signal transduction induced uniquely 
by immobilised FXIIIa suggests a distinct mechanism that allows it to promote platelet 
activation only when localised at sites of vascular damage. Since they bind to collagen 
exposed at these sites, FXIIIa and vWF may further enhance its thrombogenic potential by 
supplementing activatory signal transduction through a long-lived, integrin-mediated 
"outside-in" signalling cascade which maintains platelet contacts within aggregates and
stimulates clot-retraction (Ruggeri, 2002). Moreover, FXIIIa becomes localised on the
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surfaces of dysfunctional endothelium where it is able to recruit platelets (Dardik et al., 
2002b). Such abnormal deposition and activation of platelets may have pathological 
consequences including the aggravation of peripheral vascular disease which is characterised 
by elevated FXIIIa levels (Shemirani et al., 2008), activated platelets (Matsagas et al., 2002) 
and dysfunctional endothelium (Esper et al., 2006).
In conclusion, this chapter has described an activatory signalling cascade that occurs in FXIII- 
adherent platelets which is stimulated specifically through OnbPa integrins. Such signalling is 
crucial for the occurrence of spreading responses that stabilise platelet adhesive contacts 
with the enzyme. Furthermore, it potentially supplements the activation of platelets at sites 
of vascular injury.
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CHAPTER 6 - GENERAL DISCUSSION
The present project aimed to investigate platelet adhesive contacts with FXIII. Previous 
demonstration of specific FXIII-binding to platelet anbPs fuelled speculation that it may have 
roles in platelet function (Cox and Devine, 1994, Muszbek et al., 1999). However the 
physiological consequences of platelet-FXIII interactions have remained elusive. This is largely 
due to previous studies focussing mainly on platelet-FXIII interactions occurring in 
suspension. While platelets are able to bind suspended FXIII, the importance of these 
associations with respect to platelet function was difficult to delineate since suspended 
platelets from FXIII-deficient patients had been shown to aggregate normally (Ozsoylu and 
Hicsonmez, 1976). However, a more recent study using platelets from three FXIII-deficient 
patients gave conflicting results since it reported diminished aggregation responses to 
collagen, ADP and epinephrine (Anwar et al., 2002). Platelet-bound FXIII was also found to 
retard fibrinolysis and stabilise thrombi by cross-linking a2-antiplasmin specifically to 
platelet-rich thrombi (Reed et al., 1991). Together with a demonstration that exogenous FXIII 
activity imparts a procoagulant platelet phenotype (Dale et al., 2002), these findings renewed 
research interest into the in vivo implications of platelet-FXIII associations.
Dardik et al., (2002b) showed that FXIII-coated plastic surfaces supported platelet adhesion. 
Theirs was the pioneering investigation of platelet interactions with immobilised FXIII. They 
also reported that in vivo plasma supplementation of FXIII-deficient patients with FXIII
concentrate enhanced platelet accrual on activated, dysfunctional endothelium ex vivo. This
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reinforced hypothesised pathophysiological consequences from a study that reported 
increased platelet-FXIII associations in patients with PVD, but not matched healthy controls 
(Devine et al., 1993). However, Dardik et al., (2002b) did not demonstrate the purity of their 
source of FXIII from contaminating platelet adhesive ligands nor did they assess ensuing 
functional responses by adherent platelets. Whether FXIII also influences platelet 
recruitment by ECM proteins which are perhaps more involved in platelet thrombosis has 
since not been investigated.
Using established platelet imaging and biochemical analyses, functional platelet responses 
stimulated by interactions with FXIII were examined in the present study. Extensive effort 
was made to ensure that FXIII actually binds platelets independently of other proteins as 
described in Chapter 3. This included stringent assessment of purity of the source of plasma 
FXIII used in this study, the demonstration that platelet adhesion was reproducible on plasma 
protein-free recombinant FXIII and that it could occur independently of proteins secreted 
from platelet a-granules. Together, these data provide strong evidence to suggest that 
immobilised FXIII is indeed a true platelet ligand. Interestingly, while platelet adhesion to 
FXIII can proceed independently of other proteins, FXIII was observed to enhance platelet 
accrual by key, thrombogenic platelet-ligands, specifically collagen, fibrinogen and vWF 
(Chapter 4). Thus like other coagulation proteins which have recently been shown to bind 
platelets including protein C (White et al., 2008) and factor XI (White-Adams et al., 2009), 
FXIII may serve to enhance platelet thrombosis under physiological conditions with its 
abnormally high plasma concentrations predisposing to cardiovascular disease (Devine et al.,
1993, Bereczky et al., 2007, Shemirani et al., 2008).
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This study presents a potentially new dual-receptor mechanism which facilitates platelet 
adhesion to FXIII. The mechanism relies on the concerted roles of anb33 and avp3 integrins, 
whereby both integrins are involved in the initial platelet adhesion (Chapter 4) while 
activatory signal transduction which leads to spreading and stable adhesion is only mediated 
by otnbPs (Chapter 5). The involvement of integrins in the adhesion events is paradoxical since 
FXIII-A lacks both the canonical RGD integrin-binding motif and a KQAGDV sequence 
(Ichinose and Davie, 1988). The latter is present on fibrinogen v-chains and crucially mediates 
physiological fibrinogen-binding by a,ibP3 (Kloczewiak et al., 1982, Kloczewiak et al., 1983). 
However, FXIII-A possesses a leucine-aspartate-valine (LDV) sequence recognised by some 
integrins (Ichinose and Davie, 1988, Humphries et al., 2006). Since the LDV residues are at 
opposite ends of FXIII-A2 dimers in solution (Yee et al., 1995), they are potentially accessible 
to both integrins.
The model proposed for physiological platelet interactions with FXIII involves multipronged 
associations. Since much of the FXIII zymogen may circulate bound to fibrinogen (Greenberg 
and Shuman, 1982, Siebenlist et al., 1996), initial delivery of FXIII to vascular injury sites is 
likely to occur with it in complex with fibrinogen. At these sites, fibrinogen is captured and 
immobilises on adherent platelets, where FXIII may enhance fibrinogen-mediated platelet 
accrual as demonstrated under flow (Figure 4.12). It has been shown that fibrinogen- 
occupation of ai, b33 does not inhibit platelet-FXIII binding (Cox and Devine, 1994). 
Furthermore, avp3 plays a negligible role in platelet fibrinogen-binding (Smith et al., 1990),
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but an important role in FXIII-binding (Figure 4.4). Together, these data suggest that platelet 
binding to FXIII is indeed feasible in the presence of fibrinogen.
Due to the high local thrombin concentrations generated at vascular injury sites, zymogen 
FXIII is activated and liberated from fibrinogen (Muszbek et al., 1999). It thus becomes free to 
perform its role as a transglutaminase, cross-linking and stabilising fibrin strands. In addition, 
FXIIIa acquires the ability to localise on collagen fibres, a property unique from its zymogen 
form (Figure 4.13). By providing adhesive sites which bind OiibPs and avp3/ FXIIIa potentially 
increases platelet binding sites available per collagen fibre, facilitating increased platelet 
accrual as evidenced by greater thrombus volumes observable on FXIIIa-bound collagen 
under flow (Figure 4.14iii). Indeed, localisation of FXIIIa on the ECM is well established and 
has been shown to be critical for fibroblast proliferation and migration which are 
compromised causing poor wound healing in FXIII-deficient patients (Muszbek et al., 1999, 
Wozniak and Noll, 2002). Similar to other integrin ligands, platelet contacts with FXIII are 
influenced by shear forces imposed by flowing blood. At high shear rates typically found in 
arterial vessels, vWF is essential to facilitate platelet-FXIIIa contacts which are significantly 
enhanced by its presence (Figure 4.15). Since vWF rapidly binds to collagen exposed at 
vascular injury sites (Pareti et al., 1986), it is available to enable platelet interactions with 
FXIIIa at these sites.
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Future work
While the present study has provided new insights into the nature of platelet associations 
with FXIII a number of issues remain to be considered in future investigations. These include 
the following:
1. The exact nature and location of the platelet-binding site is yet to be established. It is 
known that platelets bind to FXIII-A, not FXIII-B (Greenberg and Shuman, 1984), but 
the exact protein domain interacting with platelets has not been characterised. 
Definitive demonstration of the involvement of LDV residues or yet other potentially 
novel integrin-binding sequences within FXIII-A awaits future investigation. This could 
be tackled in the first instance by genetic manipulation whereby FXIII-A with mutated 
LDV sequences is examined for its ability to support platelet adhesion. If LDV 
sequences are shown to be uninvolved, platelet adhesion to peptides fragmented 
from FXIII-A could be assessed to locate the binding site.
2. The role of OvPs in platelet adhesion to FXIII as described in this study requires 
confirmation. Presently, predicted involvement of this integrin derives solely from the 
use of an inhibitory antibody (LM609). While the use of this antibody to identify 
potential avp3 ligands is well-established (Takagi et a)., 1997, Jalali et al., 2001), the 
current observations will be strengthened if they are reproducible with CHO cells 
transfected with DNA to express av33 integrins. Moreover, the use of platelets
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specifically deficient in ctv or anb will enable confirmation of the dual-receptor 
mechanism hypothesised to mediate platelet-FXIII contacts.
3. The study of platelet-FXIII interactions in living animals has not been performed to 
date. Although the present study has aided appreciation of the influence of vascular 
flow conditions on the stringency of such interactions, their analysis in a more 
complex in vivo setting would provide the clearest indication. FXIII-deficient mice are 
available and have extended bleeding times (Lauer et al., 2002). Using these mice, 
platelet thrombus formation can be studied in real-time with in vivo models based on 
intravital microscopy. By fluorescently tagging FXIII, its actual immobilisation and 
platelet-interaction at vascular injury sites can be assessed. More information can 
also be obtained by generating FXIlK'/aiibPs"7" and FXIir'yovpy7" double-knockout
mice.
4. The roles of platelet-FXIII interactions in vascular pathology still await specific 
intensive investigation. The mechanisms involved in FXIII-mediated enhancement of 
thrombosis shown in this study may be potentially involved in the aggravation of 
cardiovascular disease. In the future, investigations of platelet thrombus formation 
leading to vascular occlusion in animals genetically manipulated to express elevated 
plasma FXIII levels will clarify the involvement of these events in disease. 
Furthermore, analysis of platelet-FXIII interactions in animals reared on a high-fat diet 
will provide understanding of their roles in the pathogenesis of atherosclerosis.
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Conclusion
Data presented in this thesis contribute to the better understanding of potential in vivo 
consequences of platelet interactions with FXIII which has been demonstrated to induce a 
number of platelet functional effects such as signal transduction, spreading, secretion and 
thrombus formation under flow, specifically when immobilised. In particular, FXIII-mediated 
enhancement of platelet accrual by key platelet ligands which appears to be influenced by 
FXIII concentration provides a potential premise for reported involvement of high plasma 
FXIII antigen levels in thrombotic disease.
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Summary. Background: Activated coagulation factor XIII 
(FXIIIa) is a transglutaminase that crosslinks fibrin at sites of 
vascular injury. FXIIIa also associates with blood platelets, 
although its role in platelet function is unclear and requires 
clarification. Objectives: To evaluate the ability of FXIIIa to 
support platelet adhesion and spreading under conditions of 
physiologic flow, and to identify the underpinning receptors and 
signaling events. Methods and Results: Platelet adhesion to 
immobilized FXIIIa was measured by fluorescence microscopy, 
and signaling events were characterized by immunoblotting. 
Immobilized FXIIIa supported platelet adhesion and spreading 
under static conditions through mechanisms that were dually 
and differentially dependent on integrins otribfo and OvpV 
Platelet adhesion was independent of FXIIIa transglutaminase 
or protein disulfide isomerase activity. Moreover, adhesion was 
abolished by antibodies that prevented interaction with FXIIIa, 
but maintained when potential interactions with fibrinogen 
were blocked. Platelet adhesion to FXIIIa was reduced 
significantly by either the specific otnbPs antagonist tirofiban 
or the selective ctvpyblocking antibody LM609, and abolished 
when they were used in combination. Importantly, platelet 
adhesion was preserved under venous and arterial flow 
conditions in which both integrins played essential roles. In 
contrast, FXIIIa stimulated the formation of filopodia and 
lamellipodia in adherent platelets that was mediated exclusively 
by «iibp3 and eliminated by the Src-family inhibitor 4-amino-5- 
(4-methylphenyl-7-(t-butyl)pyrazolo(3,4-d)pyrirnidine, indicat­ 
ing a tyrosine kinase-dependent mechanism. Crucially, under 
conditions of arterial shear, FXIIIa accentuated platelet 
recruitment by von Willebrand factor and collagen. Con­ 
clusions: Our data demonstrate a potential role for FXIIIa in
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supporting platelet adhesion at sites of vascular damage, 
particularly in association with other thrombogenic matrix 
proteins.
Keywords: factor XIII, integrin signaling, platelets, thrombo­ 
sis.
Introduction
The accrual of blood platelets at sites of vascular injury is an 
essential hemostatic response that precludes loss of blood. A 
plethora of studies have examined the involvement of extra­ 
cellular matrix (ECM) proteins such as collagen and von 
Willebrand factor (VWF) in platelet-vessel wall interactions, 
and inherent adhesive mechanisms have become well estab­ 
lished [1]. More recently, a number of proteins involved in the 
blood coagulation cascade, including protein C and factor XI, 
have been shown to support platelet adhesion under flow, 
adding a new dimension to our current understanding of the 
recruitment of platelets to sites of vascular injury [2,3]. It has 
been known for some time that platelets also interact with 
FXIII. FXIII is a member of the transglutaminase family of 
enzymes, which covalently join substrate molecules through 
e(y-glutamine)-lysine crosslinkages [4]. Plasma FXIII circulates 
as a tetramer of two carrier B-subunits (FXIII-B) and two 
catalytic A-subunits (FXIII-A). Upon vascular injury, throm- 
bin cleaves 4-kDa activation peptides from each of the 
A-subunits, allowing their Ca" + -dependent dissociation from 
B-subunits and engagement with substrate molecules. A major 
role for activated plasma FXIII (FXIIIa) is fibrin-clot stabil­ 
ization through crosslinking reactions [4,5]. Furthermore, a 
small amount of plasma FXIII is absorbed by platelets and 
localizes in their a-granules [6]. Following platelet activation, 
o(-granule FXIII may be released to supplement its concentra­ 
tion at sites of developing thrombi [6].
Platelets are known to bind FXIIIa through anbfc integrins 
[7]. However, platelets from Glanzmann thrombasthenia 
patients, which lack functional anbfe, maintained an ability 
to bind FXIIIa, suggesting the involvement of other, unknown, 
receptors [8]. Observations that FXIIIa binds to platelets
© 2011 International Society on Thrombosis and Haemostasis
through FXin-A but not FXIII-B [8] generated considerable 
interest in the involvement of these interactions in hemostasis 
and thrombosis [4]. However, the physiologic roles of FXIII in 
platelet function are largely undefined. FXIIIa at the platelet 
surface was ascribed a role in the development of highly 
procoagulant 'coated' platelets [9], suggesting that it may 
accentuate platelet-dependent thrombus formation. Indeed, 
investigations by Dardik et al. [10] revealed that in vivo 
supplementation of FXIII-deficient patients with FXIII con­ 
centrate almost doubled the tendency of platelets to associate 
with dysfunctional endothelium ex vivo. The investigators 
demonstrated that, by binding platelets via anbPa, FXIII(a) 
facilitated their interactions with endothelial cells. It is thus 
possible that FXIIIa may play a role in the pathogenesis of 
atherothrombosis, which is characterized by abnormal plate- 
let-endothelial associations. However, whether FXIIIa also 
enhances platelet adhesion and thrombus formation on ECM 
proteins remains unknown. Moreover, its ability to initiate 
intracellular signaling in platelets or induce characteristic 
platelet responses such as spreading and thrombus formation 
under arterial shear has not been characterized.
The aims of the present study were to extend previous 
findings by Cox and Devine [7] and Dardik et al. [10], by 
determining whether immobilized FXIIIa not only supported 
platelet adhesion, but also stimulated spreading responses, and 
to elucidate the receptors and signaling mechanisms involved. 
We demonstrate that immobilized FXIIIa supports platelet 
adhesion that triggers signal transduction, leading to spreading 
and stable adhesion under physiologic flow. These events 
depend on a dual and non-redundant mediation by otubPs and 
Ovfo. Importantly, FXIIIa synergizes with subendothelial 
matrix proteins, particularly collagen and VWF, to enhance 
platelet recruitment under conditions of arterial shear.
Materials and methods
Reagents
Rabbit monoclonal anti-phospholipase C (PLC)y2 antibody 
and mouse monoclonal anti-Syk were from Santa Cruz 
(Heidelberg, Germany). Normal mouse IgG, anti-phosphoty- 
rosine, anti-LAT, anti-SLP-76, anti-o^ (LM609) and anti- 
p-tubulin mAbs were from Millipore (Watford, UK). Mouse 
monoclonal anti-FXIII-A, fluorescein isothiocyanate-conju- 
gated goat anti-mouse antibody and rabbit polyclonal 
anti-fibrinogen and anti-FXIII-A antibodies were from Abeam 
Pic (Cambridge, UK). Phe-Pro-Arg-chloromethylketone 
(PPACK) was from Cambridge Bioscience (Cambridge, UK). 
H-Arg-Gly-Asp-Ser-OH (RODS) and 1,2-bis-(o-aminophen- 
oxy)ethane-tetra-acetic acid tetra-(acetoxymethyl) ester (BAP- 
TA-AM) were from Calbiochem (Nottingham, UK). 4-Amino- 
5-(4-methylphenyl-7-(t-butyl)pyrazolo(3,4-d)pyrimidine (PP1) 
was from BIOMOL International (Exeter, UK). Collagen horm 
reagent was from Nycomed (Zurich, Switzerland). U73122 and 
S-nitrosoglutathione (GSNO) were from Tocris Bioscience 
(Bristol, UK). Purified VWF was from LFB (Lyon, France).
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Heat-inactivated pooled human serum was from Sheffield 
University Hospital (Sheffield, UK). Tirofiban (Aggrastat) 
was from Iroko Pharmaceuticals (Philadelphia, PA, USA). 
pGEX-6P-l containing the gene sequence for recombinant 
FXIII-A (rFXIII-A) was a kind gift from R. Aliens (University 
of Leeds, Leeds, UK), and was expressed in BL21-Gold DE3 
Escherichia coli (Stratagene, CA, USA). Human a-thrombin 
and all other reagents were from Sigma (Poole, UK).
FXIII activity
Fibrogammin P (CLS Behring, Sussex, UK) was used as a 
purified source of human plasma-derived FXIII. Fibrogam­ 
min P and human rFXIII-A were activated with human a- 
thrombin (10 U rnL" 1 ) in the presence of 10 mM CaCl2 for 1 h 
at 37 °C. PPACK (20 \JLM) was then added for 10 min to 
inactivate thrombin [10]. Complete inhibition of thrombin 
under these conditions was monitored by its diminished ability 
to stimulate platelet aggregation and loss of reactivity with a 
chromogenic substrate (not shown). Transglutaminase activity 
was monitored by measuring crosslinking of biotinylated 
amines to fibrinogen, as previously described [11]. To inhibit 
transglutaminase activity, FXIIIa was incubated with the 
alkylating agent iodoacetamide (3 mM) for 30 min at 20 °C. 
Protein disulfide isomerase (PDI) activity was inhibited by 
incubation with bacitracin (1 HIM) for 1 h at 37 °C [12].
Platelet isolation
The experiments were approved by the Post-Graduate Medical 
Institute ethics committee (University of Hull, UK), in 
accordance with the declaration of Helsinki. Blood was 
obtained from healthy volunteers who had denied taking any 
medication for 2 weeks. Washed platelets were prepared with 
the prostaglandin E, method [13]. Autologous red blood cells 
(RBCs) were pelleted from whole blood by centrifugation at 
200 x g for 20 min at 20 °C. After removal of supernatant, 
they were washed twice with wash buffer (10 HIM EDTA, 
50 HIM glucose, 90 mM NaCl, 36 mM citric acid, 50 HIM KC1, 
pH 6.5), and then once with modified Tyrode's buffer [13] by 
further centrifugation at 800 x g for 12 min at 20 °C. When 
required, they were reconstituted to 50% (v/v) with washed 
platelets (2 x 10s platelets mL~', final concentration) in mod­ 
ified Tyrode's buffer supplemented with 1 mM CaCl2 and 
40 UM PPACK.
Fluorescence microscopy
Wells on glass slides were coated overnight with heat-denatured 
FXIIIa (dFXIIIa, 10UmL~'), FXIII or FXIIIa (both 
10 U mL~'), recombinant FXIII (rFXIII) or activated recom­ 
binant FXIII (rFXIIIa) (both 200 ug mL~') or fibrinogen 
(200ugmL~') for 12 h at 4 °C. Unbound protein was 
removed by washes in phosphate-buffered saline (PBS), and 
uncoated surfaces were blocked by overlay with heat-inacti­ 
vated human serum albumin (HSA; 5% in PBS) for 30 min at
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20 °C [14]. Washed platelets (5 x 107 platelets mL" 1 ) were 
allowed to adhere for 1 h at 37 °C unless stated otherwise. In 
some experiments, platelets were preincubated with U73122 
(5 MM) to inhibit PLC, BAPTA-AM (20 UM) to chelate 
intracellular Ca24 , apyrase (1 UmL' 1 ) to scavenge ADP, 
indomethacin (10 MM) to block thromboxane A2 synthesis, 
PP1 (20 MM) to inhibit Src-family kinases, GSNO~(10 UM) to 
inhibit platelet activation, RODS (500 MM) to broadly inhibit 
platelet integrins, tirofiban (2 MM) to specifically inhibit otllbp\, 
or LM609 (20 Mg mL~') to specifically inhibit o^fo. Incuba­ 
tions were performed for 20 min at 37 °C prior to platelet 
adhesion. In other experiments, coated wells were overlaid with 
polyclonal anti-fibrinogen or anti-FXIII-A blocking antibodies 
or control IgG (all 30 Mg mL~' in 10% HSA) for 30 min. Wells 
were washed, platelets were allowed to adhere, and adherent 
platelets were fluorescently stained for 1 h with tetramethyl 
rhodamine isothiocyanate--phalloidin. The slides were observed 
with an 1X71 fluorescence microscope equipped with an XM10 
CCD camera (Olympus, Tokyo, Japan). Images were captured 
under x 60 magnification and analyzed with IMAGE! software 
(NIH, Bethesda, MD, USA).
Measurement of platelet adhesion under flow
Platelets (2 x 10s platelets mL-') were stained with DIOC6 
(1 MM) at 37 °C for 10 min reconstituted with autologous 
washed RBCs (50% v/v). Flow studies were performed with 
glass microslide capillary tubes (Camlab, Cambridge, UK), 
coated with FXIIIa (1-10 U mL" 1 ) for 12 h in the presence or 
absence of VWF (20 Mg mL" 1 ) and blocked with bovine serum 
albumin (BSA) (lOmgmL" 1 ) for 1 h. To investigate how 
FXIIIa bound to collagen and influenced its ability to support 
platelet arrest, collagen (100 Mg mL" 1 ) was initially incubated 
with FXIIIa (10UmL~') for 15 min at 37 °C prior to 
immobilization. Platelets were perfused through coated tubes 
at the desired shear rate for 4 min. Images of stably adhered 
platelets and thrombi were captured by fluorescence micros­ 
copy and analyzed with IMAGE! software. Data for adhesion 
under flow are presented as surface area coverage (%), as the 
software could not fully discriminate between single platelets 
and platelet aggregates. Measurement of thrombus volume was 
performed as previously described [15]. Briefly, images of 
platelet thrombi were captured by fluorescence and stored in a 
24-bit black and white format. Thrombus surface area values 
were then multiplied by their corresponding mean gray values, 
which coincided with fluorescence intensity. The product was 
considered as thrombus volume and measured in arbitrary 
units [15-17],
Immunoprecipitation and immunoblotting
Six-well culture plates were coated overnight with dFXIIIa 
(10 U mL" 1 ) or FXIIIa (10 U mL"'). Uncoated surfaces were 
blocked by overlay with HSA (5%) [14] for 30 min at 20 °C. 
Washed platelets (5 x 108 platelets mL" 1 ) were allowed to 
adhere to dFXIIIa-coated or FXIIIa-coated wells for 45 min at
37 °C in the presence or absence of receptor antagonists. Non- 
adherent platelets were removed, and adherent platelets were 
lysed with Laemmli buffer to produce whole cell lysates, or lysis 
buffer for immunoprecipitation studies [13]. Syk, LAT, PLCy2 
and SLP-76 were then immunoprecipitated as previously 
described [13]. Immunoprecipitated proteins were separated 
by SDS-PAGE, transferred to polyvinylidene difluoride mem­ 
branes, immunoblotted with the required antibodies (all 
1 : 1000), and then visualized by enhanced chemiluminescence.
Statistical analysis
Results are expressed as means ± standard deviations, and 
were analyzed with Student's /-test or ANOVA for unpaired data 
as appropriate. P < 0.05 and P < 0.01 were considered to 
indicate statistical significance.
Results
FXIII stimulates spreading of adherent platelets
We first characterized the ability of immobilized FXIII to 
support platelet adhesion and spreading under static condi­ 
tions. Plasma FXIII, in both native and activated states, 
supported equal numbers of adherent platelets (782 ± 108 and 
712 ± 82 platelets/0.1 mm2 for FXIII and FXIIIa, respec­ 
tively, P > 0.05) (Fig. lAii). At identical concentrations of the 
A-subunit, adhesion levels were equally reproducible with 
recombinant zymogen and activated enzyme forms (548 ± 92 
vs. 608 ± 155 platelets/0.1 mm2 for rFXIII and rFXIIIa, 
respectively, P > 0.05) (Fig. lAii). Platelets did not bind 
denatured FXIIIa, suggesting a dependence on its correct 
conformation. Moreover, consistent with previous reports, 
platelets did not bind the HSA used to effectively block 
uncoated glass surfaces [14]. Platelet adhesion to both FXIII 
and FXIIIa was concentration-dependent, and increased as a 
function of time, with similar kinetics for zymogen and 
activated enzyme forms (not shown).
We observed that adherent platelets on activated and 
zymogen FX1II had a fully spread morphology (Fig. 1A), 
exhibiting both filopodia and lamellipodia formation. At 
60 min. the majority of platelets were fully spread, with 
average platelet surface areas of 24 ± 5 and 28 ± 3 unr 
(P > 0.05) for FXIII and FXIIIa, respectively (Fig. lAiii). 
Similar activation-triggered shape changes were observed in 
platelets bound to rFXIII and rFXIIIa (Fig. lAi). Thus, under 
static conditions, immobilized FXIII and FXIIIa supported 
equal levels of platelet adhesion, but also similarly triggered 
activation and spreading in adherent platelets.
As FXIII can associate with fibrinogen in plasma [18], we 
examined our source of plasma FXIII for contaminating 
fibrinogen. Immunoblotting of fibrogammin P with a poly­ 
clonal anti-fibrinogen antibody failed to reveal the presence 
of fibrinogen when compared to a purified fibrinogen control 
(Fig. SlAi). Furthermore, we confirmed the FXIII-A content 
of both fibrogammin P and rFXIII-A through immunoblot-
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ting with a specific antibody (Fig. SlAii). To confirm that 
platelets were binding FXIIIa independently of fibrinogen 
specific blocking antibodies to FXIII-A and fibrinogen were 
used. Platelet adhesion to FXIIIa was abolished by overlay­ 
ing the immobilized protein with a polyclonal anti-FXIII-A 
antibody, whereas an IgG control had no effect (Fig. IB). 
Importantly, overlaying FXRIa with an anti-fibrinogen 
antibody failed to influence platelet adhesion to FXIIIa,
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but blocked adhesion to immobilized fibrinogen. Adding 
anti-fibrinogen antibody to platelet suspensions prior to 
adhesion also did not affect platelet binding to FXIIIa (not 
shown). These data, along with those showing equally 
reproducible platelet adhesion to plasma protein-free 
rFXIII-A (Fig. 1A), indicate that the observed adhesion 
and spreading events on plasma FXIII occurred indepen­ 
dently of fibrinogen.
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Fig. 1. Activated factor XIII (FXIIIa) stimulates spreading of adherent platelets. (A) Wells on glass slides were coated overnight at 4 °C with FXIII or 
FXIIIa (10 U mL' 1 ), recombinant FXIII (rFXIII) or recombinant FXIIIa (rFXIIIa) (200 ug ml/ 1 ), or heat-denatured FXIIIa (dFXIIIa) (10 U mL"'). 
Uncoated surfaces were blocked by overlay with heat-inactivated human serum albumin (HSA) (5%) for 30 min at 20 °C. Washed platelets 
(5 x 107 platelets mL' 1 ) were allowed to adhere for 1 h, stained with tetramethyl rhodamine isothiocyanate-phalloidin. and viewed under x 60 magni­ 
fication, (i) Representative images are shown. Bar: 20 urn. (ii) Platelets were counted and expressed as number of adherent platelets per 0.1 mm2 , (iii) 
Images were used to determine platelet surface area. (B) As in (A), except that some wells were separately coated with fibrinogen (200 ug mL' 1 ) (light bars) 
or FXIIIa (10 U mL' 1 ) (dark bars), and then overlaid with the indicated polyclonal antibody (30 ug mL" 1 ) or left untreated for 30 min at room 
temperature prior to platelet adhesion. (B) (i) Representative images are shown. Bar: 20 urn. (ii) Platelets were counted and expressed as number of 
adherent platelets per 0.1 mm2 . Results are means ± standard deviations of three separate experiments with different blood donors. (C) Platelets were 
pretreated with S-nitrosoglutathione (GSNO) (10 umol mL~') for 20 min at 22 °C or left untreated (control), and the number of adherent platelets was 
determined. Results are means ± standard deviations of four separate experiments with with different blood donors. Fgn, fibrinogen; NS, not significant. 
**P < 0.01, *P < 0.05.
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Our data suggested that transglutaminase activity did not 
play a role in FXIII-mediated platelet adhesion (Fig. lAii). 
Under conditions where the transglutaminase activity of 
FXIIIa was inhibited by iodoacetamide (3 HIM) (Fig. S2A), 
platelet adhesion was unaffected (Fig. S2B). Furthermore! 
inhibition of a potential TDI-like activity' of FXIIIa [12] by 
incubation with bacitracin (1 mM) also failed to inhibit 
platelet adhesion (Fig. S2C). In contrast, adhesion was 
significantly diminished by inhibition of platelet activation 
with the nitric oxide donor GSNO (10 umol mL-') 
(Fig. 1C).
platelets, leading to stable aggregate formation at a venous 
shear rate of 300 s~' (Fig. 2). This was maintained at arterial 
shear (800 s~'), albeit to a significantly lower extent than at 
300 s~' (P < 0.01) (Fig. 2). Thus, immobilized FXIIIa sup­ 
ports platelet adhesion under physiologic conditions of flow, in 
a shear-dependent manner. Under these conditions, adhesion 
also occurred independently of transglutaminase activity, and 
was reproducible with FXIII and iodoacetamide-treated 
FXIIIa (not shown). Importantly, platelet adhesion to FXIIIa 
was observed with whole blood under flow (Fig. S5 and 
Video SIC).
FXIIIa supports platelet adhesion under flow conditions
FXIIIa predominates at sites of vascular damage and interacts 
with proteins of the ECM [4], thereby potentially playing a role 
in platelet recruitment at these sites. Therefore, for the 
remaining experiments, we concentrated on the activated form 
of the enzyme, using an in vitro flow assay [14] to assess the 
stringency of FXIIIa-platelet binding under physiologic levels 
of shear. Immobilized FXIIIa, but not BSA, recruited flowing
Flow
BSA FXIIIa FXIIIa
300 s- 1 800 s- 1
B 7-
3-
BSA FXIIIa
300s- 800s-
Fig. 2. Activated factor XIII (FXIIIa) supports platelet adhesion under 
flow. Washed platelets (2 x 10s platelets mL~') were stained with DiOC<, 
(1 HM), reconstituted blood was perfused over immobilized FXIIIa 
(10 U mL~') for 4 min at the indicated shear rate, and platelet deposition 
was then viewed by fluorescence microscopy. Images were captured under 
fluorescence using CELL'? imaging software. Magnification: x 60. (A| 
Representative images are shown. Bar: 20 um. (B) Data are shown as 
percentage area coverage and are means ± standard deviations of five 
separate experiments with different blood donors. BSA. bovine serum 
albumin. **P < 0.01.
Roles of vii 
FXIIIa
and otv p3 in platelet adhesion and spreading on
We next examined the role of integrins in platelet adhesion to 
FXIIIa. The specific ocnbP3 antagonist tirofiban (2 ^M) reduced, 
but did not eliminate, platelet adhesion to FXIIIa from 
941 ± 42 to 566 ± 72 platelets/0.1 mm2 (P < 0.05) (Fig. 3- 
Aii), suggesting the involvement of additional receptors. In 
contrast, adhesion to fibrinogen in the presence of tirofiban 
was almost abolished (Fig. 3C and S3). Integrin o^pj mediates 
FXIIIa binding to monocytes [19] and endothelial cells [10], 
and we hypothesized that it may also facilitate FXIIIa 
interactions with platelets. Specific inhibition of platelet 0^3 
with the blocking antibody LM609 [20] (20 ug mL~'), but not 
IgG control, reduced platelet adhesion to FXIIIa (941 ± 42 to 
480 ± 91 platelets/0.1 mm2,/' < 0.01). Five-fold higher con­ 
centrations of tirofiban or LM609 had no additional effect (not 
shown). Importantly, when used in combination, these inhib­ 
itors abolished adhesion to FXIIIa (Fig. 3Ai,ii). Inhibition of 
allb (33 and 0^3 had divergent effects on FXIIIa-mediated 
platelet spreading. Whereas spreading was maintained follow­ 
ing avp3 blockade (27 ± 4 um2 as compared with 3 1 ± 1 um2 
for the presence and absence of LM609 [P > 0.05]), it was 
abolished following inhibition of otnbP^ (8 ± 2 um" as com­ 
pared with 31 ± 1 um2 for the presence and absence of 
tirofiban [P < 0.05]) (Fig. 3Aiii). Consistent with the experi­ 
ments performed under static conditions, under flow, FXIIIa- 
mediated adhesion was reduced significantly by tirofiban 
(P < 0.01) or LM609 (P < 0.01), and abolished when they 
were used in combination (Fig. 3B). As with the IgG control, 
treating platelets with a blocking antibody against glycoprotein 
(GP)lb, Mab6Dl (20 ug mL-'). had no effect on adhesion to 
FXIIIa under either static or flow conditions (not shown). 
These findings suggest that platelet adhesion to FXIIIa is 
dually dependent on otnbPs and C*VP3, whereas platelet spread­ 
ing and potentially stable adhesion are driven by anbp3. In 
contrast to the results obtained with FXIIIa, inhibition of OvPa 
had no effect on adhesion to fibrinogen (Fig. 3C). As the two 
proteins can associate in plasma, we investigated whether their 
differential integrin binding influenced platelet accrual. Fibrin- 
ogen-bound FXIII dose-dependently increased platelet recruit­ 
ment by immobilized fibrinogen under physiologic flow 
(Fig. 3D). Thus, FXIII can enhance fibrinogen-mediated 
platelet accrual.
© 2011 International Society on Thrombosis and Haemostasis
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Fig. 3. Platelet adhesion to activated factor XIII (FXIIIa) is dually dependent on otubp3 and ctvpV (A) Washed platelets (5 x 107 platelets mL' 1 ) were treated with tirofiban (2 UM), LM609 (20 ug mlT1), IgG control antibody (20 ug mL'1 ), or H-Arg-Gly-Asp-Ser-OH (RODS) (500 UM), or left untreated 
(control), for 20 min, allowed to adhere to immobilized FXIIIa or heat-denatured FXIIIa (dFXIIIa) (both 10 U mL ') for 1 h at 37 °C, stained with tetramethyl rhodamine isothiocyanate-phalloidin, and viewed by fluorescence microscopy, (i) Representative images taken under x 60 magnification. Bar: 
20 urn (ii) Platelets were counted and expressed as number of adherent platelets per 0.1 mm2 , (iii) Images were used to determine platelet surface area. The 
results are from three separate experiments with different blood donors. (B) Washed platelets (2 x 108 platelets mlT 1 ) were treated with the appropriate receptor antagonists and stained with DiOC6 (1 UM), and reconstituted blood was perfused over immobilized FXIIIa for 4 min at a shear rate of 300 s . 
Images were used to calculate platelet surface area coverage. (C) As in (A), except that platelets were allowed to adhere to immobilized nbrinogen 
(200 ug mL'1 ). The results are from three separate experiments with different blood donors. (D) As in (B), except that FXIII (5 and 10 U mL ) or heat- denatured FXIII (dFXIII) (10 U mL' 1 ) were allowed to bind to fibrinogen (1 mg mL ') through a 15-min preincubation at 37 °C prior to coating of 
tubes Uncoated surfaces were blocked by overlay with bovine serum albumin (BSA) (10 mg mL' 1 ) for 30 min at 20 °C prior to blood perfusion at 800 s~ 
for 4 min. The results are from three separate experiments with different blood donors. Fbg, nbrinogen; HSA, human serum albumin; NS, not significant. 
**P < 0.01, *P < 0.05.
FXIIIa supports adhesion and spreading through a 
Src-kinase-dependent pathway
Stable platelet adhesion and spreading via ocribPs requires 
tyrosine kinase-dependent signals involving Src and Syk [21]. 
We examined the role of the signaling proteins required for 
outside-in signaling. Consistent with a tyrosine kinase-depen­ 
dent mechanism, the Src-family kinase inhibitor PP1 (20 UM), 
but not its inactive analog (not shown), reduced platelet
adhesion to FXIIIa from 762 ± 40 to 143 ± 77 platelets/ 
0.1 mm2 (P < 0.01) and abolished spreading (27 ± 1 to 
11 ± 3 |im2; P < 0.01) (Fig. 4A). Furthermore, adhesion to 
FXIIIa increased tyrosine phosphorylation of a broad range of 
proteins in whole cell lysates from FXIIIa-adherent platelets, 
with the most prominent bands being observed at 27,36,40,48, 
55, 72 and 130 kDa (Fig. 4B, arrows). These phosphorylation 
events were abolished by RODS, consistent with integrin- 
mediated signaling. Using immunoprecipitation, we found that
) 2011 International Society on Thrombosis and Haemostasis
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4 Platelet adhesion and spreading on activated factor XIII (FXIIIa) is tyrosine kinase-dependent. (A) Washed platelets (5 x 10' platelets mlT1 wJate^th 4 arL-5- 4-methylPhenyl-7-(t-butyl)Pyrazolo(3,4-d)pyrimidine (PP1) (20 ,M) or 0.01% dunethylsulfo.de (vebcle control)
immunoblotting; IP, immunoprecipitation.
adhesion to FXIIIa stimulated tyrosine phosphorylation of 
Syk and its downstream target SLP-76 (Fig. 4C), two proteins 
that play critical roles in signaling by anbPa [21]- In contrast, 
LAT remained in its unphosphorylated state, distinguishing the 
signaling cascade from that downstream of GPVI [22] (not 
shown). We could not detect phosphorylation of tyrosine 
residues when platelets were stirred with FXIIIa in suspension
37 °C
(not shown). To dissect the roles of anbfc and OvPs in signaling 
events induced by immobilized FXIIIa, we compared the 
pattern of tyrosine phosphorylation of whole cell lysates from 
adherent platelets treated with tirofiban and LM609. Tyrosine 
phosphorylation of platelet proteins was unaffected by inhibi­ 
tion of OvP3, whereas blockade of anbP3 restricted it to basal 
levels (Fig. 4D).
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Fig. 5. Phospholipase C (PLC)y2-mediated intracellular Ca2+ mobilization is required for stable platelet adhesion and spreading on activated 
factor XIII (FXIIIa). (A) (i) Washed platelets (5 x 107 platelets mL"') were treated with l,2-bis-(o-aminophenoxy)ethane-tetra-acetic acid 
tetra-(acetoxymethyl) ester (BAPTA-AM) (20 UM) or U73122 (5 UM) for 20 min, allowed to adhere to immobilized FXIIIa (10 U mL~') for 
1 h, stained with tetramethyl rhodamine isothiocyanate-phalloidin, and viewed by fluorescence microscopy. Bar: 20 um. (ii) Platelets were 
counted and expressed as number of adherent platelets per 0.1 mm", (iii) Surface areas of adherent platelets were measured with IMAGE! 
software. The results are from four separate experiments with different blood donors. **P < 0.01. (B) Washed platelets (5 x 108 platelets mL~') 
were allowed to adhere to the wells of a six-well plate coated with heat-denatured FXIIIa (dFXIIIa) (10 U mL" 1 ) or FXIIIa (10 U mL' 1 ) in 
the presence of apyrase (1 U mL"') and indomethacin (10 UM) for 45 min. PLCy2 was immunoprecipitated from adherent-platelet lysates, and 
immunoblotted for PLCy2 and phosphotyrosine (pTyr). Blots are representative of three separate experiments with different blood donors. IP, 
immunoprecipitation.
FXIIIa-mediated platelet adhesion and spreading requires the 
mobilization of intracellular Ca2*
As the mobilization of intracellular Ca2 + through PLCy2 is 
vital for integral-mediated adhesion and spreading [23], we 
examined its role in FXIIIa-stimulated platelet adhesion. The 
intracellular Ca2+ chelator BAPTA-AM (20 UM) significantly 
reduced platelet adhesion to FXIIIa from 762 ± 40 to 
123 ± 26 platelets/0.1 mm2 (P < 0.01) (Fig. 5Aii) and pre­ 
vented spreading. We next used the PLC inhibitor U73122 
(5 IIM), which completely abolished stable platelet adhesion
(Fig. 5Aii). Consistent with these data, PLCy2 was tyrosine- 
phosphorylated, suggesting its activation [24], when platelets 
adhered to FXIIIa (Fig. 5B). These data suggest that adhesion 
to FXIIIa leads to activation of PLCy2, which mobilizes the 
intracellular Ca2+ that is required for spreading.
FXIIIa enhances platelet recruitment by the KM under 
arterial flow conditions
The exposure of ECM proteins such as collagen and collagen- 
bound VWF at sites of vascular injury leads to rapid activation
© 2011 International Society on Thrombosis and Haemostasis
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and retention of platelets [25]. We hypothesized that, as FXIIIa 
could support adhesion alone, it may supplement platelet 
recruitment by other matrix proteins. We co-immobilized a 
fixed concentration of VWF (20 ug mLT 1 ) with a range of 
FXIIIa concentrations (1-10 U mL" 1 ). At a shear rate of 
800 s" 1 , immobilized VWF (20 ug mL" 1 ) supported adhesion 
of single platelets that covered 8.9% ± 0.1% of the VWF- 
coated surface. However, platelet surface coverage was 
increased significantly when VWF was immobilized together 
with FXIIIa (Fig. 6). Maximal effects were observed with 
FXIIIa (10 U mL" 1 ), where surface area coverage was 
increased from 8.9% ± 0.1% (VWF alone) to 
15.0% ± 1.6% (P < 0.05). Importantly, there was a clear 
contrast between single platelets bound on a VWF surface and 
platelet aggregates observed on a VWF/FXIIIa surface 
(Fig. 6A and Video SI A).
Factor XIII binds to collagen [26], which may allow FXIIIa 
to be immobilized at sites of vascular damage, thereby 
promoting platelet adhesion. Using methodology provided in 
the data supplement (Data SI), we observed that FXIIIa, but 
not zymogen FXIII, bound to collagen (Fig. S4), and then 
examined how this influenced platelet adhesion to collagen. 
Under our experimental conditions, collagen (100 ug mL~')
alone supported the deposition of robust platelet-rich thrombi, 
resulting in a mean thrombus volume of (3.7 ± 0.1) x 
105 arbitrary units. Importantly, collagen-bound FXIIIa facil­ 
itated a significant increase in the volumes of stable thrombi to 
(6.7 ± 0.5) x 105 arbitrary units (P < 0.05) (Fig. 7C), with­ 
out influencing surface coverage (Fig. 7B). Crucially, this 
required the correct protein folding of FXIIIa, as heat- 
denatured FXIIIa could not enhance the effects of collagen 
(P > 0.05).
Discussion
Although associations between platelets and FXIIIa are 
recognized, the physiologic consequences of these interactions 
are poorly defined. The aims of our study were three-fold: 
first, to investigate the ability of immobilized FXIIIa to 
support adhesion and spreading under static and flow 
conditions; second, to determine the molecular mechanisms 
underpinning platelet adhesion; and third, to examine 
whether FXIIIa could act cooperatively with other thromb- 
ogenic proteins to enhance platelet accrual under flow. Our 
results confirm those of Dardik et al. [10], who showed that 
platelets could bind both FXIII and FXIIIa. However, the
Flow
vWF
FXIIIa (U mL- 1 ) 10
800s-
18
FXIIIa (UmL- 1 )
vWF +
800 s- 1
Fig. 6. Activated factor XIII (FXIIIa) enhances platelet thrombus formation by von Willebrand factor (VWF). Reconstituted blood was perfused over immobilized FXIIIa (10 U mL~') or VWF (20 ug mL~') either alone or co-immobilized with increasing concentrations of FXIIIa (1-10 U mL ') for 
4 rain at 800 s~', and then viewed by fluorescence microscopy. Images from eight random fields of view were captured under fluorescence, with cEix'P imaging software (magnification: x 60). (A) Representative images are shown. Scale bar: 20 urn. (B) Data shown are means ± standard deviations of three 
separate experiments with different blood donors. NS, not significant. **P < 0.01, *P < 0.05.
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Fig. 7. Activated factor XIII (FXIIIa) is immobilized on collagen and enhances its thrombogenic capacity. FXIIIa (10 U mL~') or heat-denatured 
FXIIIa (dFXIIIa) (10 U mL~') were bound to collagen (100 ug mL~') through a 15-min preincubation at 37 °C prior to coating of tubes. 
Reconstituted blood was perfused through the coated tubes for 4 min at 800 s' 1 , and thrombus formation was viewed by fluorescence microscopy. 
(A) Representative images of stable thrombi formed on each surface are shown. Bar: 20 urn. (B) IMAGE! software was used to measure percentage 
surface area coverage. (C) Volumes of thrombi formed on each surface were measured as previously described [15]. The results are from four separate 
experiments with different blood donors. NS, not significant. *P < 0.05.
data presented here also greatly extend that work by 
demonstrating several key factors, including the fact that 
FXIIIa supports adhesion independently of transglutaminase 
and PDI-like activity, induces a tyrosine kinase signaling 
pathway downstream of anbp3 , and supports platelet accrual 
under physiologic conditions of flow.
Platelet adhesion and spreading on FXIIIa occur through 
collaborative binding by anbp3 and 0^3. Previous studies used 
the antibody 7E3 [7], or its humanized derivative abciximab 
[10], and eptifibatide [27] in attempt to specifically demonstrate 
the critical role of anbp3 in binding FXIIIa. However, unlike 
tirofiban, all three inhibitors also block 0^3 [28]. Thus, 
conclusions from these studies overlooked the potential 
contribution of 0^3. Using tirofiban for its strict specificity 
for anb (33 , we found that this integrin was only partially 
responsible for platelet binding to FXIIIa, with LM609
revealing that OvPs was needed for maximal adhesion. Platelet 
adhesion to FXIIIa was only effectively abolished when both 
integrins were blocked. It is noteworthy that platelet 0^3 has 
been shown to possess an affinity 150-fold greater than otnbPs 
for at least one common ligand [29]. Thus, despite its lower 
copy number, it is an important mediator of platelet adhesive 
events. Although FXIIIa-mediated adhesion depends on both 
receptors, platelet spreading, required for stable adhesion 
under flow, is mediated solely by anb (33 . Together, these data 
suggest a model whereby otiihPs reinforces oCvPs-mediated 
platelet adhesion to FXIIIa through signaling events that lead 
to spreading. FXIIIa stimulates platelet spreading through a 
tyrosine kinase-dependent mechanism downstream of otubfo. 
resulting in the tyrosine phosphorylation and activation of a 
number of proteins, including Syk, SLP-76, and PLCy2, 
leading to the Ca2+ mobilization required for platelet activa-
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tion. Consistent with this, platelet inhibition by GSNO 
markedly reduced stable adhesive contacts with FXIIIa. In 
contrast, 0^3 did not participate in the signaling events, in line 
with its redundancy in the spreading process. Despite the ability 
of FXIIIa to stimulate spreading, it is notable that it did not 
induce aggregation or tyrosine phosphorylation in platelet 
suspensions (not shown). This explains, in part, why previous 
studies have not reported signaling events induced by this 
enzyme. Furthermore, signal transduction induced solely by 
immobilized FXIIIa may suggest a unique mechanism that 
allows it to promote platelet activation only when it is localized 
at sites of vascular damage. Thus, in addition to identifying a 
potentially new platelet receptor for FXIIIa, we provide the 
first evidence that FXIIIa activates platelets through tyrosine 
kinase-dependent signaling.
It is possible that FXIIIa, through mediating both platelet 
adhesion and activation, could contribute to platelet recruit­ 
ment at sites of vascular injury. In plasma, FXIII can 
associate with fibrinogen, an important ligand for unbp3 . We 
demonstrate that platelets can bind FXIII independently of 
fibrinogen, as we excluded its presence from our plasma- 
purified FXIII preparation, and platelets adhered to plasma 
protein-free recombinant FXIII-A. Binding to FXin, but not 
to fibrinogen, was reduced by inhibition of Ovp3 . This is 
consistent with descriptions of a minor platelet role for otvfe 
in binding fibrinogen [29]. Importantly, it suggests that 
different, non-redundant mechanisms control platelet binding 
to the two proteins. In fact, we observed that fibrinogen- 
bound FXIII increased platelet binding to immobilized 
fibrinogen under physiologic flow, suggesting that FXIII 
can collaborate with fibrinogen in mediating platelet accrual. 
Although these data appear to contradict those of Nagy et al. 
[27], who reported that platelet-FXIII interactions were 
wholly dependent on fibrinogen, they are supported by a 
report from Cox and Devine [7], who also demonstrated that 
washed platelets and, indeed, purified am>P3 could bind 
FXIIIa in the absence of fibrinogen, with this being enhanced 
by its presence. Nevertheless, both studies examined interac­ 
tions with platelets in suspension using flow cytomery, 
whereas immobilized FXIIIa was used in the present study, 
which limits comparison of results.
Under high shear, VWF-mediated platelet tethering retards 
flowing platelets, allowing their activation in response to 
exposed collagen [25]. Platelet adhesion is then strengthened by 
integrin-mediated spreading, which is facilitated by various 
plasma proteins. We observed that, at high shear, the presence 
of surface-immobilized FXIIIa led to platelet aggregate 
formation, which was unobservable on VWF alone, indicating 
that FXIIIa can act in concert with VWF to arrest flowing 
platelets. Perhaps more importantly, FXIIIa bound to collagen 
enhanced the ability of this key matrix protein to form platelet- 
rich thrombi. By binding collagen exposed at sites of vascular 
injury, FXIIIa, like VWF, may increase platelet recruitment by 
supplementing the number of platelet-binding sites available 
per collagen fiber. This enhances the thrombotic potential of 
collagen by supplementing activatory signal transduction
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through the long-lived, integrin-mediated 'outside-in' signaling 
that is essential for maintaining interplatelet contacts within 
platelet aggregates and initiating clot retraction [25]. Thus, 
FXIIIa promotes the thrombogenic effects of key ECM 
proteins, thereby illustrating its potential role alongside other 
plasma and matrix proteins in propagating platelet activation 
at sites of vascular damage.
The present study raises the possibility of a physiologic role 
for FXIIIa in supporting platelet accrual and spreading 
through multiple integrins. Although FXIIIa does not induce 
platelet aggregation, FXni-A-deficient mice exhibit elongated 
tail bleeding times [30] and markedly diminished clot 
retraction [31], suggesting a potential role for FXIII in 
platelet-dependent thrombosis. In humans, FXIII(a) involve­ 
ment in platelet aggregation is less clear. Whereas investiga­ 
tors in an early study found that platelets aggregated 
normally in response to ADP, ristocetin, and collagen [32], 
a more recent study revealed diminished responses to ADP 
and epinephrine by platelets from three FXHI-A-deficient 
patients [33]. We speculate that the interaction of platelets 
with FXIIIa may have particular relevance at vascular injury 
sites, where it could potentiate the thrombogenic effects of 
exposed collagen and VWF and immobilized fibrinogen. 
Recent evidence from large clinical studies suggests that 
elevated plasma FXIII antigen and activity levels may be risk 
factors for myocardial infarction [34] and peripheral vascular 
disease (PVD) [35]. Taken together with the increasingly 
established involvement of platelets in the pathogenesis of 
cardiovascular disease [25], observations that patients with 
PVD have circulating platelets bound to more FXIII than 
healthy controls [36] suggest that platelet-FXIII(a) interac­ 
tions may have pathologic consequences in humans. Thus, we 
identify FXIH/FXIHa as a novel component of the growing 
numbers of proteins, including CD40, thrombospondin, FXI 
and protein C, localized to areas of vascular damage, that 
activate blood platelets through multiple integrated signaling 
pathways. Like FXIIIa, such proteins may play modest 
roles in platelet-mediated primary hemostasis, but they may 
contribute significantly to vascular occlusive pathologies. The 
involvement of platelet-FXIIIa interactions in pathologic 
thrombosis thus requires further investigation.
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